Victor J. Dzau, M.D.
Curriculum Vitae

Office Address: Office of the President
National Academy of Medicine
The National Academies
500 5th Street, NW
Washington, DC 20001

Place of Birth: Shanghai, China (U.S. citizen)

Education

1968	B.S.	McGill University, Montreal, Canada
1972	M.D.	McGill University, Montreal, Canada

Honorary Degrees

1995 Upjohn Chair in Medicine, University of Antwerp, Belgium
1996 M.A. (Hon) Harvard University, Cambridge, MA
1998 Doctor Honoris Causa, Federal University of Rio de Janeiro, Brazil
2001 Doctor Honoris Causa, National University of Cordoba, Argentina
2001 Honorary Professor of Biological Sciences, University of Warwick, UK
2008 Doctor of Science, McGill University, Montreal, Canada
2010 Doctor of Medicine, King's College London, UK
2011 Doctor of Science, University of Glasgow, UK
2014 Doctor of Science, Northeastern University, MA
2015 Doctor of Science, University of Cincinnati, OH
2015 Doctor of Science, University of Massachusetts Medical School, Worcester, MA
2016 Doctor of Science Honoris Causa, University of Hong Kong, HK
2017 Doctor of Science Honoris Causa, University of South Florida, FL
2017 Doctor of Science Honoris Causa, Case Western Reserve University, OH
2018 Doctor of Science Honoris Causa, Ross University, Portsmouth, Dominica
2019 Doctor of Science Honoris Causa, Western University, London, Ontario, Canada
2021 Doctor of Science Honoris Causa, Boston University
2021 Doctor of Science Honoris Causa, University of British Columbia

Postdoctoral Training

Internships and Residencies

1972-1973	Intern in Medicine, New York Hospital - Cornell Medical Center, New York,
1973-1974	Resident in Pathology, Peter Bent Brigham Hospital, Harvard Med School, Boston, MA
1974-1975	Assistant Resident Physician, Peter Bent Brigham Hospital, Harvard Med School, Boston
1974-1976	Clinical Fellow in Medicine, Harvard Medical School, Boston, MA
1975-1976	Senior Resident Physician, Peter Bent Brigham Hospital, Harvard Med School, Boston
1978-1979	Chief Resident Physician, Peter Bent Brigham Hospital, Harvard Med School, Boston

Research and Clinical Fellowships

1976-1978 Fellow in Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

1978-1979 Postdoctoral Research Fellow, Department of Physiology, Harvard Medical School, Boston, MA
1979-1980 Fellow in Cardiology, Massachusetts General Hospital, Boston, MA

Licensure and Certification

1976- American Board of Internal Medicine, Certificate No. 55016
1978- Massachusetts Medical License No. 42640
1991 California Medical License No. G07085
2005- North Carolina Medical License No. 01033

Academic Appointments

1978-1979 Instructor in Medicine, Harvard Medical School, Boston, MA
1980-1984 Assistant Professor of Medicine, Harvard Medical School, Boston, MA
1984-1990 Associate Professor of Medicine, Harvard Medical School, Boston, MA
1984-1990 Chief, Division of Vascular Medicine and Atherosclerosis, Brigham and Women's Hospital, Boston, MA
1990-1996 William G. Irwin Professor of Medicine, Stanford University School of Medicine, Stanford, CA
1990-1996 Director, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA
1990-1996 Chief, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA
1991-1996 Director, American Heart Association, Bugher Foundation Center for Molecular Biology at Stanford, Stanford, CA
1993-1995 Associate Chairman, Department of Medicine, Stanford University School of Medicine, Stanford, CA
1995-1996 Chairman, Department of Medicine, Stanford University School of Medicine, Stanford, CA
1995-1996 Arthur L. Bloomfield Professor of Medicine, Stanford University School of Medicine, Stanford, CA
1996-2004 Chairman, Department of Medicine, Brigham and Women’s Hospital, Boston, MA
1996-2004 Director of Research, Brigham and Women's Hospital, Boston, MA
1996-2004 Hersey Professor of the Theory and Practice of Physic (Medicine), Harvard Medical School, Boston, MA
1998-2004 Chairman, Executive Committee of Medicine, Harvard Medical School, Boston, MA
2004- James B. Duke Professor of Medicine, Duke University
2004- Executive Director, Mandel Center for Hypertension Research, Duke University
2004-2014 Chancellor for Health Affairs, Duke University
2013-2014 Executive Director & Chair, Duke Institute for Health Innovation
2014- Chancellor Emeritus, Duke University
2014-2015 President, Institute of Medicine, National Academy of Sciences, USA
2015-2018 Chair, Health and Medicine Division, National Academies of Science, Engineering and Medicine, USA
2015- Vice-Chair, National Research Council, USA
2015- President, National Academy of Medicine, USA

Health System and Hospital Appointments

1980-1987 Director, Hypertension Unit, Brigham and Women's Hospital, Boston, MA
1980-1988 Associate Physician, Brigham and Women's Hospital, Boston, MA

1980-1990	Clinical Associate in Medicine, Massachusetts General Hospital, Boston, MA
1981-1990	Assistant Physician, Beth Israel Hospital, Boston, MA
1982-1987	Director, Hypertension Center, Brigham-Beth Israel Hospitals, Boston, MA
1984-1990	Director, Molecular and Cellular Vascular Research Laboratory, Brigham and Women's Hospital, Boston, MA
1984-1990	Chief, Division of Vascular Medicine and Atherosclerosis, Brigham and Women's Hospital, Boston, MA
1988-1990	Senior Physician, Brigham and Women's Hospital, Boston, MA
1990-1996	Chief, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA
1995-1996	Physician in Chief, Stanford Health Services, Stanford University, Stanford, CA
1996-2004	Physician in Chief, Brigham and Women's Hospital, Boston, MA
1996-2004	Director of Research, Brigham and Women's Hospital, Boston, MA
1996-2004	Board of Directors, Brigham Community Practices, Inc.
1998-2004	Board of Trustees, Partners HealthCare System
2000-2004	Brigham and Women's/Faulkner Hospital Board of Trustees, Partners HealthCare System
2000-2004	Senior Academic Officer and Director of Academic Collaborations, Partners HealthCare System
2004-2014	President & CEO, Duke University Health System and Medical Center

Principal Clinical and Hospital Service Responsibilities

1980-1990	Attending Physician, Cardiology Services, Brigham and Women's Hospital
1980-1990	Attending Physician, General Medical Service, Brigham and Women's Hospital
1980-1984	Director, Hypertension Service and Clinic, Brigham and Women's Hospital
1980-1984	Attending Physician, Clinical Research Center, Brigham and Women's Hospital
1984-1990	Director and Attending Physician, Vascular Medicine Service and Clinic, Brigham and Women's Hospital
1984-1990	Consulting Physician, Stroke Service, Brigham and Women's Hospital
1990-1996	Chief, Cardiology Services, Stanford University Hospital
1995-1996	Physician in Chief, Stanford Health Services, Stanford University Hospital
1996-2004	Physician in Chief, Brigham and Women's Hospital, Boston, MA
2006-2014	President, Medical Staff, Duke University Hospital

Harvard Medical School

Brigham and Women's Hospital/Partner's Healthcare System

1977-1986	Internship Selection Committee, Department of Medicine, Brigham and Women's Hospital
1978-1979	Pharmacy and Therapeutics Committee, Peter Bent Brigham Hospital
1978-1983	Cannon Society
1982	Soma Weiss Assembly, Selection Committee
1984-1990	Executive Advisory Committee, Department of Medicine, Brigham and Women's Hospital, Boston, MA
1985-1990	Harvard Medical School and Harvard School of Dental Medicine, Committee on Human Studies
1987-1990	Preceptor, American Heart Association, Bugher Foundation Center for Molecular Biology in Cardiovascular System at Harvard Medical School
1988	Aesculapian Club
1988-1990	Standing Committee on Animals, Faculty of Medicine, Harvard Medical School
1988-1990	Animal Committee, Brigham and Women's Hospital
1996	Advisory Committee, The Center for Animal Resources & Comparative Medicine

1996	Executive Committee of Research Council, Partners HealthCare System
1996	Executive Committee, Department of Medicine, Harvard Medical School
1996	Warren Alpert Prize Selection Committee, Harvard Medical School
1996	Member, Clinical Integration Committee, Partners HealthCare System
1996	Co-Chair, Specialty Care Development Executive Committee, Partners HealthCare System
1996	PHO Executive Committee, Brigham and Women's Hospital
1996	Strategic Planning Committee, Board of Trustees, Brigham and Women's Hospital
1996	Chief's Council, Brigham and Women's Hospital
1996	PHO Board of Directors, Brigham and Women's Hospital
1996	Managed Care Advisory Committee, Brigham and Women's Hospital
1996	Director, Research Council, Brigham and Women's Hospital
1996	President, Brigham Medical Group
1996	Dean's VA Committee, Harvard Medical School
1997	Executive Committee, Partners HealthCare System
1997	Committee on Senior Appointments, Harvard Medical School
1997	Committee of Professors, Harvard Medical School
1997	Science Advisory Committee, Partners-Genzyme
1997	Chairman, Task Force on Genetics and Genomics, Partners HealthCare System
1997	Subcommittee of Professors, Harvard Medical School
1997, 1998	Scientific Advisory Board, Dana Farber Cancer Institute
1998	Governance Committee, DFCC/Harvard Comprehensive Cancer Center Grant
1998, 1999	Member, Board of Trustees Committee on Industrial Relations and Ventures, Partners HealthCare System
1998-2001	Chairman, Harvard Departments of Medicine Executive Committee
1998-2004	Harvard-Boston University VA, Dean's Committee, Harvard Medical School
1998-2000	Curriculum Committee, Harvard Medical School
1998-2001	Chairman, Executive Committee on Genetics and Genomics, Partners HealthCare System
1998-2004	Joint Faculty Committee, Harvard/MIT Health Science Technology
1998-2004	Board of Directors, Brigham Community Practices, Inc.
1998	Chairman, Harvard-wide Graduate Medical Education Committee, Harvard Medical School
1998 -2004	Board of Trustees, Brigham & Women's/Faulkner Hospitals, Inc., Partners HealthCare System
1999	Member, Scientific Advisory Committee for the Warren Alpert Foundation Prize, Harvard Medical School
1999	Oversight/External Advisory Committee, Harvard Medical School, Mind Body Center
1999-2004	Principal Investigator, General Clinical Research Center, Brigham & Women's Hospital
1999-2004	Board of Trustees, Brigham and Women's Hospital
1999	Member, Committee on Medical School Initiatives in Medical Genetics, Harvard Medical School
2000	Member, Sub-Committee of the Partners Finance Committee, Partners HealthCare System
2000-2004	Board of Trustees, Harvard Clinical Research Institute
2000-2004	Member, Partners deCODE Steering Committee, Partners HealthCare System
2000-2004	Member, Brigham and Women's Health Task Force
2000-2004	Board of Trustees, Partners HealthCare System
2001-2004	Member, Dana Farber/Partners Cancer Center Executive Committee, Partners HealthCare System
2001-2004	Chair, Dana Farber/Brigham and Women's Joint Cancer Center Leadership Committee
2001-2004	Member, Brigham and Women's Hospital Strategic Planning Council
2001-2004	Member, Joint Faculty Committee of the Harvard-MIT Division of Health Sciences and Technology
2001, 2003	Jury, Lemelson-MIT Prize for Science and Innovation

2001-2004 Executive Committee, Harvard-Partners Center for Genetics and Genomics
2001-2004 Executive Committee, Founding Member and Scholar, The Academy at Harvard Medical School
2002-2004 Advisory Committee for the Program for Chiefs of Clinical Services, Harvard School of Public Health
2002-2004 Steering Committee, The Academy at Harvard Medical School
2002-2004 Task Force on Research Strategic Planning, Partners HealthCare System
2002-2004 Member, Harvard University Provost's Science & Technology advisory Group
2003-2004 Member, Education Reform Executive Committee, Harvard Medical School
2003-2004 Steering Committee, Harvard Stem Cell Institute, Harvard University
2003-2004 Chairman, Research Strategic Planning, Brigham and Women's Hospital
2003-2004 Chairman, Executive Steering Committee, Harvard-Partners Center for Genetics and Genomics
2003-2004 Member, Harvard University Provost's Science Executive Planning Group
2003-2004 Member, Board of Directors Nominating Committee, Partners HealthCare System
2004- Oversight Committee, Harvard New Research Building, Harvard Medical School
2004- Member, National Advisory Board of the Howard Hiatt Residency on Global Health Equity and Internal Medicine
2004-2014 Member, Program Advisory Committee, Department of Health Policy and Management, Harvard School of Public Health

Stanford University

1990-1992 Chairman, Steering Committee, Stanford Center for Vascular Disease
1990-1996 Academic Program Chief's Executive Committee, Stanford University School of Medicine
1990-1996 Clinical Advisory Committee, Potential Laser Program, Stanford University Hospital, Stanford, CA
1991-1996 Committee on Clinical Program Development, Stanford University Hospital, Stanford, CA
1992-1993 Advisory Committee, General Clinical Research Center, Stanford University School of Medicine
1992-1994 Governing Board, Institute of Biological and Clinical Investigation, Department of Medicine, Stanford University, Stanford, CA
1993-1994 Senate Representative Alternate, Stanford University
1993-1996 Working Group on External Affiliations Task Force, Stanford Health Services
1993-1996 Member, Neurology Chair Search Committee
1994-1995 Senator, Academic Council, Stanford University
1994-1996 Member, Department of Medicine Diversity Council
1994-1996 Senator-At-Large, Stanford University School of Medicineγ
1994-1996 Member, Executive Committee of the Dean's Task Force on Gene Therapy, Stanford University School of Medicine
1994-1996 Stanford Health Services Board of Directors Program Review Committee
1994-1996 Advisory Committee to President Casper on V.P. Medical Affairs
1995-1996 Howard Hughes Medical Institute Faculty Advisory Committee
1995-1996 Stanford Health Services Operations Improvement Program Steering Committee
1995-1996 Stanford International Medical Services Task Force
1995-1996 Member, Faculty Council Senate, Stanford University School of Medicine
1995-1996 Co-President, Stanford Asian American Medical Faculty Association
1995-1996 Advisory Board, Program of Molecular and Genetic Medicine, Stanford University School of Medicine

1995-1996	Founder and Program Director, National Institutes of Health Stanford Asian Pacific Program in Hypertension and Insulin Resistance (SAPPHIRe) Genetic Program
1995-1996	Medical School Executive Committee, Stanford University
1995-1996	Dean's Steering Committee, Stanford University School of Medicine
1995-1996	Steering Committee Faculty Practice Organization, Stanford Health Services
1995-1996	Chairman, Stanford Faculty Practice Group Governance Committee, Stanford Health Services
1995-1996	Board of Directors, Stanford Health Services
1995-1996	Member, Stanford Health Services Operations Improvement 7 Steering Committee
1995-1996	Executive Committee, Stanford University School of Medicine
1995-1996	Stanford Faculty Practice Group (SFPG) Board Member, Stanford Health Services
1995-1996	Chair, Stanford Faculty Practice Group (SFPG) Workforce Committee, Stanford Health Services
1995-1996	Chair, Task Force on Bench to Bedside Centers, Stanford University School of Medicine
1995-1996	Steering Committee, Stanford Faculty Practice Group (SFPG) Board of Directors
1995-1996	UCSF-Stanford Health Services Merger Planning and Steering Committee
1996	Advisory Board (Alternate), Academic Council, Stanford University
2013-present	Scientific Advisory Board, Stanford Cardiovascular Institute, Stanford University

Major Committee Assignments
American Heart Association

1983	Scientific Chairman, Symposium on "Cellular and Molecular Mechanism in Cardiovascular Disease," American Heart Association
1984	Scientific Chairman, Symposium on "Molecular Biology and Genetics of Renin," Council of High Blood Pressure Research, American Heart Association
1985	Chairman, Joint Committee on Nomenclature and Standardization of Renin Angiotensin System and Atrial Natriuretic Peptides, Council of High Blood Pressure Research, American Heart Association, International Society of Hypertension and World Health Research Review Committee, American Heart Association, Massachusetts Affiliate
1988-1990	Planning Committee on AHA Prevention Conference, American Heart Association
1988-1991	CIBA Award Selection Committee, Council for High Blood Pressure Research, American Heart Association
1988-1992	Executive Committee, Member at Large, Council of Circulation, American Heart Association
1989-1990	Nomination Committee, Council of Circulation, American Heart Association
1991-1992	American Heart Association Task Force on Intercouncil Cooperation
1991-1993	American Heart Association Council on Circulation Credentials Committee
1991-1994	American Heart Association Peer Review Research Committee
1991-1994	Research Committee, Co-Chairperson, Fellowship Subgroup A, American Heart Association
1992-1996	Board of Directors, Palo Alto/Stanford Branch, American Heart Association
1992-1997	Chairman, Intercouncil Vascular Biology Working Group, American Heart Association
1992	Co-Chairman, Research Committee Subgroup A, American Heart Association
1992, 1995	Program Committee, 65th Annual Scientific Sessions, American Heart Association
1993	Member, Focus on Research, Training and Excellence Task Force, American Heart Association
1994	Member, Task Force on Structural Biology, American Heart Association
1994-1996	Member, Task Force on Integration of Councils of Atherosclerosis, Thrombosis, and Vascular Biology Working Group, American Heart Association

1997-1998	Vice Chairman, Council on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association
1998-1999	Senior Vice Chairman, Chair, Vascular Biology Session, Chair, Budget Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association
1999-2000	Chairman, Council on Artherosclerosis, Thrombosis and Vascular Biology, American Heart Association
2001	Chairman, Awards Committee, Council of ATVB, American Heart Association
2006-2007	Chairman, Heart Walk, Greater Triangle, American Heart Association
2013-	Senior Consulting Editor, *Hypertension* , American Heart Association
2014-	Senior Consulting Editor, *Circulation Research*, American Heart Association

National Institutes of Health (NIH)

1983	Consultant for site visit for NIH
1984	Ad Hoc Member, National Institutes of Health Study Sections
1985-1990	National Heart Lung & Blood Institute (NHLBI) Advisory Committee on Atherosclerosis Hypertension and Lipid Metabolism
1985	Organizing Co-Chairman, NIH workshop on "Cationic Transport and Natriuretic Factors"
1988	Scientific Chairman, NHLBI workshop on "Hypertension and Hyperlipidemia in Vascular Disease"
1988	NHLBI Select Expert Advisory Panel on Molecular Genetics of Hypertension and Atherosclerosis
1989	NHLBI Special Advisory Committee on Future Directions of Hypertension Research
1990	Scientific Chairman, NHLBI Frontiers in Basic Science Symposium on "Vascular Biology and Medicine: The Next Frontier"
1990	Chairman, Subcommittee on Basic Science, NHLBI Task Force in Hypertension
1991	National Heart, Lung and Blood Institute Expert Panel on Strategies to Understand Genetic Factors of Heart, Lung, and Blood Diseases
1991-1993	Chairman, National Heart, Lung and Blood Institute Cardiology Advisory Committee
1991	Co-Chairman, National Institutes of Health Workshop on Transforming Growth Factor-Beta in Cardiovascular Disease
1992	Scientific Organizing Committee, NHLBI Symposium on Atherosclerosis to Honor Dr. Gardner McMillan
1993	Expert consultant, National Heart, Lung and Blood Institute, Evaluation of Specialized Centers of Research in Hypertension
1993	Member, Monitoring Board, National Heart, Lung and Blood Institute, Family and Genetic Studies of Cardiovascular Disease (Family Heart Study)
1993-1994	Chairman, National Heart, Lung and Blood Institute Cardiovascular Diseases Advisory Committee
1994	Co-chairman, National Heart, Lung, and Blood Institute Special Emphasis Panel on Cardiovascular Diseases
1995	Steering Committee, NIH Genetic Determinants of Hypertension/Family Board Pressure Study
1997	Special Review Committee for Cardiology Branch, National Heart Lung and Blood Institute
1998	Special Strategic Advisory Committee (SPARK) for National Heart Lung and Blood Institute
1998-2002	Advisory Committee to the National Institutes of Health Director
2000	NIH Director’s Working Group on Oversight of Gene Therapy
2000	NIH Government Performance and Results Act Assessment Working Group

2002	Ad Hoc Member, NIH Pediatric Research Initiative Review Panel
2003	NIH Stem Cell Working Group on Supporting Technologies and Tools in Basic Research
2003	Chairman, NHLBI Expert Panel on Vascular Diseases
2006-2010	National Heart Lung & Blood Institute (NHLBI) Advisory Council
2007-present	Chairman, Protocol Review Committee, Cardiovascular Cell Therapy Network, NHLBI
2010	Member, Search Committee for Director of NHLBI
2010	National Cancer Advisory Board working group to review National Cancer Strategy and National Cancer Institute
2010-2017	Chairman, Steering Committee, NHLBI Progenitor Cell Biology Consortium
2010-2017	Chairman, Scientific Advisory Board, NHLBI Progenitor Cell Biology Consortium
2017-	Chairman, Steering Committee, NHLBI Progenitor Cell Translational Consortium
2017-	Chairman, Scientific Advisory Board, NHLBI Progenitor Cell Translational Consortium

Other Scientific Organizations

1982	Organizing Co-Chairman, Symposium on "Kidney and Cardiovascular Regulation," American Physiological Society
1982	Executive Committee, New England Council for High Blood Pressure
1985	Protocol and Evaluation Committee of the International Trial of Ketanserin and Cardiovascular Risk
1986	Organizing Committee, International Symposium on Angiotensin Converting Enzyme, International Congress of Pharmacology and Toxicology, Japan
1987	Scientific Chairman, Symposium on "Tissue Renin Angiotensin System," American Society of Hypertension
1987	Scientific Vice-Chairman, Gordon Conference on Angiotensin
1988	Scientific Co-Chairman, Advances in Renin Research Symposium, International Society of Hypertension, Kyoto, Japan
1988	Coordinating Chairperson, Hypertension, AAP/ASCI/AFCR National Meeting
1988	Scientific Chairman, Gordon Research Conference on Angiotensin and Related Hormones
1988-1989	Search Committee, Clinical Research Institute of Montreal
1988-1992	Board of Trustees, Society of Vascular Medicine and Biology
1989-1992	Louis and Artur Lucian Award Committee, McGill University
1989-1993	Steering Committee, Gordon Research Conference
1990	Support Committee, Irving H. Page International Hypertension Research Symposium, Baltimore, MD
1990	Scientific Committee, The Second International Symposium on Endothelial Derived Vasoactive Factors
1990	Scientific Co-Chairman, Symposium on "Resolved and Unresolved Issues on Circulating and Tissue Renin Angiotensin System," International Society of Hypertension, Montreal
1990	Scientific Chairman, Advance Drug Research in Heart and Vascular Disease,and President of Executive Scientific Committee
1990	Organizing Committee, 1994 International Society of Hypertension
1990	Selection Committee, Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research
1990-1992	Annual Scientific Session Program Committee, American College of Cardiology
1990-1993	CATS Policy Advisory Committee
1991, 1996	Program Co-Director, Molecular Biology for the Cardiologist, Learning Center, American College of Cardiology
1991	Scientific Chairman, Keystone symposium on Molecular Biology, "Molecular Mechanisms of Vascular Disease"

1991	National High Blood Pressure Education Program, Working Group on The Heart in Hypertension
1991	National Advisory Board, California Tobacco-Related Research Program
1991	Chairman, Advisory Board ADOPT Multicenter Trial
1991	Board of Advisors, Khorakiwala Research Foundation and Heart Institute, Bombay, India
1991	Board Member, Council on Hypertension and Atherosclerosis and Education
1992	Program Committee, Inter-American Society of Hypertension
1992	Member, Task Force, Association of Professors of Cardiology
1992	Program Committee, Vascular Prevention and Intervention International Workshop
1992	Advisory Board, International Symposium on Cardiovascular Pharmacotherapy
1992	Scientific Program Committee, Asian-Pacific Symposium on ACE Inhibition
1992	Honorary Member, Pan American College of Endothelium
1992	Chairman, Task Force on Research Resources, Association of Professors of Cardiology
1992	Organizing Committee, International Symposium on Endothelial Derived Vasoactive Substances
1993	Scientific Executive Committee, 3rd International Congress on Heart Failure - Mechanisms and Management
1993	Scientific Program Committee, The Second Asian Pacific Symposium on ACE Inhibition
1993	Executive Council, North American Vascular Biology Organization
1994	Scientific Co-Chairman and Organizing Committee, International Symposium on "Gene Therapy: Basic to Clinical Applications," Osaka, Japan
1994	Co-Chairman of Scientific Committee, International Symposium on Endothelial Derived Bioactive Substances and Vascular Protection
1994	Advisory Board, International Program of the "6th International Symposium on Cardiovascular Pharmacotherapy," Sydney, Australia
1994-1996	Olympic Prize Advisory Committee and Jury, International Olympic Committee Medical Commission
1994-1996	Councilor, Association of Professors of Cardiology
1995	Organizing Co-Chairman for the 1996 Keystone Symposia, The Molecular Biology of the Cardiovascular System
1995	Advisory Board, Program in Molecular and Genetic Medicine
1996	Scientific Advisory Board, Second International Meeting, Heart Failure '97
1996	Scientific Advisory Board, 7th International Symposium on Cardiovascular Pharmacotherapy
1996	Judging Committee, Young Investigators Awards Competition, American College of Cardiology
1996	Board of Scientific Advisors, Rhone-Poulenc Rorer
1996	Member, Advisory Committee, Cardiac Research Center, Ben Gurion University
1996	Steering Committee, International Vascular Biology Meeting
1994-1998	Advisory Board, Pfizer Scholars Program for New Faculty
1996-1998	Board of Directors and Chairman of the Publication Committee, of The Heart Failure Society of America
1997	Board Member, The 5th Alpe Adria Congress of Cardiology
1997	Scientific Executive Committee, 1st International Congress on Coronary Artery Disease
1997	Scientific Advisory Board, Tulane Astrobiology Center
1997	International Scientific Advisory Board, 8th International Congress on Cardiovascular Pharmacotherapy
1997	Advisory Council, Federation of Chinese American and Chinese Canadian Medical Societies
1997, 1998	Scientific Advisory Board, Warren Alpert Foundation Prize
1998	Scientific Executive Committee, 2nd International Congress on Coronary Artery Disease

1998	Scientific Executive Committee, 6th World Congress on Heart Failure
1998	Scientific Committee, American Society of Gene Therapy
1998	Advisory Board, POWER Trial
1998-2001	Scientific Program Committee Member, Young Investigators Awards Committee, American College of Cardiology
1998	Member, Scientific Committee, European Society of Hypertension
1999	Member, Scientific Programme Committee, The 6th International Symposium on Inhibitors of the Renin-Angiotensin System
1999	Member, Scientific Executive Committee of the International Academy of Cardiology and of the 2nd International Congress on Heart Disease
1999	Member, Honorary Committee of the First Virtual Congress of Cardiology, Federacion Argentina de Cardiologia
1999-2001	Member, International Advisory Board, 23rd World Congress of the International Society for Heart Research, 23rd Annual Meeting of the American Section of International Society for Heart Research
2000	Member, Advisory Board, 11th International Vascular Biology Meeting
2000	Member, Scientific Committee of the European Conference on Management of Coronary Heart Disease, Nice, France
2000	Member, Organizing Committee of the International Vascular Biology Meeting of the Year 2000
2000	Member, Principal's Regional Advisory Board, McGill University
2000-2001	Consultant, Federation of Chinese American and Chinese Canadian Medical Societies
2001	Member, External Advisory Panel, MIT Program Project on Molecular Physiology of the Heart and its Vasculature
2001	Member, International Advisory Board for the World Congress of Cardiology, Sydney, Australia
2001	Member, 11th International Congress on Cardiovascular Pharmacotherapy, Montreal, Canada
2001	Advisory Board to the Scientific Steering Committee, Second International Conference on Women's Health in the New Millenium
2001	Advisory Board, Institute of Circulatory and Respiratory Health, Canadian Institute of Health Research, Canada
2001	Advisory Council for the National Genomic Program, National Science Council of Taiwan
2001	Presidential Prize in Life Science Selection Committee, Taiwan
2001	Chairman, Long Range Strategic Plan Committee, APM
2002	Board of Directors, Association of Professors of Medicine (APM)
2002	Member, International Advisory Board for XVII Congress of the International Society on Thrombosis and Hemostatsis, July, 2001
2002	Member, International Advisory Board for the 10th International Congress on Cardiovascular Pharmacotherapy, Kyoto-Japan
2003	International Review Board, Ontario Research and Development Challenge Fund, Ontario, Canada
2004	Member, Scientific Advisory Board, NIH Program Project on Molecular Physiology of the Heart and Its Vasculature, Massachusetts Institute of Technology
2004 -	Member, McLaughlin Centre for Molecular Medicine's External Scientific Advisory Board
2004	Council Member, Foundation Council of the Initiative for Cardiovascular Research in Developing Countries (IC Health)
2004	Member, Program Advisory Committee, Harvard School of Public Health

2005-	Institute of Medicine, Committee on Sleep Medicine and Research, The National Academies
2005-2012	Member, Research Panel, Association of American Medical Colleges, (AAMC)
2006	Chair, Scientific Advisory Board, McLaughlin Centre for Molecular Medicine, Toronto
2006	Member, Program Planning Committee, Association of Academic Health Centers (AAHC)
2007	Advisory Board, Scientists Without Borders, NY Academy of Science
2007	Member, MIT Center for Biomedical Innovation (CBI) Strategy and Policy Council
2008	Scientific Advisory Board, BIT Life Sciences' 1st Annual World Congress of Regenerative Medicine & Stem Cell
2008	Translational Medicine Alliance Forum 2009 Advisory Committee
2008	Strategy & Policy Council Member - Center for Biomedical Innovation (CBI) at MIT
2008-2014	Scientific Advisory Board, University Hospital Consortium, University of Toronto
2008-2010	Board of Directors, David H. Murdock Research Institute
2009	Planning Committee – Josiah Macy Foundation
2009	Co-Chair, Macy Foundation Conference on Future of Primary Care
2010	Scientific Advisory Board for "Cardiovascular Biomarker Discovery in Disease & Development through Predictive Precision Proteomics (CBD3P3)", funded by the Ontario Ministry of Research and Innovation
2011	Member, Scientific Advisory Board of the Program in Global Health and Social Change, Harvard Medical School
2013- present	Chair, Scientific Advisory Board, Institute of Cardiovascular Medical Sciences, Center of Excellence, British Heart Foundation, University of Glasgow
2016	Member, Scientific Advisory Board, International Academy of Cardiology
2018	Co-chair, Conference Organizing Committee, World Life Science Conference, Beijing, China
2020-	Member, CIRM Scientific Strategy Advisory Panel
2021	Member, Subject Matter Expert Advisory Group (SMEAG), Living Laboratory, University of Glasgow
2021	Member, Steering Group, Strength in Places Fund, The Living Laboratory, University of Glasgow

Organizations, Government, Foundations

2005-2014	Medical Advisory Board, Gairdner Foundation
2008- 2013	Council and executive committee, Institute of Medicine of National Academy of Sciences, Washington, DC
2008-2014	Board of Governors, Health Industry, World Economic Forum, Davos, Switzerland
2008	World Economic Forum's Global Agenda Council on Healthcare Systems
2009	International Selection Panel – Committee for Designtion of Academic Health Sciences Centres, UK Department of Health
2009	National Task Force on Future of Academic Health Sciences Center – Canada
2009	Program Chair, International Forum of the Association of Academic Health Centers (AAHC)
2009-2015	Selection Board, Canada Excellence Research Chairs
2010	International Review Panel, Canadian Institutes of Health Research
2010	Chair, Award for Distinguished Research Selection Committee, Association of American Medical Colleges (AAMC)
2010	Chair, AAMC Distinguished Research Award Selection Committee
2010	National Cancer Advisory Board Working Group to review National Cancer Strategy and National Cancer Institute

2010	Co-Chairman of Institute of Medicine Annual Meeting
2010-present	Member, Board of Directors, ResearchAmerica
2010-present	Co-Chair, Membership Committee, ResearchAmerica
2010-present	Member, Executive Committee, ResearchAmerica
2010-present	Member, Compensation Committee, ResearchAmerica
2011-present	International Advisory Board, Academic Health System, Hamad Medical Corporation & Weill Cornell Medical College, Qatar
2011-2013	Chair, AAMC Distinguished Research Award Selection Committee
2011-2012	Member, Global Advisory Board, World Healthcare Forum
2011-2014	Co-Chair, Global Agenda Council (Health), World Economic Forum
2011-present	Chair and Co-Founder, Board of Directors, Innovations in Healthcare (formerly International Partnership for Innovative Healthcare Delivery (IPIHD))
2011-2012	Chair, Board of Directors, Association of Academic Health Center
2012-present	Chair, External Scientific Advisory Board, Institute of Cardiovascular & Medical Sciences, University of Glasgow
2012	Member, Planning Committee for the 2012 Annual Meeting, Institute of Medicine
2012-2014	Member, Institute of Medicine Roundtable on Genomic & Personalized Medicine
2012	Chair, Innovation in Healthcare Delivery, Global Health Policy Summit, London
2012-2014	Chair, Global Agenda Council, Personalized & Precision Med, World Economic Forum
2012-present	Member, Selection Board, Canadian Excellence in Research Chairs, Canada
2012-2013	US Healthcare Solutions Council, US Chamber of Commerce
2012	Moderator, White House Conference, Educating & Training Clinicians for a Transformed Delivery System, Washington DC
2012-2014	Chair, Development Committee, Institute of Medicine
2013-	FDA-Aspen Institute National Strategy on Biomedical Innovation
2013-	Chair, Peter Munk Cardiac Center, UHN, University of Toronto
2013-	Advisory Council, Hospital of Tomorrow, US News & World Report
2013-	Senior Health Policy Advisor to Her Highness Sheikha Moza bint Nasser of Qatar
2013	International Selection Panel – Committee for Designation of Academic Health Sciences Centers, UK Department of Health
2013-	Expert Advisory Board, Imperial College Health Partners, UK
2014-	Board of Directors, Gairdner Foundation, Canada
2014-	Global Agenda Council, Future of the Health Sector, World Economic Forum
2014-2015	Member, Governing Board, National Research Council
2014-	Ex-Officio Member, Government-University-Industry Research Roundtable (GUIRR) Council, National Academies of Science, Engineering, and Medicine
2014-	Ex-Officio Member, Board on Science, Technology and Economic Policy, National Academies of Science, Engineering, and Medicine
2014-	Ex-Officio Member, Committee on Science, Engineering, Medicine, and Public Policy, National Academies of Science, Engineering, and Medicine
2014-	Advisory Board, Peking University International Hospital
2014-2016	Steering Committee, Restoring the Foundation Coalition, American Academy of Arts & Science.
2015-2017	Steering Committee, Path Towards Personalized Medicine, Qatar National Research Fund
2015-	Program Committee, World Premier International (**WPI)** Research Center Initiative, Japan Society for the Promotion of Science, commissioned by the Ministry of Education, Culture, Sports, Science and Technology, Japan.
2015-	Chair, International Scientific Advisory Committee of the Qatar Biobank & Qatar Genome Project
2016-	Global Agenda Trustee, Future of Health Global Challenge, World Economic Forum

2016-	CEO Task Force, ReadyNation
2016-2018	Global Futures Council, Future of Health & Healthcare, World Economic Forum
2016-present	Board of Directors, Institute for Health Metrics and Evaluation, University of Washington, Seattle
2017	Stewards of the Health and Healthcare System, World Economic Forum
2018	Institute of Biomedicine Preparatory Committee, The Academy of Sciences of Hong Kong
2018	Steering Group Member, Science & Innovation Audit, Department for Business, Energy and Industrial Strategy, Scotland
2018-	Co-chair, Global Futures Council, Longevity and Enhancement, World Economic Forum
2018-	Inaugural Chair, International Advisory Board, School of Population & Global Health, McGill University
2018 - 2021	Member, Global Preparedness Monitoring Board, co-convened by WHO and World Bank
2019-	Technology Advisory Committee, MITRE
2019-	Working Group 3, WHO Independent High-level Commission on Noncommunicable Diseases
2019-	National Commission on Innovation and Competitiveness Frontiers, Council on Competitiveness, US
2019-	National Quality Visioning Task Force, National Quality Forum
2019-	Joint Advisory Board, Weill Cornell Medicine-Qatar
2019-	Member, Steering Group, UK Research & Innovation (UKRI) Strength in Places Fund (SIPF) Bid
2019-	Board Member, Imperial College Health Partners, London, England
2020	Member, American Academy of Arts and Sciences Class V, Section 5 (Scientific, Cultural, and Nonprofit Leadership) Membership Panel
2021	Member, CEPI/China MOST Joint Scientific Committee
2021	Member, Facilitation Council for the Access to COVID-19 Tools (ACT) Accelerator
2021	Advisor, G20 High Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response
2021	Member, High Level Scientific Panel – Global Health Summit, European Commission and the Italian G20 Presidency
2021	Member, Polaris Council, Science, Technology Assessment, and Analytics, Government Accountability Office, United States
2021	Member, Council of the Virchow Foundation for Global Health
2021-	Member, Health & Wellness Advisory Council, America250
2022-	Member, Science and Technology Action Committee, Research!America

Singapore

2005-2014	Governing Board, Duke-NUS Graduate Medical School
2008-2018	Board of Directors, Singapore Health Services, PTE, LTD
2022-	Board of Directors, Singapore Health Services, PTE, LTD
2014-	Health and Biomedical Sciences International Advisory Council: Agency of Science, Technology & Research; and Ministry of Health, Singapore
2019-2024	Academic Medicine Advisory Council, SingHealth Duke-NUS
2021-	Chair, Scientific Advisor Board, PRECISE (Precision Health Research, Singapore)

Industry Activities

1991	Member, Scientific Advisory Board, Pharmagenesis
1991	Member, Scientific Advisory Board, Gensia
1991	Member, Scientific Advisory Board, Mimetics

1992	Chairman, Scientific Advisory Board, CV Therapeutics, Inc.
1996	Scientific Advisory Board, AtheroGenics, Inc.
1998	Founder and Board of Directors, Clingenix, Inc.
1998-2004	Scientific Advisory Board, Cardion AG
2000-2011	Scientific Advisory Board, United Therapeutics, Inc.
2000-2011	Board of Directors, Genzyme Corporation
2001-2005	Founder and Board of Directors, Corgentech, Inc.
2002-2011	Corporate Governance Committee, Genzyme Corporation
2002-2011	Nominating Committee, Genzyme Corporation
2002-2011	Compensation Committee, Genzyme Corporation
2002-2006	Clinical Advisory Board, MPM Capital
2003-2007	Board of Directors, Optobionics
2004-2006	Scientific Advisor, ChondroGene Corporation
2005-2011	Founder and Chairman, Clerigen Inc.
2005-2014	Board of Directors, Pepsico Inc.
2005-2013	Goverance Committee, Pepsico Inc.
2005-2013	Compensation Committee, Pepsico Inc.
2007-2008	Management Executives' Society
2007-2014	Board of Directors, Alnylam Inc.
2007-2014	Nominating & Governance Committee, Alnylam
2007-2014	Science & Technology Committee, Alnylam Inc
2008-2014	Board of Directors, Medtronic, Inc.
2008-2014	Governance Committee, Medtronic Inc
2008-2014	Quality & Technology Committee, Medtronic Inc
2009-2010	Board of Directors, Akebia, Inc.
2013-2014	Audit Committee, Pepsico Inc

North Carolina Activities

2004-2014	Chair, Durham Health Summit
2005-2014	Board Member, North Carolina Institute of Medicine
2006-2011	Board of Directors, Durham Chamber of Commerce
2006-2014	Board of Advisors, Raleigh Chamber of Commerce
2006-2012	Board of Directors, North Carolina Chamber of Commerce
2007-2011	Executive Committee, Board of Directors, North Carolina Chamber of Commerce
2008-2014	Board of Directors, North Carolina Biotechnology Center
2009-2014	Co-chair, Durham Chamber Campaign
2009-2014	Co-Chair, Development Council of EDGE4 Campaign
2010-2014	Executive Committee, North Carolina Biotechnology Center
2010-2013	Governor's China Council, North Carolina
2010-2013	Governor's Innovation Council, North Carolina
2010-2013	Lt. Governor's New Schools Project, North Carolina
2012-2014	North Carolina Biotechnology Center's Special Committee on Strategic Oversight
2013-2014	North Carolina Biotechnology Center Legislative Committee
2013	Chair, Chamber Orchestra of the Triangle Gala
2013-2015	Chair, North Carolina Triangle YMCA Campaign
2013-2014	Chair, Task Force, "Made In Durham", Education to Career System
2014-present	Chair, Board of Directors, Made In Durham.

Awards and Honors

1976 National Research Service Award, National Institute of Health

1979 George W. Thorn Award, Peter Bent Brigham Hospital
1979 Young Investigator Award (Runner-up), American College of Cardiology
1980 Louis N. Katz Award (Runner-up), American Heart Association
1980 Clinical Investigator Award, National Institutes of Health
1984 Established Investigator Award, American Heart Association
1987 Goldblatt Award for Cardiovascular Research, Council of High Blood Pressure Research, American Heart Association
1987 Pfizer Fellow, Clinical Research Institute of Montreal
1990 William N. Creasy Award in Clinical Pharmacology, Burroughs-Wellcome Fund
1990 Bristol-Myers/Squibb in Cardiovascular Research
1990 Honorary Member, British Hypertension Society
1992 Distinguished Scientist Award, American College of Clinical Pharmacology
1992 Annual Distinguished Award, Chinese Hospital Board of Trustees and Medical Staff, San Francisco, CA
1993 Clinical Medicine and Allied Health Award of Excellence, Association of American Publishers, Professional and Scholarly Publishing Division
1994 The First Raymond L. Kalil Memorial Award, Keynote Speaker, Boston, MA
1994 Distinguished Physician Award of the Chinese American Physicians' Society
1994 National Institutes of Health MERIT Award
1995 Honorary Fellow, First Congregation of the Hong Kong College of Cardiology, Hong Kong
1995 Scientific Award, Chinese American Medical Society, New York, NY
1996 Upjohn Chair in Medicine, University of Antwerp, Belgium
1997 Special Recognition Award, Council of Arteriosclerosis, Thrombosis and Vascular Biology American Heart Association
1998 The First Distinguished Asian American Award (shared with Dr. David Ho), Federation of Chinese American and Chinese Canadian Societies, Los Angeles, CA
1998 Commemorative Gold Medal, Ludwig-Maxmilian University of Munich and E.K. Frey-E. Werle Foundation, Germany
1999 Scientific Councils Distinguished Achievement Award, American Heart Association
1999 Louis and Artur Lucian Award for Research in Circulatory Disease, McGill University
2000 Eugene Drake Award, American Heart Association, New England Affiliate, Rockport Maine
2000 First Maurice Hatter Institute Award, University College London, UK and Cape Town University, RSA
2001 Gustav Nylin Medal, Swedish Royal College of Medicine and Swedish Society of Cardiology
2001 Research Achievement Award, InterAmerican Society of Cardiology
2001 Novartis Award for Hypertension Research, Council for High Blood Pressure Research, American Heart Association
2001 Merck Award for Scientific Excellence, Annual Scientific Sessions, American Heart Association
2001 Astra Zeneca Award, International Society of Hypertension, Prague, Czech Republic
2003 Onassis Cardiac Surgery Center Award, Contribution to Molecular Cardiology and Gene Therapy, Athens, Greece
2003 Kurt Polzer Prize in Biomedical Science, European Academy of Science and Arts
2004 Distinguished Scientist - American Heart Association
2004 Max Delbruck Medal, Berlin, Germany, Humboldt-Universitat, Charite, Free University, Max Planck Institute, Max Delbruck Center for Molecular Medicine and Ernst-Schering Research Foundation
2005 Golden Door Award, International Institute of Boston
2005 Ellis Island Medal of Honor
2006 Medal of Merit, International Academy of Cardiovascular Sciences
2006 Robert H. Williams Distinguished Chair of Medicine, Association of Professors of Medicine Award

2007 Distinguished Physician Award, Chinese American Physician Society
2007 Robert Beamish Leadership Award, Inistitute of Cardiovascular Sciences
2010 McGill Alumni Global Life Achievement Award
2010 Research Achievement Award, American Heart Association
2010 Kuumba Award, Old North State Medical Society
2011 Henry G. Friesen International Prize in Health Research, Canadian Institutes of Health Research
2014 Distinguished Master Laureate, American Board of Cardiology
2014 Key to the City of Durham, presented by Mayor Bell
2014 Order of the Long Leaf Pines, North Carolina, conferred by Governor McCory
2014 Outstanding Service Award, National University of Singapore
2014 Singapore National Day Public Service Medal conferred by President of Singapore
2015 Medal of Honor, University of Illinois at Chicago College of Medicine
2015 Asian American Corporate Directors' Award
2015 Project HOPE Global Health Partnership Award
2015 Rotary Club of Durham Community Service Award
2015 McGovern Medal, Association of American Colleges of Nursing
2015 100 Most Influential People in Healthcare, Modern Healthcare
2015 50 Most Influential Physician Executives and Leaders, Modern Healthcare
2016 100 Most Influential People in Healthcare, Modern Healthcare
2016 50 Most Influential Physician Executives and Leaders, Modern Healthcare
2018 Inaugural National Award for Outstanding Leadership in Support of Clinician Well-Being, Ohio State University
2019 Honorary Citizen Award (the highest level of honor bestowed to a foreign citizen conferred by the President of Singapore), Singapore
2019 Foreign Member, Chinese Academy of Engineering
2020 Detlev Ganten Excellence Award in Hypertension and Global Health Implementation, World Hypertension League
2020 Honorary Member, The Japan Academy
2021 Dean's Distinguished Gold Medal for Science and Public Service, University of Maryland School of Medicine
2021 Honoree, Bicentennial Gala Dinner, McGill University
2022 Porter Prize, University of Pittsburgh Graduate School of Public Health

Honors at Harvard, Duke, and Stanford Universities

2005 Victor J Dzau Lectureship in Global Health, Brigham & Women's Hosp, Harvard Medical School
2007 Victor J Dzau Endowed Chair in Medicine (Dzau Professor of Medicine), Harvard University
2014 Victor J Dzau Award in Graduate Medical Education Innovation, Duke University Health System
2014 Victor J Dzau Award in Patient Advocacy, Duke University Health System
2014 Victor J Dzau MD Lobby, Duke Medicine Pavillion
2017 Victor J Dzau Lectureship in Global Health, Duke Univeristy
2018 Victor J Dzau Distinguished Lectureship in Population & Global Health, McGill University
2020 Victor J Dzau Distinguished Lecture in Cardiovascular Medicine, Stanford University
2020 Victor J Dzau Lecture Series in Cardiovascular Research, Duke University

Named Lectureships

1987 Pfizer Lectureship in Clinical Pharmacology, University of Vermont, Burlington, VT
1987 Pfizer Lectureship in Clinical Pharmacology, Washington University, St. Louis, MO
1989 Sir George Pickering Memorial Lecturer, British Hypertension Society
1990 William Goldring Memorial Lecture, New York University, New York, NY
1990 Robert H. Lyons Memorial Lecture, State University of New York, Syracuse, NY

1992 Borun Visiting Professorship and Lectureship, Division of Cardiology, UCLA, Los Angeles, CA
1992 25th Annual George C. Griffith Lectureship, American Heart Association, Los Angeles, CA
1992 Peter T. Bohan Lectureship, Department of Pharmacology, University of Kansas Medical Center, Kansas City, MO
1993 Hans Hecht Memorial Lectureship, Division of Cardiology, University of Chicago, Chicago, IL
1994 Ira Pores Memorial Lectureship, Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ
1994 S. Gilbert Blount Lectureship, Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO
1994 Simon Dack Visiting Professorship, Mount Sinai Medical Center, New York, NY
1995 Hong Kong Heart Foundation Lectureship, Hong Kong
1995 Arnold H. Blaufuss Memorial Lecture, Saint Agnes Hospital and the American Heart Association, Fresno, CA
1995 Calabresi Lectureship, Yale University School of Medicine, New Haven, CT
1995 First James O. Davis Distinguished Graduate Lectureship, University of Missouri, Columbia, MO
1995 Leonard Share Distinguished Lectureship, University of Tennessee, Memphis, TN
1996 Kaiser-Permanente Distinguished Lecture, Santa Clara, CA
1996 Rose Weiss Visiting Professor, Lahey Clinic, Burlington, MA
1996 Grollman Lectureship, University of Virginia, Charlottesville, VA
1996 Helen M. Ranney Lecturer, University of California, San Diego School of Medicine, San Diego, CA
1996 Bloomfield-Arnold Lectureship, Case Western Reserve University, Cleveland, OH
1997 Parker B. Francis Lectureship, Thomas L. Petty Aspen Lung Conference, Aspen, CO
1997 Howard Hughes Visiting Professor, University of Florida, Gainsville, FL
1997 Morton Memorial Lecture, Columbia Cedars Medical Center, Miami, FL
1997 Annual Hamilton Southworth Memorial Lecture, College of Physicians and Surgeons of Columbia University, New York, NY
1997 Harrington Visiting Professor, University of Miami, FL
1997 Schueler Distinguished Lecture in Pharmacology, Tulane University, New Orleans, LA
1997 Robert R. Linton Distinguished Address, New England Society for Vascular Surgery, Sagamore Resort, Lake George, NY
1997 Amy Crockcraft Lecturer, University of South Carolina School of Medicine
1997 Arvilla Berger Lecture, American College of Cardiology (New York Chapter) and New York Cardiological Society, New York, NY
1998 42nd James B. Herrick Lectureship of the American Heart Association, Chicago, IL
1998 Isadore E. Smith Lecturer, 9th Annual Scientific Symposium, Centre for Cardiovascular Research, University of Toronto, Canada
1998 35th Mikamo Memorial Lecture, Japanese Circulation Society, Tokyo, Japan
1998 Frank Norman Wilson Lecture, University of Michigan, Ann Arbor, MI
1998 The Robert Tigerstedt Lecture, 100 Years Robert Tigerstedt Memorial Symposium on Discovery of Renin, Helsinki, Finland
1998 Euriclides de Jesus Zerbini Distinguished Presidential Lectureship, XII World Congress of Cardiology, Rio De Janiero, Brazil
1998 Quen San Nam Memorial Lecture, 9th International Conference, Federation of Chinese American and Chinese Canadian Societies, Los Angeles, CA.
1998 Heart and Stroke Foundation of Canada Lectureship, Canadian Cardiovascular Society, Ottawa, Canada
1999 6th Shin Kong Wu Ho-Su Memorial Lecture, Taipei, Taiwan
1999 Neufield Presidential Lecture, 8th International Congress on Cardiovascular Pharmacotherapy, Amsterdam, The Netherlands

1999 Bishop Lecturer, 48th Annual Scientific Session, American College of Cardiology, New Orleans, LA
1999 32nd Annual Nathan Kiven Oration, Miriam Hospital, Brown University, Providence, RI
1999 Don C. and George C. Sutton Memorial Millenium Lecture in Cardiology, Evanston, IL
1999 Arthur Gordon Lecture, University of California at Los Angeles Medical School, Los Angeles, CA
1999 37th Hugo Roessler Memorial Lecture, Temple University School of Medicine, Philadelphia, PA
1999 Millennium Lecture, Symposium on Cardiovascular Medicine in the Next Millenium, London, UK
2000 Tenth Annual Donald and Lois Roon Visiting Lecturer in Heart, Lung and Vascular Medicine, Scipps Clinic, La Jolla, CA
2000 Master Lecturer, European Conference on Management of Coronary Heart Disease, Nice, France
2000 Winans Visiting Professor, University of Texas, Southwestern, Dallas, TX
2000 Mark Brothers Lectureship, University of Indiana, Indianapolis, IN
2000 30th William McDonald Lecture, Heart and Stroke Foundation of Ontario and University of Toronto, Canada
2000 R.T. Hall Lecture, Australian and New Zealand Cardiac Society, Melborne, Australia
2000 Sir Thomas Lewis Lecturer, British Cardiac Society Annual Conference, Glasgow, Scotland
2001 Robert E. Flynn Lectureship, St. Elizabeth Medical Center, Tufts University, Boston, MA
2001 Theodore Cooper Lecturer, Hypertension, American Heart Association, New Orleans, LA
2001 Irwin R. Callen, M.D. Memorial Lectureship, Miami Heart Research Institute, Miami, FL
2001 Ricardo Podio Inaugural Lecture, XX Congreso Nacional Cardiologia, Argentina
2001 Jean and Ira Belfer Lecture, Johns Hopkins University, Baltimore, MD
2001 Irving H. Page Lecture, Cleveland Clinic, Cleveland, OH
2001 Gustav Nylin Honorary Lecture, Swedish Cardiovascular Meeting, Gothenburg, Sweden
2001 Gertrude and Florian Nelson Cardiovascular Research Lecture, American Heart Association and Center for Cardiorenal Research, University of Mississippi
2001 Laennec Society Lecture, Council of Clinical Cardiology, Annual Scientific Sessions, American Heart Association
2001 Paul Dudley White Lecture, Annual NY Conference, American College of Cardiology, NY
2001 Santa Fe Lecture, American College of Cardiology, Santa Fe, NM
2002 AΩA Visiting Professor, University of Southern Illinois
2002 AΩA Visiting Professor, University of Arkansas for Medical Sciences
2002 William Kelley Visiting Professor, University of Michigan, Ann Arbor, MI
2002 Tinsley Harrison Lecture and Visiting Professor, Vanderbilt University
2002 Eldon R. Smith Lecture in Cardiovascular Health, University of Calgary
2003 Lazaridis Lecture, Onassis Cardiac Surgery Center, Athens, Greece
2003 Aaron Feder Lecture and Visiting Professorship, Cornell Medical Center
2003 Third Annual Backer Memorial Lecture, St. Vincent's Medical Center, Bridgeport, CT
2004 James J. Smith Memorial Lecture, Department of Physiology, University of Wisconsin, Milwaukee, Wisconsin
2004 John J. Sampson Visiting Professor at the University of California, San Francisco
2004 Kenneth W.G. Brown Memorial Lecture, St. Michael's Hospital, Toronto, Canada
2004 Simon Dack Lecture, 2004 ACC Presidential Plenary Session, American College of Cardiology
2004 Jacques Genest, Sr., Landmark Lecture, 2004 Young Investigator Forum, Canadian Institute of Health Research, Winnipeg, Manitoba, Canada
2004 Berlin Lecture on Molecular Medicine, Berlin Germany
2005 Reves Lecture, Duke Heart Center, Duke University Medical Center, Durham, NC
2005 Jay Cohn Lecture, University of Minnesota, Minneapolis
2005 Leonard Leight Lecture, University of Louisville
2005 William McBride Memorial Lecture, COSEHC, Nashville, TN

2005 Maurice C. Pincoffs Lecture, University of Maryland, College Park, Maryland
2006 Carl J. Wiggers Memorial Lecture, American College of Cardiology, Cleveland, Ohio
2006 Robert Frye Lecture, Mayo Clinic, Rochester, Minnesota
2007 Simon Dack Lecture, Mount Sinai Medical Center, NY
2007 Neil Schulman Lecture, International Society of Hypertension in Blacks
2007 James T. Willerson Distinguished Lecture, University of Texas Health Sciences Center, Houston, TX
2007 Frances Feinberg Memorial Lecture, Northwestern University, Chicago, IL
2008 Inaugural Luis Melo Memorial Lecture, Queen's University, Kingston, Ontario
2009 25th Annual Edward Massie Lecturer, Washington University School of Medicine, St. Louis MO
2009 Case Western School of Medicine Dean's Distinguished Lecture, Case Western Reserve University, Cleveland, OH
2009 Philip Poole Wilson Memorial Lecture, Cardiovascular Research Institute, University of Glasgow
2009 Diane Wolf Memorial Inaugural Lecture, 3rd New York Sketal Biology & Medicine Conference, New York, NY
2011 Wilbert Keone Endowed Lecture, Ottawa Heart Institute, Ottawa, Canada
2011 George Stamatoyannopoulos Lecture, American Society of Gene & Cell Therapy
2011 Joseph Price Oration, American Gynecological & Obstetrical Society
2011 Luther Hodges Ethics Lecture, Rotary Club, Research Triangle, NC
2013 Maastrict University Lecture, Maastricht, Netherlands
2013 30th Lawrence Green Lecture, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
2014 Inaugral Chicago Scholar Lecture, University of Chicago & Northwestern University
2014 Leonard Leight Lecture, University of Louisville
2015 McGovern Leccture, Asssociation of American Colleges of Nursing
2015 Watson Lecture, University of Texas, Southwestern, Dallas
2016 George Altman Lecture, Beth Israel Deaconess Medical Center
2016 Andrew F. Holmes Dean of Medicine Distinction Lecture, McGill University
2016 Bernard Langer Lecture in Health Sciences, University of Toronto
2017 T.H. Seldon Memorial Lecture, International Anesthesia Research Society, Annual Meeting
2018 Li Dak Sum Lecture, Hong Kong
2018 Wilbert J. Keon Endowed Lectureship, University Lecture, Ottawa Heart Institute, Ottawa, ON, Canada
2018 Raymond C. Grandon Lecture, Jefferson College of Population Health, Philadelphia, PA
2018 Michael E. Johns Lecture on Health Care Policy, Johns Hopkins University
2018 Shun Hing Distingushed Lecture, Chinese University of Hong Kong
2018 Centennial William Harvey Lecture, Harvey Club, Western Ontario, Canada
2018 Wilder Penfield Lecture, Montreal Neurological Institute, McGill University
2018 200th Congregation, University of Hong Kong
2019 College of Medicine Alumni Council Latta Lecture, University of Nebraska, Omaha, NE
2019 Inaugural Gerald Choa Oration, Chinese University of Hong Kong
2019 Ignacio Chevaz Master Lecture, Sociedad Mexicana Cardiologia, XXXI Congress of Cardiology, Mexico
2019 Usher Annual Lecture, Usher Institute, The University of Edinburgh, Edinburgh, Scotland
2019 Frolich Lecture, UK Royal Society of Medicine, London, England
2020 DeLisa Lecture, International Society of Physical and Rehabilitation Medicine-Association of Academic Physiatrists
2021 Vivek H. Murthy Distinguished Lecture Series for Public Health Leadership
2021 Wilson Ko Memorial Leadership Lecture, Chinese American Medical Society

Keynote, Plenary and Distinguished Lectures

1981 Keynote speaker, Maine High Blood Pressure Council, Annual Meeting
1984 State of the Art speaker, International Society of Hypertension, Switzerland
1984 State of the Art speaker, International Congress of Endocrinology, Quebec
1986 Invited State of the Art speaker, Tenth National Congress of Cardiology, Argentina
1986 Invited State of the Art lecturer, Annual Meeting of the American Society of Nephrology
1987 State of the Art lecture, Japan Endocrine Society Annual Meeting
1988 State of the Art Lecture, 42nd Annual Scientific Conference, Council of High Blood Pressure Research, American Heart Association
1989 State of the Art Lecture, InterAmerican Society of Hypertension
1989 Inaugural Lecturer, IV Jornada Integrada (Cardiology-Nephrology) in Arterial Hypertension, Brazil and InterAmerican Society of Hypertension
1990 State of the Art Lecture, International Society of Hypertension, Montreal
1991 Keynote speaker, American Heart Association Young Investigator's Conference, Asilomar, CA
1991 Distinguished Medical Lecturer, Mayo Clinic, Rochester, MN
1992 Inaugural Speaker, International Convention on Interventional Cardiology and Cardiac Surgery
1992 Plenary Speaker, Western Association of Physicians, Carmel, CA
1992 Plenary Lecturer, Zimmerman Conference on Vascular Biology, Hemostasis and Thrombosis, Scripps Research Institute, La Jolla, CA
1992 Special Lecturer, American College of Cardiology, Fourth Annual Advances in Diagnostic and Therapeutic Cardiac Catheterization, Orlando, FL
1992 Featured Speaker, National Meeting of American Federation of Clinical Research/American Society of Clinical Investigation/American Association of Physicians, Baltimore, MD
1993 Keynote speaker, American College of Cardiology, Peripheral Artery Disease: Contemporary Strategies for Diagnosis and Therapy
1993 Keynote speaker, Inauguration of Vascular Biology and Medicine Seminar Series and the Vascular Medicine Center, University of Texas Health Sciences Center, Houston, TX
1993 Featured Speaker, Meet the Investigator, "Is Triple Threat Possible in This Era?" Association of American Physicians, American Society for Clinical Investigation, and the American Federation for Clinical Research, Washington, D.C.
1994 Plenary Speaker: Gene Therapy, 6th Annual California State University Biotechnology Symposium, Pomona, CA
1994 Plenary Speaker: Western Society of Pharmacology, "Angiotensin receptor antagonists: basic science and clinical efficacy," Kona, HI
1994 Plenary Lecturer, Gene Therapy for Cardiovascular Disease. Third International Symposium on Multiple Risk Factors, Florence, Italy
1995 Keynote Speaker, The Stanley J. Sarnoff Endowment for Cardiovascular Science Annual Meeting, Washington, D.C.
1995 Plenary Speaker, Tsumagoi Conference, Japan
1996 Keynote Speaker, 6th International Congress on Cardiovascular Pharmacotherapy, Sydney, Australia
1996 Plenary Lecture, International Society of Nephrology, Snowbird, UT
1996 Keynote Speaker, Annual National Meeting of Chinese American Medical Students Society
1996 Plenary lecture, 4th International Conference on Preventive Cardiology, Montreal, Canada
1997 Plenary Speaker, XIV International Congress of Nephrology, Sydney, Australia
1997 Distinguished Basic Research Lecture, American College of Cardiology, Bethesda, MD
1997 Distinguished Basic Science Lecture, National Heart Lung Institute & Imperial College of Medicine, United Kingdom
1997 The Inaugural Lecture, The First Meeting of the Japanese Society of Cardiovascular Endocrinology and Metabolism.

1997 Special Memorial Lecture in Honor of Dr. Edgar Haber, 9th International Symposium on SHR and Cardiovascular Genetics
1998 Distinguished Lecturer, Spaulding Rehabilitation Hospital, Boston, Massachusetts
1998 Special Lecture: Gene Therapy for Revascularization, 10th Annual Advances in Diagnostic and Therapeutic Cardiac Catherization, American College of Cardiology
1998 Plenary Lecture, International Society of Hypertension in Blacks (ISHIB), Charleston, SC
1998 State of the Art Lecture, 52nd Annual Conference and Scientific Sessions of the Council of High Blood Pressure Research, American Heart Association
1998 Keynote Speaker, 100th Anniversary Joslin Diabetes Center Symposium, Boston, MA
1999 Presidential Basic Science Lecturer, The American Association for Thoracic Surgery Annual Meeting, New Orleans, LA
1999 ASH Special Awards Lecture, The Fourteenth Scientific Meeting of the American Society of Hypertension, New York, NY
2000 Distinguished Medical Lecturer, Mayo Clinic, Rochester, MN
2000 State of the Art Lecture, International Society of Hypertension, Chicago, IL
2000 Keynote Speaker, University of Massachusetts Medical School 30th Year Symposium, Worcester MA
2001 Plenary Lecture, Japanese Circulation Society, Kyoto, Japan
2001 Keynote Lecture, 10th International Congress of Cardiovascular Pharmacotherapy, Kyoto, Japan
2001 Inaugural Lecture of the British Heart Foundation Glasgow Cardiovascular Center, Glasgow, Scotland, UK
2001 Special Lecture, Japanese Hypertension Society, Osaka, Japan
2002 State of the Art Lecture, ACCIS, 52nd Annual Scientific Sections, American College of Cardiology, Atlanta, GA
2002 Keynote Lecture, TCT Scientific Congress, Washington, DC
2003 Distinguished Lecture on Regenerative Medicine in Cardiovascular Disease, XXV Annual Meeting of the International Society for Heart Research
2004 Presidential Lecture, 77th Annual Meeting of the Japanese Endocrine Society, Kyoto, Japan
2006 Keynote Lecture, Paul Dudley White Society, University of Michigan Health System, Ann Arbor, MI
2006 Keynote Lecture, International Society of Hypertension, Fukuoko, Japan
2007 Plenary Lecture, American Society of Hypertension
2007 Opening Lecture, International Society of Hypertension in Blacks
2007 Plenary Lecture, AACC
2008 Distinguished Lecture Series, North Carolina Central University, Biomedical/Biotechnology Research Institute
2008 Commencement speaker, McGill University Health Sciences Graduation
2009 Panel Moderator, WEF Annual Meeting, Davos, Switzerland
2009 Panel Moderator, Academic Health Science International Panel for the Department of Health, London, England
2009 Keynote Address, AHSC, King's College, London, England
2009 Guest Speaker, Keystone Symposium, Aspen, Colorado
2009 Keynote Speaker, AAHC International Forum, Washington, DC
2009 Panel Moderator, Brookings Academic Medical Center Advisory Board,
2009 Keynote Speaker, Strategy & Governance in European Academic Medical Centres, Amsterdam
2009 Keynote Speaker, Aspen Health Forum, Aspen, Colorado
2009 Panelist, World Health Executive Forum, Quebec, Canada
2010 Keynote Speaker, Macy Foundation Meeting, New York, NY
2010 Guest Speaker, Royal Canadian Institute, Toronto, Canada
2010 Guest Speaker, Economic Forecast Forum – North Carolina Chamber
2010 President's Lecture, Robert Wood Johnson Foundation, Princeton, NJ

2010 Distinguished Presenter, 2010 Healthcare Conference, CXO Summit, Boca Raton, Florida
2010 Keynote Speaker, 6th International Congress of Pathiophysiology, Montreal, Canada
2010 Guest Presenter/Discussion Leader, World Economic Forum, Industry Partnership Stragtegists Meeting for Health, New York, NY
2010 Panelist, Global Health Services Research Forum, World Economic Forum, Montreux, Switzerland
2010 Keynote Speaker, University of Toronto Academic Physicians, Toronto, Canada
2010 Keynote Speaker, East Coast Healthcare Executive Summit, New York, NY
2011 Keynote Speaker, University of California Retreat, San Francisco, CA
2011 Featured Speaker, Council of Academic Societies (AAMC), Providence, RI
2011 Guest Speaker, RTP Rotary Club-Luther Hodges Ethics Luncheon, RTP, NC
2011 Panelist, North Carolina Biotechnology Center State Capitol Group Meeting, Charlotte, NC
2011 Opening Address, AAHC International Forum, Washington, DC
2011 Panelist, International Review Panel, Canadian Institute of Health Research, Ottawa, Canada
2011 Keynote Speaker, World Healthcare Congress, World Health Innovations Summit, Washington, DC
2011 Panelist, National Research Forum, Washington Press Club, Washington, DC
2011 Panelist, Atlantic Healthcare Forum, Washington, DC
2011 Panelist, United Therapeutics Scientific Advisory Board Meeting, RTP, NC
2011 Panelist, National Network for Health Innovations Annual Meeting, Boston, MA
2011 Keynote Speaker, McKinsey Forum for Health, Geneva, Switzerland
2011 Special Speaker, International Symposium on Clinical Investigation, University of Kyoto, Kyoto, Japan
2011 Featured Speaker, 43rd Japanese Arteriosclerosis Society, Sapporo, Japan
2011 Guest Lecturer, SPDM International Forum, Sao Paulo, Brazil
2011 Guest Speaker, 2011 North Carolina CEO Forum, Cary, NC
2011 Keynote Speaker, Academic Health System Launch, Doha, Qatar
2011 Panelist, World Health Care Congress, Abu Dhabi
2011 Keynote Speaker, Stanford Cardiovascular Institute Annual Retreat, Palo Alto, California
2011 Keynote, Speaker, Summit on Academic Health, Melbourne, Australia
2012 Keynote speaker, 100th Anniversary of Peking University Health Sciences Center
2012 Keynote speaker, 60th Anniversary of Shanghai Jiao tao University
2012 Global Health Policy Summit, Imperial College & Qatar Foundation
2012 Keynote Speaker, Association of Academic Health Centers, International Forum, Shanghai, China
2012 Panelist, World Health Care Congress, Washington, DC
2012 Panelist, World Economic Forum, Davos, Switzerland
2012 Moderator, White House Conference,
Educating & Training Clinicians for a Transformed Delivery System, Washington
2013 Major Health Reform Conference, Healthy Innovations, London, UK
2013 Keynote Speaker, AAHC International Forum, Doha, Qatar
2013 Health Industry Forum, Washington, DC
2013 Keynote Speaker, Aspen Institute Regional Meeting, Raleigh, NC
2013 Keynote Speaker, RNA therapeutics, Cold Spring Harbor, NY
2013 Moderator and Panelist, World Economic Forum, Davos, Switzerland
2013 Chair, Panel on Innovation in Health Delivery, World Innovation Summit in Health, Qoha, Qatar
2014 Moderator and Panelist, World Economic Forum, Davos, Switzerland
2014 Commencement speaker, Graduation, Northeastern Univeristy
2014 Keynote Opening speaker, Summit on Human Genomics & Personalized Medicine, Qatar
2014 Keynote speaker, 100th Anniversary Celebration, China Medical Board, Beijing, China
2015 USAID Bureau on Global Health Distinguished Speaker Series, Washington, DC

2015 Medal of Honor Lecture, University of Illinois, Chicago
2015 Commencement speaker, University of Massachusetts Medical School
2015 10th Anniversary International Lecture, Canadian Academy of Health Sciences
2015 Founder's Lecture, Society for Vascular Medicine's Scientific Sessions, Baltimore, MD
2016 1st Global Ministerial Summit on Patient Safety, London, UK
2016 International Master Lecture, Sun Yat Sen University,Guangzhou, China
2017 Keynote Lecture, 2nd Global Ministerial Summit on Patient Safety, Bonn, Germany
2017 Commencement speaker, University of South Florida
2017 Commencement speaker, Case Western Reserve School of Medicine, Cleveland, OH
2017 Keynote speaker, Stanford China Cardiovascular Research Symposium
2018 Keynote Lecture, 3rd Global Ministerial Summit on Patient Safety, Tokyo, Japan
2018 Commencement speaker, Ross University
2018 Keynote, International Society of Hypertension, Beijing, China
2018 200th Congregation Speaker, Hong Kong University, Faculty of Medicine
2019 Keynote, Sarnoff Cardiovascular Research Foundation 39th Annual Scientific Meeting, Boston, MA
2019 Keynote, Global CardioVascular Clinical Trialists Forum, Washington, DC
2020 Keynote, 16th Annual Meeting, Broad Stem Cell Research Center, University of California, Los Angeles
2020 Keynote, Music Festival for Brain Health, OneMind
2020 Plenary Lecture, Heart Failure Society of America
2020 Keynote, Global Health Day, Institute for Global Health, Feinberg School of Medicine, Northwestern University
2021 Commencement speaker, University of Maryland School of Medicine
2021 Commencement speaker, Boston University
2022 Presidential Lecture, Association of University Cardiologists

Official Visiting Professorships

1985 Visiting Professor of Pharmacology, Department of Pharmacology, Osaka City University Medical School, Osaka City, Japan
1989 Visiting Professor of Cardiology, Mt. Sinai Hospital and School of Medicine
1990 William N. Creasy Visiting Professor of Medicine and Pharmacology, Creighton University Medical Center
1990 Visiting Professor of Medicine, Department of Medicine, Duke University Medical Center
1991 Cardiovascular Fellows' Visiting Professor, Mayo Clinic, Rochester, MN
1992 Borun Visiting Professor, University of California, Los Angeles, CA
1992 Peter T. Bohan Visiting Professor of Pharmacology, University of Kansas, Kansas City, MO
1992 George C. Griffith Visiting Professor, Cedars-Sinai Medical Center, Los Angeles, CA
1992 George C. Griffith Visiting Professor, University of Southern California, Los Angeles, CA
1992 Visiting Professor of Cardiology, University of Michigan, Ann Arbor, MI
1993 Hans Hecht Professor, Division of Cardiology, University of Chicago
1993 Pfizer Visiting Professor in Cardiovascular Medicine, Baylor University, Houston, TX
1994 S. Gilbert Blount Professor, University of Colorado, Denver, CO
1994 Ira Pores Memorial Visiting Professor, Beth Israel Hospital, Newark, NJ
1994 Simon Dack Visiting Professor, Mount Sinai Medical Center, New York, NY
1995 Calabresi Visiting Professor, Yale University School of Medicine, New Haven, CT
1995 Rose Weiss Visiting Professor, Lahey Clinic, Burlington, MA
1995 First James O. Davis Distinguished Visiting Professor, University of Missouri, Columbia, MO
1995 Leonard Share Distinguished Visiting Professor, University of Tennessee, Memphis, TN
1995 Kaiser Permanente 1995 Distinguished Visiting Professor, Santa Clara, CA

1996 Marjorie and Jaye Grollman Visiting Professor, University of Virginia, Charlottesville, VA
1997 Amy Crockcroft Visiting Professor in Cardiology, University of South Carolina School of Medicine and Richland Memorial Hospital, Columbia, South Carolina
1998 Frank Norman Wilson Visiting Professor, University of Michigan, Ann Arbor, MI
1998 Annual Visiting Professor, Department of Medicine, University of Massachusetts, Worcester, MA
1999 Frederick M. Hanes Visiting Professor of Medicine, Duke University
2000 Burroughs Wellcome Visiting Professor in the Basic Medical Sciences, University of Western Ontario Faculty of Medicine, London, Ontario, Canada
2000 Winans Visiting Professor, University of Texas, Southwestern, Dallas, Texas
2001 Mark Brothers Lectureship, University of Indiana, Indianapolis
2002 Robert E. Flynn, MD, Visiting Professor, St. Elizabeth Medical Center, Boston, MA
2002 William Kelly Visiting Professor, University of Michigan, Ann Arbor, MI
2002 Tinsley Harrison Visiting Professor, Vanderbilt University, TN
2002 Eldon R. Smith Lecture in Cardiovascular Health, University of Calgary
2003 Lazaridis Lecture, Onassis Cardiac Surgery Center, Athens, Greece
2003 John J. Sampson Visiting Professor at the University of California, San Francisco
2003 Aaron Feder Lecture and Visiting Professorship, Cornell Medical Center
2003 Third Annual Backer Memorial Lecture, St. Vincent's Medical Center, Bridgeport, CT
2004 James J. Smith Memorial Lecture, Department of Physiology, University of Wisconsin, Milwaukee, Wisconsin
2004 John J. Sampson Visiting Professor at the University of California, San Francisco
2005 Jay Cohn Visiting Professor, University of Minnesota
2006 Robert Frye Visiting Professor, Mayo Clinic
2007 Simon Dask Visiting Professor, Mt. Sinai Medical Center, NY
2007 James T. Willerson Visiting Professor, University of Texas Health Sciences Center, Houston
2009 Massie Visiting Professor, Washington University, St. Louis, MO
2010 Visiting Professor in the Faculty of Medicine – University of Glasgow
2013 Visiting Professor, Maastricht University, Maastricht, Netherlands
2013 Larry Green Visiting Professor, Brigham & Women's Hospital, Boston, MA
2018 Wilbert J. Keon Endowed Visiting Professorship, Ottawa Heart Institute, Ottawa, ON, Canada
2018 Michael E. Johns Visiting Professorship, Johns Hopkins University
2018 Wilder Penfield Visiting Professorship, Montreal Neurological Institute, McGill University
2019 College of Medicine Alumni Council, University of Nebraska, Omaha, NE

Editorships and Editorial Board Memberships

Editor

1983-1988 Associate Editor, *Hypertension*
1987 Guest Co-Editor, Special NHLBI Supplement on "Cation Transport and Natriuretic Factors," *Hypertension*
1987 Guest Editor, Special Supplement, "Tissue Renin Angiotensin System: Physiological and Pharmacological Implications," *Circulation*
1989 Guest Editor, "Mechanisms of Selective Alpha 1-Inhibition on Lipid Metabolism," *Journal of Cardiovascular Pharmacology*
1989 Guest Editor, "Reduction in Blood Pressure and Coronary Heart Risk Factors Reduction: A Conjoint Approach," *American Journal of Medicine*
1989 Consulting Editor (Molecular Biology), *Hypertension*

1989-1992	Editor-in-Chief and Founding editor, *Journal of Vascular Biology and Medicine*
1993	Associate Editor, *American College of Cardiology Extended Learning, ACCEL*
1994-2001	Editor, *Receptors in Cardiovascular Disease*
1999-	Consulting Editor, *Hypertension*
1998-2003	Editor in Chief and Founding Editor, *Physiological Genomics* (American Physiological Society)
2013	Co- Editor in Chief and Founding Co-Editor, *Journal of Global Medical& Health Education* (Qatar Foundation)
2013-	Senior Consulting Editor, *Hypertension* , American Heart Association
2014-	Senior Consulting Editor, *Circulation Research*, American Heart Association

Editorial Board

1984-1988	Editorial Board member, *Journal of Clinical Hypertension*
1985	Editorial Board member, *Heart Failure*
1988-1990	Editorial Board Member, *Perspectives in Renal Disease and Hypertension*
1990-1993	Editorial Board Member, *Journal of Hypertension*
1990-1996	Editorial Advisory Board, *Choices in Cardiology*
1990-	Editorial Board Member, *Journal of Nutrition, Metabolism, and Cardiovascular Disease*
1990-	Editorial Board Member, *Trends in Cardiovascular Medicine*
1990-	Editorial Board Member, *Cardiovascular Pharmacology*
1991-1994	Board of Editors, Regional Editor for North America *Pharmaceutical and Pharmacological Letters*
1991-	Editorial Board Member, *Current Opinion in Nephrology and Hypertension*
1991-	Editorial Board Member, *Hypertension Research*
1991-	Editorial Board Member, *Journal of Cardiovascular Drugs and Therapy*
1991-	Editorial Board Member, *High Blood Pressure Research*
1992	Editorial Board Member, *The American Journal of Geriatric Cardiology*
1992	Editorial Board Member, *Blood Pressure*
1992	Advisory Board Member, *Endothelium*
1992	Editorial Board Member, *Heart and Vessels*
1992	Editorial Board Member, *Circulation*
1992	Editorial Board Member, *Journal of Hong Kong College of Cardiology*
1992	Editorial Board Member, *Journal of Cardiovascular Electrophysiology*
1993-1995	Editorial Board, *American College of Cardiology Extended Learning, ACCEL*
1993-1999	Editorial Board, *Journal of Cardiac Failure*
1994-1995	Editorial Board Member, *Journal of Heart Failure*
1994	Editorial Board, *The Journal of Molecular Medicine*
1994	Founding Member, *Society for Cardiovascular Disease in the Elderly*
1994-2000	Consulting Editor, *Circulation*
1994	Editorial Board Member, *Heart Failure Reviews*
1995-1998	Editorial Board Member, *American Journal of Physiology: Endocrinology and Metabolism*
1995	Consulting Editor, *Journal of Cardiovascular Pharmacology and Therapeutics*
1995	International Advisory Editorial Board Member, *European Heart Journal*
1995	Editorial Board, *Biology and Chemistry of Nitric Oxide*
1996	Editorial Board, *Nitric Oxide*
1996-1999	Consulting Editor, *Dialogues in Cardiovascular Medicine*
1997	Senior Editor, *Congestive Heart Failure*
1997	Consulting Editor, *Journal of the Hong Kong College of Cardiology*
1998	Editorial Board, *American Journal of Medicine*

1998	Editorial Board, *Current Treatment Options in Cardiovascular Disease*
1998	Editorial Advisory Board, *Journal of Cardiovascular Disease Prevention*
1998	Editorial Board Member, *European Heart Journal*
1999	Editorial Board, *Current Hypertension Reports*
1999-2000	Editorial Board, *The Journal of Heart Disease*
2000-2002	Editorial Board, *European Journal of Heart Failure*
2000	Editorial Board Member, *Journal of the Renin-Angiotensin-Aldosterone System*
2000	Editorial Board Member, *Molecular Therapy*
2000	Editorial Advisory Board, *REMEDICA Journal*
2000	Editorial Board, *Cardiac and Vascular Regeneration: Angiogenisis and Myogenesis*
2000	Editorial Board, *The Journal of Heart Failure*
2000	Editorial Board, *Current Drug Targets-Cardiovascular & Haematological Disorders*
2001-2004	Editorial Board Member, *Cardiovascular Drugs and Therapy*
2003	Editorial Board Member, *European Heart Journal*
2007-	Editorial Board Member, *Cardiovascular Drugs and Therapy*
2008-	Editorial Board Member, The Proceedings of the Chinese Academy of Sciences – Life Sciences
2008-	Editorial Board, Stem Cell
2011-present	Editorial Board Member, Stem Cells Translational Medicine
2015-	Editorial Advisory Board, TEDMED

Memberships in Professional Societies

1974	American Federation for Clinical Research
1976-	American Heart Association
1978	American Medical Association
1981	The Endocrine Society
1982-	American Physiological Society
1982	Fellow, Council for High Blood Pressure Research, American Heart Association
1982	Fellow, Council of Clinical Cardiology, American Heart Association
1983-	Fellow, American College of Cardiology (FACC)
1985	Fellow, Kidney Council, American Heart Association
1985	Fellow, Circulation Council, American Heart Association
1985	Fellow, Basic Science Council, American Heart Association
1986-	American Society of Clinical Investigation
1988	Founding Member and Board of Trustees, Society of Vascular Medicine and Biology
1990	Honorary Member, British Hypertension Society
1991-	Association of University Cardiologists
1991	Western Association of Physicians
1991-	Association of American Physicians
1992	California Academy of Medicine
1992	Association of Professors of Cardiology
1992	Honorary Member, Pan American College of Endothelium
1995	Honorary Fellow, Hong Kong College of Cardiology
1995-	Association of Professors of Medicine
1996	Interurban Clinical Club
1997	Founding Member, Heart Failure Society of America
1998-	Elected to Institute of Medicine, National Academy of Sciences (USA)
2000	Fellow, Royal College of Physicians and Surgeons (Glasgow)
2001	Elected to Academia Sinica (National Academy of Science), Republic of China
2001	Honorary Fellow, Royal Society of Medicine, London, UK
2001-	Elected to European Academy of Sciences and Arts

2005- Elected to North Carolina Institute of Medicine
2005- Association of Academic Health Centers
2007- Council for Entrepreneurial Development
2010- North Carolina Medical Society
2011- Fellow, Royal Society of Medicine, London, UK
2012 International Honorary Membership, Japanese Circulation Society
2012 Elected to American Academy of Arts and Sciences
2014 Fellow, National Academy of Inventors (NAI)
2015 Master of the Society for Vascular Medicine
2015 Fellow, American College of Physicians (ACP)
2017 Honorary Fellow, United Kingdom Academy of Medical Sciences
2018 Honorary Member, National Academy of Medicine, Mexico

Research Interests

1. Vascular biology
2. Molecular and cellular biology of cardiovascular diseases.
3. Pathophysiology and therapy of vascular disease, congestive heart failure, and hypertension.
4. Genetics and genomics of cardiovascular disease
5. Gene- and cell-based therapy of cardiovascular disease
6. Paracrine mechanism of stem cell biology & action
7. Direct reprogramming for tissue regeneration

Health Interests

1. Health Innovation
2. Healthcare Delivery Science
3. Translational Medicine
4. Global Health
5. Academic Health Systems
6. Health & Science Policy
7. Emerging Science & Technology

PUBLICATIONS

I Original Contributions

1. Kovacs K, Horvath E, Szabo S, **Dzau VJ**: Effect of vinblastine on neurohypophysial and adenohypophysial microtubules. *Steroid Lipid Res* 5:167-172, 1974.

2. Szabo S, Kovacs K, Horvath E, **Dzau VJ**: Vinblastine-induced ultrastructural changes in the rat adrenal cortex. *J Steroid Biochem* 5:311-312, 1974.

3. Kovacs K, Horvath E, Szabo S, **Dzau VJ**: Effects of vinblastine on the fine structure of rat adrenal cortex. *Horm Metab Res* 7:365-366, 1975.

4. Szabo S, Reynolds ES, Lichtenberger LM, Haith LR, **Dzau VJ**: Pathogenesis of duodenal ulcer. Gastric hyperacidity caused by propionitrile and cysteamine in rats. *Res Comm Chem Path Pharmacol* 16:311-323, 1977.

5. Kovacs K, Horvath E, Szabo S, **Dzau VJ**, Reynolds ES: Effect of vinblastine on rat liver ultrastructure. *Drug Res* 27:825-828, 1977.

6. Slater EE, Cohn RC, **Dzau VJ**, Haber E: Purification of human renal renin. *Clin Sci Molec Med* 55:117s-119s, 1978.

7. **Dzau VJ**, Slater EE, Haber E: Complete purification of dog renal renin. *Biochemistry* 18:5224-5228, 1979.

8. **Dzau VJ**, Kopelman RI, Barger AC, Haber E: Renin specific antibody for study of cardiovascular homeostasis. *Science* 207:1091-1093, 1980.

9. **Dzau VJ**, Brenner A, Emmett N, Haber E: Identification of renin and renin-like enzymes in rat brain by renin-specific antibody. *Clin Sci* 59:45s-47s, 1980.

10. **Dzau VJ**, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK: Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. *N Engl J Med* 302:1371-1379, 1980.

11. **Dzau VJ**, Siwek LG, Rosen S, Farhi ER, Mizoguchi H, Barger AC: Sequential renal hemodynamics in experimental benign and malignant hypertension. *Hypertension* 3:I-63-I-68, 1981.

12. Pratt R, **Dzau VJ**, Ouellette AJ: Abundant androgen regulated mRNAs in mouse submandibular gland: Cell free translation of renin precursor mRNA. *Nucleic Acid Res* 14:3433-3449, 1981.

13. **Dzau VJ**, Mudget-Hunter M, Kapler G, Haber E: Monoclonal antibodies binding renal renin. *Hypertension* 3:II-4 - II-8, 1981.

14. **Dzau VJ**, Ouellette AJ, Pratt R: Studies of the biosynthesis of renin using a cell-free translation system. *Clin Sci* 61:241s-243s, 1981.

15. **Dzau VJ**, Colucci WS, Williams GH, Hollenberg NK: Relation of renin-angiotensin-aldosterone to clinical state in congestive heart failure. *Circulation* 63:645-651, 1981.

16. Kaplan M, Larsen R, Crantz F, **Dzau VJ**, Rossing T: Prevalence of abnormal thyroid function tests in patients with acute medical illness. *Am J Med* 72:9-16, 1982.

17. **Dzau VJ**, Herrmann HC: Hormonal control of angiotensinogen production. *Life Sci* 30: 577-584, 1982.

18. Re RN, Fallon JT, **Dzau VJ**, Quay S, Haber E: Renin synthesis by canine aortic smooth muscle cells in culture. *Life Sci* 30:99-106, 1982.

19. **Dzau VJ**: Isolation and regulation of brain renin. *Exp Brain Res Suppl* 4:92-108, 1982.

20. **Dzau VJ**, Brenner A, Wolfsohn S, Haber E: Characterization of antibodies to canine renal renin. Studies of interspecies homology of renin using antibodies as probe. *Hypertension* 4:341-347, 1982.

21. **Dzau VJ**, Brenner A, Emmett NL: Evidence for renin in rat brain: Differentiation from other renin-like enzymes. *Am J Physiol* 242:E292-E297, 1982.

22. **Dzau VJ**, Sands K: Regulation of brain renin: Evidence for an independent brain renin. *Clin Sci* 63:163s-166s, 1982.

23. **Dzau VJ**, Tanaka A, Pratt RE: The nature of renin precursor and inactive renin. *Clin Exp Hypertens* 4:1973-1975, 1982.

24. Mizoguchi H, **Dzau VJ**, Siwek L, Barger AC: Effect of intrarenal administration of dopamine on renin release in conscious dogs. *Am J Physiol* 244:H39-H45, 1983.

25. Kopelman RI, **Dzau VJ**, Shimabukuro S, Barger AC: Compensatory response to hemorrhage in conscious dogs on normal and low salt intake. *Am J Physiol* 244:H351-H356, 1983.

26. Herrmann HC, **Dzau VJ**: Feedback regulation of angiotensinogen production by components of the renin-angiotensin system. *Circ Res* 52:328-334, 1983.

27. Hsueh WA, Carlson EJ, **Dzau VJ**: Characterization of inactive renin from human kidney and plasma: Evidence of a renal source of circulating inactive renin. *J Clin Invest* 71:506-517, 1983.

28. Ikemoto F, **Dzau VJ**, Haber E, Takaori K, Yamamoto K: Immunoaffinity chromatography of canine high-molecular-weight renin: Partial purification characterization. *Clin Sci* 65:117-120, 1983.

29. **Dzau VJ**, Devine D, Mudgett-Hunter M, Kopelman RI, Barger AC, Haber E: Antibodies as specific renin inhibitors: Studies with polyclonal and monoclonal antibodies and fab fragments. *Clin Exp Hypertens* A5:1207-1220, 1983.

30. Pratt RE, Ouellette AJ, **Dzau VJ**: Biosynthesis of renin: Multiplicity of active and intermediate forms. *Proc Natl Acad Sci USA* 80:6809-6813, 1983.

31. Ichikawa I, Ferrone RA, Cuchin KL, Manning M, **Dzau VJ**, Brenner BM: Relative contributions of vasopressin and angiotensin II in two kidney Goldblatt hypertension.*Circ Res* 53:592-602, 1983.

32. Hricik DE, Browning PJ, Kopelman RK, Goorno WE, Madias NE, **Dzau VJ**: Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in solitary kidney. *N Engl J Med* 308:373-376, 1983.

33. Captopril Multicenter Heart Failure Group: A placebo-controlled trial of captopril in refractory chronic congestive heart failure. *J Am Coll Cardiol* 2:755-763, 1983.

34. Given BD, Taylor T, Lilly LS, **Dzau VJ**: Symptomatic hypotension following clonidine suppression test for pheochromocytoma. *Arch Intern Med* 143:2195-2196, 1983.

35. **Dzau VJ**, Packer M, Swartz SL, Lilly LS, Hollenberg NK, Williams GH: Prostaglandins in heart failure: Relationship to renin-angiotensin system and hyponatremia. *N Engl J Med* 310:347-352, 1984.

36. **Dzau VJ**: Vascular wall renin-angiotensin pathway in control of the circulation. A hypothesis. *Am J Med* 77:31-36, 1984.

37. Given BD, Phillippe M, Sander Sp, **Dzau VJ**: Procainamide cardioversion of fetal supra-ventricular tachyarrhythmia. *Am J Cardiol* 53:1460-1461, 1984.

38. **Dzau VJ**, Hollenberg NK: Renal response to captopril in severe heart failure: Role of furosemide in natriuresis and reversal of hyponatremia. *Ann Intern Med* 100:777-782, 1984.

39. Lilly LS, **Dzau VJ**, Williams GH, Rydstedt L, Hollenberg NK: Hyponatremia in congestive heart failure: Implications for neurohormonal activation and responses to orthostasis. *J Clin Endocrinol Metab* 59:924-930, 1984.

40. **Dzau VJ**, Kopelman RI, Barger AC, Haber E: Comparison of renin-specific IgG and antibody fragments in studies of blood pressure regulation. *Am J Physiol* 246:H404-H409, 1984.

41. Wintroub BU, Klickstein LB, **Dzau VJ**, Watt WK: Granulocyte-angiotensin system: Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. *Biochem* 23:227-232, 1984.

42. Pratt RE, **Dzau VJ**: Purification and characterization of one- and two-chain renins of mouse submandibular gland. *Hypertension* 6(suppl I):I-101-I-105, 1984.

43. Husain A, Smeby R, Wiek D, **Dzau VJ**, Bumpus FM: Biochemical and immunological properties of dog brain isorenin. *Endocrinology* 114:2210-2215, 1984.

44. Pratt RE, **Dzau VJ**, Ouellette AJ: Influence of androgen on translatable renin mRNA in mouse submandibular gland. *Hypertension* 6:615-621, 1984.

45. **Dzau VJ**, Ellison KE, McGowen D, Gross KW, Ouellette AJ: Hybridization studies with a renin cDNA probe: Evidence for widespread expression of renin in the mouse. *J Hypertension* 2(suppl 3):235-237, 1984.

46. **Dzau VJ**, Devine D, Mudgett-Hunter M, Haber E: Monoclonal antibodies specific for human renin. *Trans Assoc Am Phys* 97:146-150, 1984.

47. Husain A, Wilk D, Smeby RR, **Dzau VJ**, Bumpus FM: Isorenin in dog brain and other tissues. *Clin Exp Hypertension* A6 (10 & 11):1795-1799, 1984.

48. **Dzau VJ**: *In vivo* inhibition of renin by antirenin antibodies: Potential experimental and clinical applications. *J Cardiovasc Pharm* 7(suppl 4):S53-S57, 1985.

49. Lilly LS, Pratt RE, Alexander RW, Larson DM, Ellison KE, Gimbrone MA, **Dzau VJ**: Renin expression by vascular endothelial cells in culture. *Circ Res* 57:312-318, 1985.

50. Quay SC, Heropoulos A, Commes K, **Dzau VJ**: Probing the renin active site by collisional quenching of endogenous fluorescence. *J Biol Chem* 260:15055-15058, 1985.

51. Given BD, Lee TH, Stone PH, **Dzau VJ**: Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. *Arch Int Med* 145:281-283, 1985.

52. Chatterjee K, Parmley WW, Cohn JN, Levine TB, Awan NA, Mason DT, Faxon DP, Creager M, Gavras HP, Fouad FM, Tarazi RC, Hollenberg NK, **Dzau V**J, Lejemtel TH, Sonnenblick EH, Turini GA, Brunner HR: Captopril Multicenter Research Group: I. A cooperative multicenter study of captopril in congestive heart failure: Hemodynamic effects and long-term response. *Am Heart J* 110: 439-447, 1985.

53. Given BD, Vita NA, Black HR, Francis C, Lasseter K, Morray RL, Mickiewicz C, Akester J, Koury K, **Dzau VJ**: Prostaglandin E2 analog elicits renal and hormonal compensatory mechanisms in human hypertension. *Hypertension* 8:489-496, 1986.

54. Naftilan AJ, **Dzau VJ**, Loscalzo J: Preliminary observations on abnormalities of membrane structure and function in essential hypertension. *Hypertension* 8:II-174-II-179, 1986.

55. Shemin RJ, Phillippe M, **Dzau V**: Acute thrombosis of a composite ascending aortic conduit containing a Bjork-Shiley valve during pregnancy: Successful emergency Caesarian section and operative repair. *Clin Cardiol* 9:299-301, 1986.

56. **Dzau VJ**, Wilcox CS, Sands K, Dunckel P: Dog inactive renin: Biochemical characterization and secretion into renal plasma and lymph. *Am J Physiol* 250:E55-E61, 1986.

57. Rogart RB, deBruyn Kops A, **Dzau VJ**: Identification of two calcium channel receptor sites for [3H]nitrendipine in mammalian cardiac and smooth muscle membrane. *Proc Natl Acad Sci USA* 83:7452-7456, 1986.

58. **Dzau VJ**, Mudgett-Hunter M, Haber E: Monoclonal antibodies as molecular probes to study structural heterogeneity between human and animal renins and other aspartyl proteinases. *J Clin Endocrin Metab* 62:424-428, 1986.

59. Ingelfinger JR, Pratt RE, Ellison KE, Roth TP, **Dzau VJ**: Multiple sites of regulation of mouse renin expression in ontogeny. *Clin Exp Hypertens* 8(4-5):687-694, 1986.

60. Fritz LC, Arfsten AA, **Dzau VJ**, Atlas SA, Baxter JD, Fiddes JC, Shine J, Cofer CL, Kushner P, Ponte PE: Characterization of human prorenin expressed in mammalian cells transfected with cloned cDNA. *Proc Natl Acad Sci USA* 83:4114-4118, 1986.

61. Day RP, Hui KY, Gune M, Carlson WJ, **Dzau VJ**, Haber E: A monoclonal antibody specific for the amino terminal sequence of human prorenin identifies a common epitope on renal and amniotic fluid inactive renins. *J Hypertension* 4:375-381, 1986.

62. **Dzau VJ**, Ingelfinger JR, Pratt RE, Ellison KE: Identification of renin and angiotensin messenger RNA sequences in mouse and rat brains. *Hypertension* 8:544-548, 1986.

63. Ingelfinger JR, Pratt RE, Ellison K, **Dzau VJ**: Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. *J Clin Invest* 78:1311-1315, 1986.

64. **Dzau VJ**, Ingelfinger JR, Pratt RE: Regulation of tissue renin and angiotensin gene expressions. *J Cardiovasc Pharm* 8(suppl 10):S11-S16, 1986.

65. **Dzau VJ**, Kriesberg J: Cultured glomerular mesangial cells contain renin: Influence of calcium and isoproterenol. *J Cardiovasc Pharm* 8(suppl 10):S6-S12, 1986.

66. Ingelfinger JR, Pratt RE, Ellison K, **Dzau VJ**: Angiotensin mRNA is expressed in renal cortex and medulla. *J Hypertension* 4(suppl 6):S434-S436, 1986.

67. Paganelli WC, Cant JR, Barger AC, **Dzau VJ**: Influence of acute changes in atrial pressures of plasma natriuretic factor in the conscious dog. *J Hypertension* 4(suppl 6):S516-S518, 1986.

68. Pratt RE, Carleton JE, Heusser C, Ritchie J, **Dzau VJ**: Biosynthesis of multiple forms of renin in human kidney. *J Hypertension* 4(suppl 6):S456-S458, 1986.

69. **Dzau VJ**, Robertson JIS, Richards AM, Gaines Das RE, Poole S: International collaborative study of the proposed international standard for atrial natriuretic factor. Interim report. *J Hypertension* 4(suppl 6):S483-S485, 1986.

70. Hirsch AT, **Dzau VJ**, Creager MA: Baroreceptor function in congestive heart failure: Effect on neurohumoral activation and regional vascular resistance. *Circulation* 75:36-40, 1987.

71. Nabel EG, Colucci WS, Lilly LS, Cutler SS, Majzoub JA, St John Sutton MG, **Dzau VJ**, Creager MA: Relationship of cardiac chamber volume to baroreflex activity in normal humans. *J Clin Endocrinol Metab* 65:475-481, 1987.

72. **Dzau VJ**, Swartz SL: Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. *Am J Cardiol* 60:1101-1105, 1987.

73. **Dzau VJ**, Gonzalez D, Ellison K, Churchill S, Emmett N: Characterization of purified rabbit uterine renin: Influence of pregnancy on uterine inactive renin. *Endocrinology* 120: 358-364, 1987.

74. **Dzau VJ**, Re RN: Evidence for the existence of renin in the heart. *Circulation* 73:I-134 - I-136, 1987.

75. **Dzau VJ**, Gonzalez D, Kaempfer C, Dubin D, Wintroub BU: Human neutrophils release serine proteases capable of activating prorenin. *Circ Res* 60:595-601, 1987.

76. **Dzau VJ**, Ellison KE, Brody T, Ingelfinger J, Pratt RE: A comparative study of the distributions of renin and angiotensin messenger ribonucleic acids in rat and mouse tissues. *Endocrinology* 120:2334-2338, 1987.

77. **Dzau VJ**: Possible prorenin activating mechanisms in the blood vessel wall. *J Hypertension* 5(suppl 2):515-518, 1987.

78. Kifor I, **Dzau VJ**: Endothelial renin-angiotensin pathway: Evidence for intracellular synthesis and secretion of angiotensins. *Circ Res* 60:422-428, 1987.

79. **Dzau VJ**, Brody T, Ellison KE, Pratt RE, Ingelfinger JR: Tissue specific regulation of renin expression in the mouse. *Hypertension* 9:III-36-III-41, 1987.

80. Farhi ER, Cant JR, Paganelli WC, **Dzau VJ**, Barger AC: Stimulus-response curve of the renal baroreceptor: Effect of converting enzyme inhibition and changes in salt intake. *Circ Res* 61:670-677, 1987.

81. Wood J, Carleton J, Baum HP, **Dzau VJ**: Inhibition of renin-like activity in marmoset tissues by the renin inhibitor CGP 29 287. *J Hypertension* 5(suppl 2):567-569, 1987.

82. Pratt RE, Carleton JE, Richie JP, Heusser C, **Dzau VJ**: Human renin biosynthesis and secretion in normal and ischemic kidneys. *Proc Natl Acad Sci USA* 84:7837-7840, 1987.

83. Chui PJS, Vemulapalli S, Policelli M, Kifor I, Sybertz EJ, **Dzau VJ**: The response of atrial natriuretic factor concentrations to acute volume changes in conscious rats. *Life Sci* 41:2339-2347, 1987.

84. **Dzau VJ**: Molecular studies of human renin structure and synthesis using monoclonal antibodies. *Clin Exp Hypertension* A9(8&9):1291-1304, 1987.

85. Creager MA, Hirsch AT, Nabel EG, Cutler SS, Colucci WS, **Dzau VJ**: Responsiveness of atrial natriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. *J Am Coll Cardiol* 11:1191-1198, 1988.

86. Ingelfinger JR, Pratt RE, **Dzau VJ**: Regulation of extra-renal renin during ontogeny. *Endocrinology* 122:782-786, 1988.

87. Paganelli WC, Cant JR, Pintal RR, Kifor I, Barger AC, **Dzau VJ**: Plasma atrial natriuretic factor during chronic thoracic inferior vena caval constriction. *Circ Res* 62:279-285, 1988.

88. Pratt RE, Flynn JA, Hobart PM, Paul M, **Dzau VJ**: Different secretory pathways of renin from mouse cells transfected with human renin gene. *J Biol Chem* 262:3137-3141, 1988.

89. **Dzau VJ**, Pratt RE: Renin gene expression, biosynthesis, and cellular pathways of secretion. *Clin Physiol Biochem* 6:210-216, 1988.

90. Paul M, Nakamura N, Pratt RE, **Dzau VJ**: Glycosylation influences intracellular transit time and secretion rate of human prorenin in transfected cells. *J Hypertension* 6(suppl 4): S487-S489, 1988.

91. Tang SS, **Dzau VJ**: Partial purification and characterization of a prorenin-activating enzyme in the bovine aorta. *Clin Exp Hypertens*ion A10:1251-1257, 1988.

92. Burt DW, Nakamura N, Kelley P, **Dzau VJ**: Functional human renin promoter in transfected cells: Evidence for cell-specific expression. *J Hypertension* 6(suppl 4):S429-S431, 1988.

93. Paul M, Burt DW, Nakamura N, Pratt RE, **Dzau VJ**: Mapping of the human renin transcription start site: Evidence for a single functional promoter. *Clin Exp Hyperten* A10: 1313-1316, 1988.

94. Pratt RE, Burt DW, Nakamura N, Paul M, **Dzau VJ**: Identification of potential regulatory regions in the renin gene. *Clin Exp Hyperten* A10:1141-1146, 1988.

95. Pratt RE, Carleton JE, Roth TP, **Dzau VJ**: Evidence for two cellular pathways of renin secretion by the mouse submandibular gland. *Endocrinol* 123:1721-1727, 1988.

96. **Dzau VJ**, Roth T, Gonzalez D: Endothelial derived prorenin activating enzyme. *J Vasc Med Biol* 1:13-17, 1989.

97. Nakamura N, Burt DW, Paul M, **Dzau VJ**: Negative control elements and cAMP responsiveness sequences in the tissue specific expression of mouse renin genes. *Proc Natl Acad Sci USA* 86:56-59, 1989.

98. Burt DW, Nakamura N, Kelley P, **Dzau VJ**: Identification of negative and positive regulatory elements associated with the human renin gene. *J Biol Chem* 264:7357-7362, 1989.

99. Pratt RE, Zuo WM, Naftilan AJ, Ingelfinger JR, **Dzau VJ**: Altered sodium regulation of renal angiotensinogen mRNA in the spontaneously hypertensive rat. *Am J Physiol* 256: F469-F474, 1989.

100. Naftilan AJ, Pratt RE, **Dzau VJ**: Induction of PDGF A-chain and c-myc gene expressions by angiotensin II in cultured vascular smooth cells. *J Clin Invest* 83:1419-1424, 1989.

101. Tang SS, Loscalzo J, **Dzau VJ**: Tissue plasminogen activator activates renin angiotensin system in vitro. *J Vasc Med Biol* 1:67-74, 1989.

102. Ingelfinger JR, Pratt RE, Roth TP, **Dzau VJ**: Processing of one-chain to two-chain renin in the mouse submandibular gland is influenced by androgen. *Pediatr Res* 25:332-335, 1989.

103. Dubin D, Pratt RE, **Dzau VJ**: Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. *J Vasc Med Biol* 1:150-154, 1989.

104. Dubin D, Hui K, Pratt RE, **Dzau VJ**: Synthetic peptide inhibitors of prorenin activation. *J Hypertension* 7:571-573, 1989.

105. Ellison KE, Ingelfinger JR, Pivor M, **Dzau VJ**: Androgen regulation of rat renal angiotensin messenger RNA expression. *J Clin Invest* 83:1941-1950, 1989.

106. Naftilan AJ, Pratt RE, Lin SH, **Dzau VJ**: Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. *Hypertension* 13:706-711, 1989.

107. Rudd MA, Plavin ST, Hirsch AT, Ingelfinger JR, **Dzau VJ**: Atrial natriuretic factor-specific antibody as a tool for physiological studies. Evidence for role of ANF in aldosterone and renal electrolyte regulation. *Circ Res* 65:1324-1329, 1989.

108. Hirsch AT, Creager MA, **Dzau VJ**: Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in human congestive heart failure. *Am J Cardiol* 63: 211-216, 1989.

109. Hirsch AT, Levenson DJ, Cutler SS, **Dzau VJ**, Creager MA: Regional vascular responses to prolonged lower body negative pressure in normal subjects. *Am J Physiol* 26: H219-H225, 1989.

110. Sacks FM, Creager MA, Gallagher SJ, Loscalzo J, **Dzau VJ**: Effects of alpha- and beta-adrenergic antagonists on plasma apolipoproteins and forearm blood flow in patients with mild hypertension. *Am J Med* 86(1B):8-13, 1989.

111. Hirsch AT, **Dzau VJ**, Majzoub JA, Creager MA: Vasopressin-mediated forearm vasodilation in normal humans: Evidence for a vascular vasopressin V-2 receptor. *J Clin Invest* 84:418-426, 1989.

112. Naftilan AJ, Williams R, Burt D, Paul M, Pratt RE, Hobart P, Chirgwin J, **Dzau VJ**: A lack of genetic linkage of renin gene restriction fragment length polymorphisms with human hypertension. *Hypertension* 14:614-618, 1989.

113. Prevention of Atherosclerotic Complications with Ketanserin Trial Group: Prevention of atherosclerotic complications: Controlled trial of ketanserin. *Br J Med* 298:424-430, 1989.

114. PACK Claudication Substudy Investigators, **Dzau VJ**: Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. *Circulation* 80:1544-1548, 1989.

115. PACK Trial Group: Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis: A multi-center, double-blind, placebo-controlled trial. *Thromb Res* 55:13-23, 1989.

116. Naftilan AJ, Pratt RE, Eldridge CS, Lin HL, **Dzau VJ**. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. *Hypertension* 13:706-711, 1989.

117. Tang SS, Stevenson LF, **Dzau VJ**: Endothelial renin-angiotensin pathway: Adrenergic regulation of angiotensin secretion. *Circ Res* 66:103-108, 1990.

118. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, **Dzau VJ**: *In situ* hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule: A hypothesis for the intrarenal renin angiotensin system. *J Clin Invest* 85:417-423, 1990.

119. Creager MA, Hirsch AT, **Dzau VJ**, Nabil E, Cutler S, Colucci W: Baroreflex regulation of regional blood flow in congestive heart failure. *Am J Physiol* 258:H1409-H1414, 1990.

120. Creager MA, Cooke JP, Mendelson ME, Gallagher SJ, Coleman SM, Loscalzo J, **Dzau** VJ: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. *J Clin Invest* 86:228-234, 1990.

121. Schunkert H, **Dzau VJ**, Tang SS, Hirsch AT, Apstein CS, Lorell BH: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility and relaxation. *J Clin Invest* 86:1913-1920, 1990.

122. Girerd XJ, Hirsch AT, Cooke JP, **Dzau VJ**, Creager, MA: L-arginine augments endothelium-dependent vasldilation in cholesterol-fed rabbits. *Circ Res* 67:1301-1308, 1990.

123. Takeuchi K, Nakamura N, Cook NS, Pratt RE, **Dzau VJ**: Angiotensin II can regulate gene expression by the AP-1 binding sequence via a protein kinase C-dependent pathway. *Biochem & Biophys Res Comm* 172:1189-1194, 1990.

124. Sigmund CD, Okuyama K, Ingelfinger J, Jones CA, Mullins JJ, Kane C, Kim U, Wu C, Kenny L, Rustum Y, **Dzau VJ**, Gross KW: Isolation and characterization of renin-expressing cell lines

from transgenic mice containing a renin-promoter viral oncogene fusion construct. *J Biol Chem* 265:19916-19922, 1990.

125. Ingelfinger JR, Schunkert H, Ellison KE, Pivor M, Zuo WM, Pratt R, **Dzau VJ**. Intrarenal angiotensinogen: localization and regulation. *Pediatr Nephrol* 4:424-428, 1990.

126. Creager MA, Hirsch AT, **Dzau VJ**, Nabel EG, Cutler SS, Colucci WS. Baroflex regulation of regional blood flow in congestive heart failure. *Am J Physiol* 258:1409-1414, 1990.

127. Itoh H, Pratt RE, **Dzau VJ**. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. *J Clin Invest* 86:1690-1697, 1990.

128. Jacob H, Sigmund CD, Shockley TR, Gross KW, **Dzau VJ**: Renin promoter-SV 40 T antigen transgenic mouse: a model of primary renal vascular hyperplasia. *Hypertension* 17:1167-1172, 1991.

129. Dubin D, Pratt RE, Hui KY, **Dzau VJ**: Characterization of prorenin activation using a synthetic substrate. *J Hypertension* 9:483-486, 1991.

130. Itoh H, Pratt RE, **Dzau VJ**: Growth inhibitory action of atrial natriuretic polypeptide (ANP) on vascular smooth muscle cell: New antagonistic relationship to the renin-angiotensin system (RAS). *J Clin Invest* 86:1690-1697, 1991.

131. Naftilan AJ, Zuo WM, Ingelfinger J, Ryan TJ, Pratt RE, **Dzau VJ**: Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. *J Clin Invest* 87:1300-1311, 1991.

132. Horiuchi M, Nakamura N, Tang SS, Barett G, **Dzau VJ**: Molecular mechanism of tissue specific regulation of mouse renin gene expression by cAMP: identification of an inhibitory protein that binds nuclear transcriptional factor. *J Biol Chem* 266:16247-16254, 1991.

133. Creager MA, Roddy MA, Holland KM, Hirsch AT, **Dzau VJ**: Sodium depresses arterial baroreflex function in normotensive humans. *Hypertension* 17:989-996, 1991.

134. Sigmund CD, Jones CA, Jacob HJ, Ingelfinger J, Kim U, Gamble D, **Dzau VJ**, Gross KW: Pathophysiology of vascular smooth muscle in renin promoter-T-antigen transgenic mice. *Am J Physiol* 260:F249-F257, 1991.

135. Hirsch AT, Talsness CE, Schunkert H, Paul M, **Dzau VJ**. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. *Circ Res* 69:475-482, 1991.

136. Andrawis NS, Brock TA, **Dzau VJ**, Pratt RE. Mas oncogene receptor coupling and peptide specificity in balb 3T3 and vascular smooth muscle cells. *Am J Med Sci* 302:329-334, 1991.

137. Cooke JP, Rossitch E. Andon NA, Loscalzo J, **Dzau VJ**: Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. *J Clin Invest* 88:1663-1671, 1991.

138. **Dzau VJ**, Gibbons GH, Pratt RE: Molecular mechanism of vascular renin-angiotensin system in myointimal hyperplasia. *Hypertension* 18(Suppl II):II-100-II-105, 1991.

139. Pratt RE, Itoh H, Gibbons GH, **Dzau VJ**. Role of angiotensin in the control of vascular smooth muscle growth. *J Vasc Med Biol* 3:25-29, 1991.

140. Jacob HJ, Lindpainter K, Lincoln SE, Kusumi K, Bunker RK, Mao YP, Ganten D, **Dzau VJ**, Lander ES. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. *Cell* 67:213-224, 1991.

141. Itoh H, Pratt RE, **Dzau VJ**: Interaction of ANP and angiotensin II on protooncogene expression and vascular cell growth. *Biochem Biophys Res Comm* 176:1601-1609, 1991.

142. Barrett G, Horiuchi M, Paul M, Pratt RE, Nakamura N, **Dzau VJ**. Identification of negative regulatory element involved in tissue-specific expression of mouse renin genes. *Proc Natl Acad Sci* 89:885-889, 1992.

143. Zuo WM, Pratt RE, Heusser CH, Bews JPA, deGasparo MM, **Dzau VJ**. Characterization of a monoclonal antibody specific for human active renin. *Hypertension* 19:249-254, 1992.

144. Paul M, Nakamura N, Pratt RE, Burt DW, **Dzau VJ**: Cell-dependent posttranslational processing and secretion of recombinant mouse renin-2. *Am J Physiol* 262:E224-E229, 1992.

145. Itoh H, Pratt RE, Ohno M, **Dzau VJ**. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. *Hypertension* 19:758-761, 1992.

146. Tang SS, Rogg H, Schumacher R, **Dzau VJ**. Characterization of nuclear angiotensin II in binding sites in rat liver and comparison with plasma membrane receptors. *Endocrinol* 131:374-380, 1992.

147. Hirsch AT, **Dzau VJ**, Cutler SS, Levenson DJ, Creager MA: The effect of cardiopulmonary baroreflex function, regional blood flow, and vascular responsiveness in hypertensive patients. *J Cardiovasc Pharmacol* 19:272-281, 1992.

148. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, **Dzau VJ**: Cloning, characterization and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. *Biochem Biophys Res Comm* 185:253-259, 1992.

149. Paul M, Burt DW, Krieger JE, Nakamura N, **Dzau VJ**: Tissue specificity of renin promoter activity and regulation in the mouse. *Am J Physiol* 262:E644-E650, 1992.

150. Wilcox CS, **Dzau VJ**. Effect of captopril on the release of the components of the renin-angiotensin system into plasma and lymph. *J Am Soc Nephrol* 2:1241-1250, 1992.

151. Gibbons GH, Pratt RE, **Dzau VJ**: Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-ß1 expression determines growth response to angiotensin II. *J Clin Invest* 90:456-461, 1992.

152. Schunkert H, Ingelfinger JR, Jacob H, Jackson B, Bouyounes B, **Dzau VJ**. Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. *Am J Physiol* 263:E863-E869, 1992.

153. Andrawis NS, **Dzau VJ**, Pratt RE. Autocrine stimulation of mas oncogene leads to altered growth control. *Cell Biol Intl Rep* 16:547-556, 1992.

154. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, **Dzau VJ**, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. *J Clin Invest* 90:1248-1253, 1992.

155. Schunkert H, Ingelfinger JR, Hirsch AT, Talsness CE, **Dzau VJ**: Evidence for tissue specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. *J Clin Invest* 90:1523-1529, 1992.

156. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, **Dzau V**, Fauad-Tarazi F, Horan M, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. *N Engl J Med* 327:998-1008, 1992.

157. Itoh H, Mukoyama M, Pratt RE, **Dzau VJ**. Specific blockade of basic fibroblast growth factor gene expression in endothelial cells by antisense oligonucleotide. *Biochem Biophys Res Comm* 188:1205-1213, 1992.

158. Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, **Dzau VJ**. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. *Circ Res* 72:312-318, 1993.

159. Paul M, Wagner J, **Dzau VJ**. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. *J Clin Invest* 91:2058-2064, 1993.

160. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, **Dzau VJ**. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. *J Clin Invest* 91:2268-2274, 1993.

161. Horiuchi M, Pratt RE, Nakamura N, **Dzau VJ**. Distinct nuclear proteins competing for an overlapping sequence of cyclic adenosine monophosphate and negative regulatory elements regulate tissue-specific mouse renin gene expression. *J Clin Invest* 92:1805-1811, 1993.

162. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, **Dzau VJ**. Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells. *J Clin Invest* 91:894-899, 1993.

163. Morishita R, Gibbons GH, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. Novel and effective gene transfer technique for study of vascular renin angiotensin system. *J Clin Invest* 91:2580-2585, 1993.

164. Schunkert H, Tang SS, Litwin SE, Diamant D, Riegger G, **Dzau VJ**, Ingelfinger JR. Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. *Cardiovasc Res* 27:731-735, 1993.

165. Ohno M, Gibbons GH, **Dzau VJ**, Cooke JP. Shear stress elevates endothelial cGMP: role of a potassium channel and G protein coupling. *Circulation* 88:193-197, 1993.

166. Cooke JP, Wang B-Y, Andon N, Loscalzo J, **Dzau VJ**. S-nitrosocaptopril: a novel nitrovasodilator resistant to nitrate tolerance. *J Vasc Med Biol* 4:115-121, 1993.

167. Gregory CR, Pratt RE, Huie P, Shorthouse R, Billingham ME, **Dzau VJ**, Morris RE. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. *Transplant Proc*. 25:770-771, 1993.

168. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. *Proc Natl Acad Sci* 90:8474-8478, 1993.

169. Malek AM, Gibbons GH, **Dzau VJ**, Izumo S. Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium. *J Clin Invest* 92:2013-2021, 1993.

170. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, **Dzau VJ**. Expression cloning of type-2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. *J Biol Chem* 268:24539-24542, 1993.

171. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, **Dzau VJ**. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. *Biochem Biophys Res Comm* 197:393-399, 1993.

172. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, **Dzau VJ**. Novel in vitro gene transfer method for study of local modulators in vascular smooth muscle cells. *Hypertension* 21:894-899, 1993.

173. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy. *Trans Assoc Am Phys* CVI:54-61, 1993.

174. Kim DK, Zhang L, **Dzau VJ**, Pratt RE. H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells following injury. *J Clin Invest* 93:355-360, 1994.

175. Rakugi H, Kim DK, Krieger JE, Wang DS, **Dzau VJ**, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. *J Clin Invest* 93:339-346, 1994.

176. Koike G, Krieger JE, Jacob HJ, Mukoyama M, Pratt RE, **Dzau VJ**. Angiotensin converting enzyme and genetic hypertension: cloning of rat cDNAs and characterization of the enzyme. *Biochem Biophys Res Comm* 198:380-386, 1994.

177. Morishita M, Gibbons GH, Ellison KE, Nakajima M, Von der Leyen H, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. Intimal hyperplasia after vascular injury is inhibited by antisense CDK 2 kinase oligonucleotides. *J Clin Invest* 93:1458-1464, 1994.

178. Rakugi H, Wang D, **Dzau VJ**, Pratt RE. Potential importance of tissue angiotensin converting enzyme inhibition in preventing neointima formation. *Circulation* 90:449-455, 1994.

179. Gibbons GH, **Dzau VJ**. The emerging concept of vascular remodeling. *N Engl J Med* 330:1431-1438, 1994.

180. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, Ogihara T, **Dzau VJ**. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth *J Clin Invest* 94:824-829, 1994.

181. Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, **Dzau VJ**. Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. *Biochem Biophys Res Commun* 203:1842-1850, 1994.

182. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, **Dzau VJ**. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. *J Clin Invest* 94:978-984,1994.

183. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, **Dzau VJ**. Pharmacokinetics of antisense oligonucleotides (cyclin B_1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. *Gene* 149:13-19, 1994.

184. Jacob HJ, Brown DM, Bunker RK, Daly MJ, **Dzau VJ**, Goodman A, Koke G, Kren V, Kurtz T, Lernmark A, Levan G, Mao YP, Petterson A, Pravenec M, Simon JS, Szpirer C, Szpirer J, Trolliet MR, Winer ES, Lander ES. A genetic linkage map of the laboratory rat, Rattus norvegicus. *Nature Genetics* 9:63-69, 1995.

185. Gregory CR, Huang X, Pratt RE, Shorthouse R, Billingham ME, **Dzau VJ**, Morris RE. Treatment with Rapamycin and Mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. *Transplantation* 59:655-661, 1995.

186. von der Leyen H, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, **Dzau VJ**. Gene therapy inhibiting neointimal vascular lesion : *In vivo* transfer of endothelial cell nitric oxide synthase gene. *Proc Natl Acad Sci USA* 92:1137-1141, 1995.

187. Morishita R, Gibbons GH, Ellison, KE, Horiuchi M, Nakajima M, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. A gene therapy strategy using a transcription factor decoy of E2F binding site inhibits smooth muscle proliferation in vivo. *Proc Natl Acad Sci* 92:5855-5859, 1995.

188. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, **Dzau VJ**. Genetic engineering of vein grafts resistant to atherosclerosis. *Proc Natl Acad Sci* 92:4502-4506, 1995.

189. Katsuya T, Koike G, Yee T, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, **Dzau VJ**, MacMahon S. Angiotensin gene T235 variant is associated with increased risk of coronary heart disease. *Lancet* 345:1600-1603, 1995.

190. Koike G, Jacob JJ, Krieger JE, Szpirer C, Hoehe MR, Horiuchi M, **Dzau VJ**. Investigation of the phenylethanolamine N-methyltransferase gene as a candidate gene for Bp1 in the stroke prone spontaneously hypertensive rat. *Hypertension* 26:595-601, 1995.

191. Yamada T, Horiuchi M, Morishita R, Pratt RE, **Dzau VJ**. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. *J Clin Invest* 96:1230-1237, 1995.

192. Horiuchi M Koike G, Yamada T, Mukoyama M, Nakajima M, **Dzau VJ**. The growth-dependent expression of angiotensin II type 2 receptor is regulated by transcription factors interferon regulatory factor-1 and 2. *J Biol Chem* 270:20225-20230, 1995.

193. Hein L, Barsh G, Pratt RE, **Dzau VJ**, Kobilka B. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. *Nature* 377:744-747, 1995.

194. Nakajima M, Morishita R, Zhang L, Horiuchi M, Pratt RE, **Dzau VJ**. The angiotensin II type 2 receptor antagonizes the growth effects of the AT1 receptor: gain of function study using in vivo gene transfer. *Proc Natl Acad Sci* 92:10663-10667, 1995.

195. Mukoyama M, Horiuchi M, Nakajima M, Pratt RE, **Dzau VJ**. Characterization of rat type 2 angiotensin II receptor stably expressed in 293 cells. *Mol and Cell Endocrinol* 112:61-68, 1995.

196. Schork NJ, Krieger JE, Trolliet MR, Franchini KG, Koike G, Krieger EM, Lander ES, **Dzau VJ**, Jacob HJ. A biometrical genome search in rats reveals the multigenic basis of blood pressure variation. *Genome Research* 5:164-172, 1995.

197. Yamada T, Horiuchi M, **Dzau VJ**. Angiotensin II type 2 receptor mediates programmed cell death. *Proc Natl Acad Sci* 93:156-160, 1996.

198. Dubin D, Peters JH, Brown L, Logan B, Kent KC, Berse B, Berven S, Cercek B, Sharifi BG, Pratt RE, **Dzau VJ**, Van De Water L. Balloon catheterization induces arterial expression of embryonic fibronectins. *Arterioscl Thromb Vasc Biol* 15:1958-1967, 1996.

199. Ellison KE, Bishopric NH, Webster KA, Morishita R, Gibbons GH, Kaneda Y, Sato B, **Dzau VJ**. Fusigenic Liposome-medicated DNA Transfer into Cardiac Myocytes, *Journal of Molecular and Cellular Cardiology* 28:1385-1399, 1996.

200. Wu D-A, Bu X, Warden CH, Shen DDC, Jeng C-Y, Sheu WHH, Fuh MMT, Katsuya T, **Dzau VJ**, Reaven GM, Lusis AJ, Rotter JI, Chen Y-DI. Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. *J Clin Invest* 97:2111-2118,1996.

201. **Dzau VJ**, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral Liposome for Gene Therapy in Cardiovascular Diseases. *Proc Natl Acad Sci*, USA. 93:11421-11425, 1996.

202. Diet F, **Dzau VJ**, Pratt RE: Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery Disease. *Circulation* 94(11):2756-2767, 1996.

203. Gibbons GH, **Dzau VJ**: Molecular therapeutics for vascular disease. *Science* 272; 689-693, 1996.

204. Hayashida W, Horiuchi M, **Dzau VJ**. Intracellular third loop domain of angiotensin II type-2 receptor: role in mediating signal transduction and cellular function. *J Biol Chem* 271:21985-21992,1996.

205. Katsuya T, Horiuchi M, Minami S, Koike G, Nanetto S, Hsueh AJW, **Dzau VJ**. Genomic organization and polymorphism of human angiotensin II type 2 receptor: a study of two families of human premature ovarian failure syndrome. *Mol Cell Endocrinol* 127(2):221-228,1997.

206. Mann MJ, Gibbons GH, Tsao PS, Von der Leyen HE, Cooke JP, Buitrago R, Kernoff R, **Dzau VJ**. Cell Cycle Inhibition Preserves Endothelial Function in Genetically Engineered Rabbit Vein Grafts. *J Clin Invest.* 99(6): 1295-1301, 1997.

207. Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, **Dzau VJ**. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. *Proc Natl Acad Sci* 94(12):6397-6396, 1997.

208. Horiuchi M, Yamada T, Hayashida W, **Dzau VJ**. Interfron regulatory Factor -1 Up-regulates Angiotenson II Type 2 Receptor and Induces Apoptosis. *J Biol Chem.* 272:11952-11958, 1997.

209. Horiuchi M, Hayashida W, Kambe T, Yamada T, **Dzau VJ**. Angiotensin Type 2 Receptor Dephosphorylates Bcl-2 by Activating Mitogen-activated Protein Kinase Phosphatase-1 and Induces Apoptosis. *J Biol Chem.* 272: 19022-19026, 1997.

210. Hein L, Pratt RE, **Dzau VJ**, Kobilka BK. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. *Mol Endocrinol* 11(9): 1266-77, 1997.

211. Mann MJ, Morishita R, Gibbons GH, von der Leyen H, **Dzau VJ**. DNA transfer into vascular smooth muscle using fusigenic sendai virus (HVJ)-liposomes. *Mol Cell Biochem* 172(1-2): 3-12, 1997.

212. Masaki H, Kurihara T, Yamaki A, Norio I, Nozawa Y, Mori Y, Mursawa S, Kizima K, Maruyama K, Horiuchi M, **Dzau VJ**, Takahashi H, Iwasaka T, Inada M, Matsubara H. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. *J Clin Invest* 101(3): 527-535, 1998.

213. Braun-Dullaeus R, Mann M, **Dzau VJ.** Cell cycle progression. New therapeutic target for vascular proliferative disease. *Circulation* 98; 82-89, 1998.

214. Ryuichi M, Gibbons G, Horiuchi M, Kaneda Y, Ogihara T, **Dzau VJ.** Role of AP-1 complex in angiotensin II-mediated transforming growth factor -β expression and growth of smooth muscle cells: Using decoy approach against AP-1 binding site. *Biochem and Biophys Res Comm* 243: 361-367, 1998.

215. Yamada T, Akishita M, Pollman M, Gibbons GH, **Dzau VJ**, Horiuchi M. Angiotensin II type 2 receptor mediates vascular muscle cell apoptosis and antagonizes angiotensin II type 2 receptor action: An in vitro gene transfer study. *Life Sciences* 63(19): PL 289-295, 1998.

216. Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim J, Baran D, **Dzau VJ**. An oligonucleotide decoy for the transcription factor E2F inhibits mesangial cell proliferation in vitro. *Am J Physiol* 275(2 Pt 2): F278-284, 1998.

217. Poston RS, Tran KP, Mann MJ, Hoyt EG, **Dzau VJ**, Robbins RC. Prevention of ischemically induced neointimal hyperplasia using ex vivo antisense oligodeoxynucleotides. *J Heart Lung Transplant* 17(4): 349-355, 1998.

218. Akishita M, Ito M, Lehtonen JY, Daviet L, **Dzau VJ**, Horiuchi M. Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. *J Clin Invest* 103(1): 63-71, 1999.

219. Horiuchi M, Yamada H, Akishita M, Ito M, Tamura K, **Dzau VJ**. Interferon regulatory factors regulate interleukin-1beta-converting enzyme expression and apoptosis in vascular smooth muscle cells. *Hypertension* 33(1): 162-166, 1999.

220. Horiuchi M, Akishita M, **Dzau VJ**. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. *Hypertension*, 33(2): 613-621, 1999.

221. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, **Dzau VJ**. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. *Circ Res* 84(8): 876-882, 1999.

222. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, **Dzau VJ**. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. *Proc Natl Acad Sci U S A* 96(11): 6411-6416, 1999.

223. Ing, DJ, Zang J, **Dzau VJ,** Webster KA, Bishopric NH. Modulation of Cytokine-Induced Cardiac Myocyte Apoptosis by Nitric Oxide, Bak and Bcl-x. *Circ Res* 84(1): 21-33, 1999.

224. Tomita S, Tomita N, Yamada T, Zhang L, Kaneda Y, Morishita R, Ogihara T, **Dzau VJ**, Horiuchi M. Transcription factor decoy to study the molecular mechanism of negative regulation of renin gene expression in the liver in vivo. *Circ Res* 84(9): 1059-1066, 1999.

225. Yamada H. Akishita M, Ito M. Tamura K, Daviet L, Lehtonen JY, **Dzau VJ**, Horiuchi M: AT2 receptor and vascular smooth muscle cell differentiation in vascular development. *Hypertension* 33(6): 1414-1419, 1999.

226. Lehtonen JY, Horiuchi M, Daviet L, Akishita M, **Dzau VJ**. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. *J Biol Chem* 274(24): 16901-16906, 1999.

227. Daviet L, Lehtonen JY, Tamura K, Griese DP, Horiuchi M, **Dzau VJ**. Cloning and characterizaton of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. *J Biol Chem* 274(24): 17058-17062, 1999.

228. Ruediger BC, Mann MJ, Ziegler A, von der Leyen HE, **Dzau VJ**. A novel role for the cyclin-dependent kinase inhibitor p27KIP1 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. *J. Clin.Invest* 104 (6): 815-823, 1999.

229. Proston RS, Mann MJ, Hoyt EG, Ennen M, **Dzau VJ**, Robbins RC. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. *Transplantation* 68(6):825-832, 1999.

230. von der Leyen HE, Braun-Dullaeus R, Mann MJ, Zhang L, Niebauer J, **Dzau VJ**. A pressure – mediated nonviral method for efficient arterial gene and oligonucleotide transfer. *Hum Gene Ther* 20;10(14):2355-2364, 1999.

231. Mann M, Whittemore A, Donaldson MC, Pollack MD, Orav J, **Dzau VJ**. Ex vivo gene therapy of vascular bypass graft with E2F decoy: the PREVENT single-centre, randomized, controlled trial. *Lancet 30;*354(9189)1493-1498, 1999.

232. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. *Arterioscler Thromb Vasc Biol* 20(4):915-922, 2000.

233. Akishita M, Horiuchi M, Yamada H, Zhang L, Tamura K, Ouchi Y, **Dzau VJ**. Inflammation influencesvascular remodeling through AT2 receptor expression and signaling. *Physiol Genomics* . 2(1):13-20, 2000.

234. Tamura K, Chen YE, Horiuchi M, Chen Q, Daviet L, Yang Z, Lopez-Ilasaca M, Mu H, Pratt RE, **Dzau VJ.** LXralpha as a cAMP-responsive transcriptional regulator of gene expression. *Proc. Natl. Acad. Sci.* 97(15): 8513-8518, 2000.

235. Tamura K, Chen YE, Horiuchi M, Chen Q, Daviet L, Yang Z, Lopez-Ilasaca M, Mu H, Pratt RE, **Dzau VJ**, Umemura S. Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular smooth muscle cells. *J Biol Chem* 275(44):34619-27, 2000.

236. Tomita N, Morishita R, Tomita S, Gibbons GH, Zhang L, Horiuchi M, Kaneda Y, Higaki J, Ogihara T, **Dzau VJ**. Transcription factor decoy for NFκB inhibits TNF-α-induced cytokine and adhesion molecule expression *in vivo*. *Gene Therapy*, 7:1326-1332, 2000.

237. Mann MJ, Afshin E, **Dzau VJ**. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. *The Journal of Thoracic Cardiovascular Surgery* 121:714-722, 2001.

238. Hwang JJ, **Dzau VJ**, Liew CC. Genomics and the pathophysiology of heart failure. *Curr Cardiol Rep* 3:198-207, 2001.

239. Braun-Dullaeus, RC, **Dzau VJ**. Cell cycle protein expression in vascular smooth muscle cells *in vitro* and *in vivo* is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. *Arteriosclerosis, Thrombosis and Vascular Biology,* 21:1152, 2001.

240. von Der Leyen HE and **Dzau VJ**. Therapeutic potential of nitric oxide synthase gene manipulation. *Circulation*, 103:2760-2765, 2001.

241. Ranade K, Wu KD, Risch N, Olivier M, Pei D, Hsiao C, Chuang L, Ho L, Jorgenson E, Pesich R, Chen YI, **Dzau VJ**, Lin A, Olshen RA, Curb D, Cox DR, Bostein D. Genetic variation in aldosterone synthase predicts plasma glucose levels. *Proc Natl Acad Sci U S A*, 98: 13219-13224, 2001.

242. Ranade K, Chang M-S, Ting CT, Pei D, Hsiao C-F, Olivier M, Pesich R, Hebert J, Chen Y-I, **Dzau VJ**, Curb D, Olshen R, risch N, Cox DR, Bostein D. High-throughput genotyping with single nucleotide polymorphisms. *Genome Research*, 11:1262-1268, 2001.

243. Glueck SB, **Dzau VJ**, Lee R, Pratt RE. Challenges of comparative expression profiling studies of complex diseases: mouse models of myocardial hypertrophy: Focus on divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. *Physiol Genomics* , 6:1-2, 2001.

244. Dempsey AA, **Dzau VJ**, Liew CC. Cardiovascular genomics: estimating the total number of genes expressed in the human cardiovascular system. *J Mol Cell Cardiol*: 33;1879-1886, 2001.

245. Wu, K.D., Hsiao, C.F., Ho, L.T., Sheu, W.H., Pei, D., Chuang, L.M., Curb, D., Chen, Y.D., Tsai, H.J., **Dzau, V.J.** et al. Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study. *Hypertens Res*, 25, 529-536, 2002.

246. Ton, C., Stamatiou, D., **Dzau, V.J.** and Liew, C.C. Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. *Biochem Biophys Res Commun*, 296, 1134-1142, 2002.

247. Tomita, N., Morishita, R., Yamamoto, K., Higaki, J., **Dzau, V.J.**, Ogihara, T. and Kaneda, Y. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. *J Gene Med*, 4, 527-535, 2002.

248. Morishita, R., Gibbons, G.H., Kaneda, Y., Zhang, L., Ogihara, T. and **Dzau, V.J.** Apolipoprotein E-deficient mice created by systemic administration of antisense oligodeoxynucleotides: a new model for lipoprotein metabolism studies. *J Endocrinol*, 175, 475-485, 2002.

249. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell'Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, **Dzau VJ**. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. *Circulation*; 105:602-607, 2002.

250. Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, **Dzau VJ**. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. *Circulation*; 9;105(14):1686-1692, 2002.

251. Barrans JD, Allen PD, Stamatiou D, **Dzau VJ**, Liew CC.Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. *Amer J Pathology*, 160(6):2035-2043, 2002.

252. Hwang JJ, Allen PD, Tseng GC, Lam CW, Fananapazir L, **Dzau VJ**, Liew CC. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. *Physioll Genomics*, 10(1):31-44, 2002.

253. Ton C, Stamatiou D, **Dzau VJ**, Liew C. Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. *Biochem Biophys Res Commun*, 296(5):1134, 2002.

254. Tomita N, Morishita R, Yamamoto K, Higaki J, **Dzau VJ**, Ogihara T, Kaneda Y. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. *J Gene Medicine*, 4(5):527-535, 2002.

255. **Dzau VJ**, Braun-Dullaeus R, Sedding DG. Vascular Proliferation and Atherosclerosis : New Perspectives and Therapeutic Strategies. *Nat Med* 8(11):1249-1256, 2002.

256. Ranade K, Hinds D, Hsuing C-A, Chuang L-M, Chang M-S, Chen Y-T, Pesich R, Hebert J, Chen Y-D. I, **Dzau VJ**, Olshen R, Curb D, Bostein D, Cox DR, Risch N. A Genome Scan for Hypertension Susceptibility Loci in Populations of Chinese and Japanese Origins. *Am J Hypertens* 16: 158-162, 2003.

257. Weisberg EO, Miritsou M, Gannon J, **Dzau VJ**, Lee RT, Pratt RE. Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. *Physiol Genomics* , 12(2):113-127, 2003.

258. Barrans JD, Ip J, Lam CW, Hwang IL, **Dzau VJ**, Liew CC. Chromosomal distribution of the human cardiovascular transcriptome. *Genomics,* 81(5):519-524, 2003.

259. Huber PE, Mann MJ, Melo LG, Ehsan A, Kong D, Zhang L, Rezvani M, Peschke P, Jolesz F, **Dzau VJ**, Hynynen K. Focused ultrasound (HIFU) induces localized enhancement of reporter gene expression in rabbit carotid artery. *Gene Ther,* 10(18):1600-1607, 2003.

260. Anderson LM, Choe SE, Yukhananov RY, Hopfner RL, Church GM, Pratt RE, **Dzau VJ**. Identification of a novel set of genes regulated by a unique liver X receptor-alpha -mediated transcription mechanism. *J Biol Chem*. 278(17):15252-15260, 2003.

261. Mangi A, Noiseux N, Kong D, Rezvani M, Ingwall J, **Dzau VJ**, Mesenchymal stem cells genetically modified with AKT prevent remodeling and restore performance of infarcted hearts. *Nat Med,* 9(9):1195-1201, 2003.

262. Durier S, Fassot C, Laurent S, Boutouyrie P, Couetil J, Fine Em Lacolley P, **Dzau VJ**, Pratt R. Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness. *Circulation,* 108(15):1845-1851, 2003.

263. Griese D, Ehsan A, Melo L, Kong D, Zhang L, Mann M, Pratt RE, Mulligan R, **Dzau VJ**. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthertic grafts: implications for cell-based vascular therapy. *Circulation,* 108(21):2710-2715, 2003.

264. Mirotsou M, Watanabe C, Schultz P, Pratt R, **Dzau VJ**. Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. *Physiol Genomics* , 15(2):115-126, 2003.

265. Lopez-Ilasaca, M., Liu, X., Tamura, K., and **Dzau, VJ.** The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. *Mol Biol Cell*, 14(12):5038-5050, 2003.

266. Ranade, K., Hinds, D., Hsiung, C.A., Chuang, L.M., Chang, M.S., Chen, Y.T., Pesich, R., Hebert, J., Chen, Y.D., Dzau, V. et al. (2003) A genome scan for hypertension susceptibility loci in populations of Chinese and Japanese origins. *Am J Hypertens*, 16, 158-62.

267. Pachori AS, Melo LG, Zhang L, Loda M, Pratt RE, **Dzau VJ**. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. *Biochem Biophys Res Commun*, 313(3):528-533, 2004.

268. Agrawal RS, Muangman S, Layne MD, Melo L, Perrella MA, Lee RT, Zhang L, Lopez-Ilasaca M, **Dzau VJ.** Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutaes protects heart against ischemic repferusion injury, improves ventricular function and prolongs survival. *Gene Ther*, 11:692-699, 2004.

269. Tomita N, Kim JY, Gibbons GH, Zhang L, Kaneda Y, Stahl RA, Ogborn M, Venderville B, Morishita R, Baran, **Dzau VJ**. Gene therapy with E2F transcription factor decoy inhibits cells cycle progression in rat anti-Thy 1 glomerulonephritis. *Int J Mol Med*, 13(5):629-636, 2004.

270. Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, **Dzau VJ**. Cell cycle-dependent regulation of smooth muscle cell activation. *Artherioscler Thromb Vasc Biol*, 24(5):845-850, 2004.

271. Zhu Q, Ricardo RR, Zhang L, Ogueta S, Agrawal RS, **Dzau VJ**, Marasco WA. Development of constitutive and inducible SIN lentiviral vextors and their application in cardiovascular gene transfer. *Gene Ther Mol Biol*, 8:91-102, 2004.

272. Tamura, K., Chen, Y.E., Tanaka, Y., Sakai, M., Tsurumi, Y., Koide, Y., Kihara, M., Pratt, R.E., Horiuchi, M., Umemura, S. et al. Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression. *Mol Cell Endocrinol*, 224: 11-20, 2004.

273. Pachori, A.S., Melo, L.G., Hart, M.L., Noiseux, N., Zhang, L., Morello, F., Solomon, S.D., Stahl, G.L., Pratt, R.E. and **Dzau, V.J.** Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. *Proc Natl Acad Sci U S A*, 101:12282-12287, 2004.

274. Morello, F., de Bruin, T.W., Rotter, J.I., Pratt, R.E., van der Kallen, C.J., Hladik, G.A., **Dzau, V.J.**, Liew, C.C. and Chen, Y.D. Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. *Arterioscler Thromb Vasc Biol*, 24:2149-2154, 2004.

275. Kong, D., Melo, L.G., Gnecchi, M., Zhang, L., Mostoslavsky, G., Liew, C.C., Pratt, R.E. and **Dzau, V.J.** Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. *Circulation*, 110:2039-2046, 2004.

276. Lopez-Ilasaca, M.A., Bernabe-Ortiz, J.C., Na, S.Y., **Dzau, V.J.** and Xavier, R.J. Bioluminescence resonance energy transfer identify scaffold protein CNK1 interactions in intact cells. *FEBS Lett*, 579:648-654, 2005

277. Guo, S., Lopez-Ilasaca, M. and **Dzau, V.J.** Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of Ang II-mediated NFAT activation. *J Biol Chem* 280(13):12536-12547, 2005.

278. Morello F, De Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, Anderson LM, Lawn RM, Gustafsson JK, Lopez-Ilasaca M, Pratt RE, **Dzau VJ**. Liver X receptors alpha and beta regulate renin expression in vivo. *J Clin Investi*, 115(7);1913-1922, 2005

279. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseus N, Zhang L, Pratt RE, Ingwall JS, **Dzau VJ.**, Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. *Nature Medicine*, 11(4):367-368, 2005

280. Cunha-Neto E, **Dzau VJ**, Allen PD, Stamatio D, Benvenutti L, Higuchi ML, Koyama NS, Silva JS, Kalil J, Liew CC. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. *Amer J Pathology*, 167(2):305-313, 2005

281. **Dzau VJ,** Lopez-Ilasaca M. Searching for transcriptional regulators of Ang II-induced vascular pathology. *J Clin Invest*, 115(9):2319-2322, 2005

282. Goldschmidt-Clermont PJ, Creager MA, Lorsordo DW, Lam GK, Wassef M, **Dzau VJ**. Atherosclerosis 2005: recent discoveries and novel hypotheses. *Circulation*, 112(21):3348-3353. 2005

283. Sales VL, Sukhova GK, Lopez-Ilasaca MA, Libby P, **Dzau VJ**, Pratt RE. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. *Circulation*, 112(21)21:3328-3336. 2005

284. **Dzau VJ,** Gnecchi M. Pachori AS. Enhancing stem cell therapy through genetic modification. *J Am Coll Cardiol*, 4;46(7):1351-1353. 2005

285. Liu X, Pachori AS, Ward CA, Davis JP, Gnecchi M, Kong D, Zhang L, Murduck J, Yet SF, Perrella MA, Pratt RE, **Dzau VJ**, Melo LG. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. *FASEBJ*, 20(2):207-216. 2006

286. Pachori AS, Melo LG, Zhang L, Solomon S, **Dzau VJ**. Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery. *J Am Coll Cardiol.* Feb 7:47(3):635-643. 2006

287. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, **Dzau VJ.** Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. *FASEBJ*, 20(6):661-669. 2006

288. Wu Y, Ip JE, Huang J, Zhang L, Matsushita K, Liew CC, Pratt RE, **Dzau VJ**. Essential Role of ICAM-1/CD18 in Mediating Endothelial Progenitor Cell Recruitment, Angiogenesis, and Repair to the Infarcted Myocardium. *Circ Res* 99(3);315-322. 2006

289. Mirotsou M, **Dzau VJ**, Pratt RE, Weinberg E. Physiological Genomics of Cardiac Disease: Quantitative Relationships Between Gene Expression and Left Ventricular Hypertrophy. *Physiological Genomics*, Oct 3:27(1): 86-94. 2006

290. Noiseux N, Gnecchi M, Pachori A, Pratt RE, **Dzau VJ**. Mesenchymal Stem Cells Over-expressing AKT Dramatically Repairs Infarcted Myocardium and Improves Cardiac Function Despite Infrequent Cellular Fusion or Differentiation. *Molecular Therapy* 14(6): 840-850. 2006

291. Matsushits K, Wu Y, Okamoto Y, Pratt RE, **Dzau VJ**. Local rennin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. *Hypertension* 48(6): 1095-1102. 2006

292. **Dzau VJ**, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). *Circulation* 114(25):2850-2870. 2006

293. **Dzau VJ,** Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. *Circulation* 114(25): 2871-2891. 2006

294. Mirotsou M, Zhang ZY, Deb A, Zhang L, Pachori A, Pratt RE, **Dzau VJ**. Secreted Frizzle Related Factor 2 is the Key Stem Cell Paracrine Factor Mediating Myocardial Survival and Repair. *Proc Natl Acad Sci USA* 104(5): 1643-1648. 2007

295. Liu X, Simpson JA, Brunt KR, Ward CA, Hall SR, Kinobe RT, Barrette V, Tse MY, Pang SC, Pachori AS, **Dzau VJ**, Ogunyankin K, Melo LG. Pre-Emptive Heme Oxygenase-1 Gene Delivery Reveals Reduced Mortality and Preservation of Left Ventricular Function One Year After Acute Myocardial Infarction. *Am J Physiol Heart Circ Physiol*. 2007 July;293(1):H48-59.

296. Matsushita K, Zhang Z, Pratt R, **Dzau VJ**. Molecular mechanism of juxtaglomerular cell hyperplasia: A unifying hypothesis. *J Amer Soc Hypertension* 1(3): 164-168. 2007

297. Deb A, Davis BH, Guo J, Ni A, Huang J, Zhang Z, Mu H, and **Dzau VJ.** SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional auto-feedback loop of Wnt3a. *Stem Cells.*2008 Jan;26(1):35-44.

298. Pachori, AS, Smith A, McDonald P, Zhang L, Dzau VJ, Melo LG. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interation with PI3K/Akt pathway. J Mol Cell Cardiol. 2007 Nov;43(5):580-92.

299. Ip JE, Wu Y, Juang J, Zhang L, Pratt RE, **Dzau VJ**. Mesenchymal Stem Cells Utilize Integrin {beta}1 Not CXCR4 for Myocardial Migration and Engraftment. *Mol Biol Cell*. 2007 Aug;18(8):2873-82.

300. Frenkel D, Pachori AS, Zhang L, Dembinsky-Vaknin A, Farfara D, Petrovic-Stojkovics, **Dzau VJ**, Weiner NL. Nasal Vaccination with Troponin Reduces Troponin Specific T-Cell Responses Imporves Heart Function in Myocardial Ischemia-Reperfusion Injury. *International Immunology; 2009 Jul;21(7):817-29.*

301. Zhang Z, Deb A, Zhang Z, Pachori A, He W, Guo J, Pratt R, **Dzau VJ**. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. *J Mol CellCardiol*. 2009 Mar; 46(3):370-7.

302. Gnecchi M, He H, Melo LG, Noiseaux N, Morello F, de Boer RA, Zhang L, Pratt RE, **Dzau VJ**, Ingwall JS. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. *Stem Cells*, 2009 Apr;27(4):971-9.

303. Matsushita K, Morello F, Wu Y, Zhang L, Iwanaga S, Pratt RE, **Dzau VJ.** Mesenchymal Stem Cells Differentiate into Renin-Producing Juxtaglomerular (JG)-like Cells under the Control of Liver X receptor-alpha. J Biol Chem. 2010 April 16;285(16): 11974-82.

304. Zhang Z, **Dzau VJ**. Angiotensin II Type 1 Receptor-Associated protein is an Endogenous inhibitor of Angiotensin II Type 1 Receptor Action in Cardiac Hypertrophy. Role in Check and Balance. Hypertension. 2010 May;55(5):1086-7.

305. Huang J, Zhang Z, Guo J, Ni A, Deb A, Zhang L, Mirotsou M, Pratt RE and **Dzau VJ** Genetic Modification of Mesenchymal stem cells Overexpressing CCR1 Increases Cell Viability, Migration, Engraftment and Capillary Density in the Injured Myocardium Circulation Research. 2010 June 11;106(11):1753-62.

306. He W, Zhang L, Ni A, Zhang Z, Mirotsou M, Mao L, Pratt RE, **Dzau VJ**. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21110-5

307. Hodgkinson CP, Gomez JA, Mirotsou M, **Dzau VJ**. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther. 2010 Nov;21(11):1513-26.

308. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, **Dzau VJ**. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011 Feb;50(2):280-9.

309. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mirotsou M, **Dzau VJ**. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res. 2012 May 25;110(11):1465-73

310. Beigi F, Schmeckpeper J, Pow-Anpongkul P, Payne JA, Zhang L, Zhang Z, Huang J, Mirotsou M, **Dzau VJ**. C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway. Circ Res. 2013 Aug 2;113(4):372-80.

311. Wang H, Gomez JA, Klein S, Zhang Z, Seidler B, Yang Y, Schmeckpeper J, Zhang L, Muramoto GG, Chute J, Pratt RE, Saur D, Mirotsou M, **Dzau VJ**. Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am Soc Nephrol. 2013 Jul;24(8):1263-73.

312. Hodgkinson CP, Naidoo V, Patti KG, Gomez JA, Schmeckpeper J, Zhang Z, Davis B, Pratt RE, Mirotsou M, **Dzau VJ**. Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology. Stem Cells. 2013 Aug;31(8):1669-82.

313. Huang J, Guo J, Beigi F, Hodgkinson CP, Facundo HT, Zhang Z, Espinoza-Derout J, Zhou X, Pratt RE, Mirotsou M, **Dzau VJ**. HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection. J Mol Cell Cardiol. 2014 Jan;66:157-64.

314. Jayawardena T, Mirotsou M, **Dzau VJ**. Direct reprogramming of cardiac fibroblasts to cardiomyocytes using microRNAs. Methods Mol Biol. 2014;1150:263-72.

315. Hodgkinson C, Gomez J, Payne JA, Zhang L, Wang X, Dal-Pra S, Pratt RE, **Dzau VJ**. Abi3bp Regulates Cardiac Progenitor Cell Proliferation and Differentiation. Circ Res. 2014 Dec 5;115(12):1007-16.

316. Jayawardena TM, Finch EA, Zhang L, Zhang H, Hodgkinson C, Pratt RE, Rosenberg PB, Mirotsou M, **Dzau VJ**. MicroRNA Induced Cardiac Reprogramming In Vivo: Evidence for Mature Cardiac Myocytes and Improved Cardiac Function. Circ Res. 2015 Jan 30;116(3):418-24.

317. Hodgkinson CP, **Dzau VJ.** Conserved microRNA program as key to mammalian cardiac regeneration: Insights from Zebra Fish. Circ Res. 2015 Mar 27;116(7):1109-11.

318. Yang Y, Gomez JA, Herrera M, Perez-Marco R, Repenning P, Zhang Z, Payne A, Pratt RE, Koller B, Beierwaltes WH, Coffman T, Mirotsou M, **Dzau VJ**. Salt Restriction Leads to

Activation of Adult Renal Mesenchymal Stromal Cell–Like Cells via Prostaglandin E2 and E-Prostanoid Receptor 4. Hypertension. 2015; 65: 1047-1054.

319. Hodgkinson CP, Kang MH, Dal-Pra S, Mirotsou M, **Dzau VJ**. MicroRNAs and Cardiac Regeneration. Circ Res. 2015 May 8;116(10):1700-1711.

320. Schmeckpeper J, Verma A, Yin L, Beigi F, Zhang L, Payne A, Zhang Z, Pratt RE, **Dzau VJ**, Mirotsou M. Inhibition of Wnt6 by Sfrp2 regulates adult cardiac progenitor cell differentiation by differential modulation of Wnt pathways. J Mol Cell Cardiol. 2015. Jun 10. 2828(15)00189-3.

321. Matsushita K, Wu Y, Pratt RE, Dzau VJ. Blockade of angiotensin II type 2 receptor by PD123319 inhibits osteogenic differentiation of human mesenchymal stem cells via inhibition of extracellular signal-regulated kinase signaling. J Am Soc Hypertens. 2015 Jul;9(7):517-25.

322. Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. Circ Res. 2016 Jan 8;118(1):95-107.

323. Matsushita K, Morello F, Zhang Z, Masuda T, Iwanaga S, Steffensen KR, Gustafsson JÅ, Pratt RE, Dzau VJ. Nuclear hormone receptor LXRα inhibits adipocyte differentiation of mesenchymal stem cells with Wnt/beta-catenin signaling. Lab Invest. 2016 Feb;96(2):230-8.

324. Wang X, Hodgkinson CP, Lu K, Payne AJ, Pratt RE, **Dzau VJ**. Selenium Augments microRNA Directed Reprogramming of Fibroblasts to Cardiomyocytes via Nanog. Science Rep. 2016 Mar 15;6:23017

325. Yuan H, Gomez JA, Chien JS, Zhang L, Wilson CM, Li S, Fales AM, Liu Y, Grant GA, Mirotsou M, **Dzau VJ**, Vo-Dinh T. Tracking mesenchymal stromal cells using an ultra-bright TAT-functionalized plasmonic-active nanoplatform. J Biophotonics. 2016 Apr;9(4):406-13.

326. MatsushitaK, WuY, Pratt RE, **Dzau VJ**. Deletion of angiotensin II type 2 receptor accelerates adipogenesis in murine mesenchymal stem cells via Wnt10b/beta-catenin signaling. Lab Inves. 2016 Aug; 96: 909-917.

327. Li Y, Dal-Pra S, Mirotsou M, Jayawardena TM, Hodgkinson CP, Bursac N, **Dzau VJ**. Tissue-engineered 3-dimensional (3D) microenvironment enhances the direct reprogramming of fibroblasts into cardiomyocytes by microRNAs. Science Rep. 2016 Dec 12;6:38815.

328. Bareja A, Hodgkinson CP, Payne AJ, Pratt RE, Dzau VJ. HASF (C3orf58) is a novel ligand of the insulin-like growth factor 1 receptor. Biochem J. 2017 Feb 20;474(5):771-780.

329. Dal-Pra S, Hodgkinson CP, Mirotsou M, Kirste I, Dzau VJ. Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo. Circ Res. 2017 Apr 28;120(9):1403-1413.

330. Bareja A, Hodgkinson CP, Soderblom E, Waitt G, **Dzau VJ**. The proximity-labeling technique BioID identifies sorting nexin 6 as a member of the insulin-like growth factor 1 (IGF1)-IGF1 receptor pathway. J Biol Chem. 2018 Apr 27;293(17):6449-6459. doi: 10.1074/jbc.RA118.002406. Epub 2018 Mar 12.

331. Hodgkinson CP, Pratt RE, Kirste I, Dal-Pra S, Cooke JP, Dzau VJ. Cardiomyocyte Maturation Requires TLR3 Activated Nuclear Factor Kappa B. Stem Cells. 2018 Aug;36(8):1198-1209. doi: 10.1002/stem.2833. Epub 2018 Apr 22.

332. Bareja A, Patel S, Hodgkinson CP, Payne A, Dzau VJ. Understanding the mechanism of bias signaling of the insulin-like growth factor 1 receptor: Effects of LL37 and HASF. Cell Signal. 2018 Jun;46:113-119. doi: 10.1016/j.cellsig.2018.02.013. Epub 2018 Feb 28.

333. Hodgkinson CP, Gomez JA, Baksh SS, Payne A, Schmeckpeper J, Pratt RE, Dzau VJ. Insights from molecular signature of in vivo cardiac c-Kit(+) cells following cardiac injury and β-catenin inhibition. J Mol Cell Cardiol. 2018 Oct;123:64-74. doi: 10.1016/j.yjmcc.2018.08.024. Epub 2018 Aug 29.

334. Saleem M, Hodgkinson CP, Xiao L, Gimenez-Bastida JA, Rasmussen ML, Foss J, Payne AJ, Mirotsou M, Gama V, **Dzau VJ**, Gomez JA. Sox6 as a new modulator of renin expression in the kidney. Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F285-F297. doi: 10.1152/ajprenal.00095.2019. Epub 2019 Nov 25. PMID: 31760770; PMCID: PMC7052657.

335. Kang MH, Hu J, Pratt RE, Hodgkinson CP, Asokan A, **Dzau VJ**. Optimizing delivery for efficient cardiac reprogramming. Biochem Biophys Res Commun. 2020 Nov 26;533(1):9-16. doi: 10.1016/j.bbrc.2020.08.104. Epub 2020 Sep 9. PMID: 32917363.

336. Hu J, Hodgkinson CP, Pratt RE, Lee J, Sullenger BA, **Dzau VJ**. Enhancing cardiac reprogramming via synthetic RNA oligonucleotides. Mol Ther Nucleic Acids. 2020 Oct 27;23:55-62. doi: 10.1016/j.omtn.2020.10.034. PMID: 33335792; PMCID: PMC7723775.

337. Sun H, Pratt RE, Hodgkinson CP, **Dzau VJ**. Sequential paracrine mechanisms are necessary for the therapeutic benefits of stem cell therapy. Am J Physiol Cell Physiol. 2020 Dec 1;319(6):C1141-C1150. doi: 10.1152/ajpcell.00516.2019. Epub 2020 Oct 7. PMID: 33026832.

338. Wang X, Hodgkinson CP, **Dzau VJ**. Production of Cardiomyocytes by microRNA-Mediated Reprogramming in Optimized Reprogramming Media. Methods Mol Biol. 2021;2239:47-59. doi: 10.1007/978-1-0716-1084-8_4. PMID: 33226612.

339. Sun H, Hodgkinson CP, Pratt RE, **Dzau VJ**. CRISPR/Cas9 Mediated Deletion of the Angiotensinogen Gene Reduces Hypertension: A Potential for Cure? Hypertension. 2021 Jun;77(6):1990-2000. doi: 10.1161/HYPERTENSIONAHA.120.16870. Epub 2021 Apr 5. PMID: 33813849.

340. Gomez, J.A, Payne, A.J., Pratt, R.E., Hodgkinson, C.P., **Dzau, V.J**. (2021) A role for Sfrp2 in cardiomyogenesis in vivo. Proc Natl Acad Sci USA. 118 (33) e2103676118; https://doi.org/10.1073/pnas.2103676118

II. Healthcare and policy:

1. Martin AR, Wolf MA, Thibodeau L, **Dzau VJ**, Braunwald E: A trial of two strategies to modify the test-ordering behavior of medical residents. *N Engl J Med* 303:1330-1336, 1980.

2. Cooke JP, **Dzau VJ**. The time has come for vascular medicine. *Ann Intern Med*, 112:138-139. 1990.

3. Holmes EW, Burks TF, **Dzau VJ**, Hindery MA, Jones RF, Kaye CK, Korn D, Limbird LE, Marchase RB, Perlmutter R, Sanfilippo F, Strom BL. Measuring Contributions to the Research Mission of Medical Schools. *Academic Medicine*, 75(3), 2000.

4. Goldzser RC, Winshall JS, Brown M, Hurwitz S, Masachi NL, **Dzau VJ**. Improving patient satisfaction on an academic general medical service. *J Clinical Outcomes Manag*, 9:27-32, 2002.

5. Sussman AJ, Otten JR, Goldszer RC, Hanson M, Trull DJ, Paulus K, Brown M, **Dzau V**, Brennan TA. Intergration of an Academic Medical Center and a Community Hospital: The Brigham and Woman's/ Faulkner Hospital Experience. *Acad Med.* 81 Suppl:18-25. 2006

6. Michener JL, Yaggy S, Lyn M, Warburton S, Champagne M, Black M, Cuffe M, Califf R, Gilliss C, Williams RS, **Dzau VJ**. Improving the health of the community: Duke's experience with community engagement. Acad Med. 2008 Apr;83(4):408-13. doi: 10.1097/ACM.0b013e3181668450. PubMed PMID: 18367904.

7. Williams RS, Casey PJ, Kamei RK, Buckley EG, Soo KC, Merson MH, Krishnan RK, **Dzau VJ**. A global partnership in medical education between Duke Univ and the National University of Singapore. Acad Med. 2008 Feb;83(2):122-7. doi:10.1097/ACM.0b013e318160b8bc. PubMed vPMID: 18303355.

8. **Dzau VJ,** Ackerly DC, Sutton-Wallace P, Merson MH, Williams RS, Krishnan KR, Taber RC, Califf RM. The Role of Academic Health Science Sysems in the Transformation of Medicine. Lancet 2010 March 13;375 (9718):949-53

9. Ackerly DC, Sangvai DG, Udayakumar K, Shah BR, Kalman NS, Cho AH, Schulman KA, Fulkerson WJ Jr, **Dzau VJ**. Training the Next Generation of Physician-Executives: An Innovative Residency Pathway in Management and Leadership. Acad Med. 2011 Mar

10. Ackerly DC, Udayakumar K, Taber R, Merson MH, **Dzau VJ**. Perspective: global medicine: opportunities and challenges for academic health science systems. Acad Med. 2011 Sep;86(9):1093-9.

11. **Dzau VJ**, Yoediono Z, Ellaissi WF, Cho AH. Fostering innovation in medicine and health care: what must academic health centers do? Acad Med. 2013 Oct;88(10):1424-9.

12. Andolsek KM, Murphy G, Nagler A, Moore PR, Schlueter J, Weinerth JL, Cuffe MS, **Dzau VJ**. Fostering creativity: how the Duke Graduate Medical Education Quasi-Endowment encourages innovation in GME. Acad Med. 2013 Feb;88(2):185-91.

13. **Dzau VJ**, Cho A, Ellaissi W, Yoediono Z, Sangvai D, Shah B, Zaas D, Udayakumar K. Transforming academic health centers for an uncertain future. N Engl J Med. 2013 Sep 12;369(11):991-3.

14. **Dzau VJ**, Pizzo PA. Relieving pain in America: insights from an Institute of Medicine committee. JAMA. 2014 Oct 15;312(15):1507-8.

15. **Dzau VJ,** Fineberg HV. Restore the US Lead in Biomedical Research.

JAMA. 2015 Jan 13;313(2):143-4

16. Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, Bleyl S, Chakravarti A, Chantratita W, Chisholm RL, Dissanayake VH, Dunn M, **Dzau VJ**, Han BG, Hubbard T, Kolbe A, Korf B, Kubo M, Lasko P, Leego E, Mahasirimongkol S, Majumdar PP, Matthijs G, McLeod HL, Metspalu A, Meulien P, Miyano S, Naparstek Y, O'Rourke PP, Patrinos GP, Rehm HL, Relling MV, Rennert G, Rodriguez LL, Roden DM, Shuldiner AR, Sinha S, Tan P, Ulfendahl M, Ward R, Williams MS, Wong JE, Green ED, Ginsburg GS . Science Translational Medicine. 2015. Global Implementation of Genomic Medicine. Jun 3;7(290):290 ps13

17. **Dzau VJ**, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23;385 (9982):2118-9.

18. **Dzau VJ**, Cicerone RJ. Responsible Use of Human Gene Editing Technologies. Hum Gene Ther. 2015 Jul;26(7):411-2.

19. **Dzau VJ,** Soo KC. Mentorship in Academic Medicine: A Catalyst of Talents. Ann Acad Med Singapore. 2015 Jul;44(7):232-4.

20. **Dzau VJ,** Rodin J**.** Creating a Global health Risk Framework. N Engl J Med. 2015 Nov 24;314(20):2127-8.

21. **Dzau VJ.** The Institute of Medicine: Ensuring Integrity and Independence in Scientific Advice on Health. Lancet 2015 Oct 16 pii: S0140-6736(15)00468-7.

22. **Dzau VJ.** The National Academy of Medicine's Vision: Leadership, Innovation, and Impact for a Healthier Future. JAMA 2015 Nov 24;314(20):2127-8.

23. Sands P, Mundaca-Shah C, and **Dzau VJ**. The Neglected Dimension of Global Security — A Framework for Countering Infectious-Disease Crises. N Engl J Med. 2016 Jan 13; doi: 10.1056/NEJMsr1600236

24. **Dzau VJ**, Sands P. A Stitch in Time Saves Nine: Financing Pandemic Preparedness through Domestic Resource Mobilization. Global Health and Diplomacy. 2016 Apr 14; 57–60.

25. Sands P, El Turabi A, Saynisch PA, **Dzau VJ**. Assessment of economic vulnerability to infectious disease crises. Lancet. 2016 Nov 12;388(10058):2443-2448. doi: 10.1016/S0140-6736(16)30594-3. Epub 2016 May 19.

26. Gostin LO, Tomori O, Wibulpolprasert S, Jha AK, Frenk J, Moon S, Phumaphi J, Piot P, Stocking B,**Dzau VJ**, Leung GM. Toward a Common Secure Future: Four Global Commissions in the Wake of Ebola. PLoS Med. 2016 May 19;13(5):e1002042.

27. Sridhar D, Kickbusch I, Moon S, **Dzau VJ**, Heymann D, Jha A, Saavendra J, Stocking B, Woskie L, and Piot P. Facing Forward After Ebola: Questions for the Next Director General of the World Health Organization. BMJ. 2016 May 20

28. **Dzau, VJ**. National Academy of Medicine and the Cardiovascular Community: Partnering for a Healthier Future. Circulation. 2016.

29. **Dzau VJ**, Sands P. Beyond the Ebola Battle--Winning the War against Future Epidemics. N Engl J Med. 2016 Jul 21;375(3):203-4.

30. **Dzau VJ**, McClellan M, McGinnis JM. Vital Directions for Health and Health Care: An Initiative of the National Academy of Medicine. JAMA. 2016 Aug 16;316(7):711-2.

31. **Dzau VJ**, Ginsburg G, et al. Realizing the Full Potential of Precision Medicine in Health and Health Care: A Vital Direction for Health and Health Care. National Academy of Medicine Perspective. 2016 Sept 19.

32. **Dzau VJ**, Ginsburg GS. Realizing the Full Potential of Precision Medicine in Health and Health Care. JAMA. 2016 Oct 25;316(16):1659-1660.

33. Califf RM, Robb MA, Bindman AB, Briggs JP, Collind FS, Conway PH, Coster TS, Cunningham FE, De Lew N, DeSalvo KB, Dymek C, **Dzau VJ**, Fleurence RL, Frank RG, Gaziano JM, Kaufmann P, Lauer M, Marks PW, McGinnis JM, Richards C, Selby JV, Shulkin DJ, Shuren J, Slavitt AM, Smith SR, Washignton BV, White PJ, Woodcock J, Woodson J, Sherman RE. Transforming Evidence Generation to Support Health and Healthcare Decisions. New Eng J Med. 2016 Dec 15; 375:24

34. **Dzau VJ**, Balatbat CA. Cardiovascular Research and the National Academy of Medicine: Advancing Progress in Science and Medicine. Part 1: Who We Are. Circulation Research. 2017 Jan 5;120:23-26.

35. **Dzau VJ**, Balatbat CA. Cardiovascular Research and the National Academy of Medicine: Advancing Progress in Science and Medicine. Part 2: What We Do. Circulation Research. 2017 Jan 5;120:23-26.

36. Moon S, Leigh J, Woskie L, Checchi F, **Dzau VJ**, Fallah M, Fitzgerald G, Garrett L, Gostin L, Heymann DL, Katz R, Kickbusch I, Morrison JS, Piot P, Sands P, Sridhar D, Jha AK. Post-Ebola reforms: ample analysis, inadequate action. BMJ. 2017 Jan 23; 356:j280

37. **Dzau VJ**, McClellan MB, McGinnis JM, Burke SP, Coye MJ, Diaz A, Daschle TA, Frist WH, Gaines M, Hamburg MA, Henney JE, Kumanyika S, Leavitt MO, Parker RM, Sandy LG, Schaeffer LD, Steele GD Jr, Thompson P, Zerhouni E. Vital Directions for Health and Health Care: Priorities From a National Academy of Medicine Initiative. National Academy of Medicine Perspectives. 2017 Mar 21.

38. **Dzau VJ**, McClellan MB, McGinnis JM, Burke SP, Coye MJ, Diaz A, Daschle TA, Frist WH, Gaines M, Hamburg MA, Henney JE, Kumanyika S, Leavitt MO, Parker RM, Sandy LG, Schaeffer LD, Steele GD Jr, Thompson P, Zerhouni E. Vital Directions for

Health and Health Care: Priorities From a National Academy of Medicine Initiative. JAMA. 2017 Apr 11;317(14):1461-1470.

39. **Dzau VJ**, Asch DA, Hannaford B, Aggarwal R, Pugh C. A Debate on the Cost of Innovation in Healthcare: Is it too costly? BMJ Simulation & Technology Enhanced Learning. 2017;3(Suppl 1):S33–S36.

40. Yamey G, Schäferhoff M, Aars OK, Bloom B, Carroll D, Chawla M, **Dzau VJ**, Echalar R, Gill IS, Godal T, Gupta S, Jamison D, Kelley P, Kristensen F, Mundaca-Shah C, Oppenheim B, Pavlin J, Salvado R, Sands P, Schmunis R, Soucat A, Summers LH, El Turabi A, Waldman R, Whiting E. Financing of international collective action for epidemic and pandemic preparedness. Lancet. 2017 May 18.

41. Batson A, Merson M, **Dzau VJ**. Innovating through "interesting times" in global health. Lancet. 2017 Sept 25. [ePub ahead of print]

42. **Dzau V**, Fuster V, Frazer J, Snair M. Investing in Global Health for Our Future. New Eng J Med 2017 Sept 28: 377; 1292-1296.

43. Tuckson RV, **Dzau VJ**, Lurie N. Creating Healthy Communities after Disasters. New Eng J Med 2017 Nov 15: 377:1806-1808.

44. Fuster V, Frazer J, Snair M, Vedanthan R, **Dzau V**. The Future Role of the United States in Global Health: Emphasis on Cardiovascular Disease. JACC. 2017 Nov 30. [ePub ahead of print]

45. **Dzau VJ**, Lurie N, Tuckson RV. After Harvey, Irma, and Maria, an Opportunity for Better Health—Rebuilding Our Communities as We Want Them. Am J Pub Health 2017 Dec 6. [ePub ahead of print]

46. **Dzau VJ**. Commentary: Vaccines-Protecting Health and Saving Lives. Psychol Sci Public Interest. 2017 Dec;18(3):147-148. doi: 10.1177/1529100618760522.

47. **Dzau VJ**, Kirch DG, Nasca TJ. To Care Is Human — Collectively Confronting the Clinician-Burnout Crisis. New Eng J Med. 2018 Jan 25; 378:312-314

48. Leshner AI, **Dzau VJ**. Good gun policy needs research. Science 2018 Mar 16: 359 (6381): 1195.

49. **Dzau VJ**, Leshner AI. Public Health Research on Gun Violence: Long Overdue. Ann Intern Med. 2018 Jun 19;168(12):876-877. doi: 10.7326/M18-0579. Epub 2018 Mar 20.

50. Daniels R, **Dzau V**. Supporting the Next Generation of Biomedical Researchers. JAMA 2018 June 14; [epub ahead of print].

51. **Dzau VJ**, Balatbat CA. Reimagining population health as convergence science. Lancet. 2018 Aug 4;392(10145):367-368. doi: 10.1016/S0140-6736(18)31372-2.

52. **Dzau VJ**, Johnson PA, Ending Sexual Harassment in Academic Medicine NEJM 2018 Sep 10: 23:44

53. **Dzau VJ**, Balatbat CA. Health and societal implications of medical and technological advances. Sci Transl Med. 2018 Oct 17;10(463). pii: eaau4778. doi: 10.1126/scitranslmed.aau4778.

54. Kishore S, Ripp J, Shanafelt T, Melnyk B, Rogers D, Brigham T, Busis N, Charney D, Cipriano P, Minor L, Rothman P, Spisso J, Kirch D, Nasca T, **Dzau V**. Making The Case For The Chief Wellness Officer In America's Health Systems: A Call To Action. Health Affairs Blog, October 26, 2018. DOI: 10.1377/hblog20181025.308059

55. Jiang L, Krumholz HM, Meng Q, Cheng KK, Yip W, Maeseneer J, Mossialos EA, Chunharas S, **Dzau VJ**, Gao X, Guerra R, Ji H, Ke Y, Li C, Li L, Normand ST, Pan Z, Peto R, Wu X, Xiao S, Xie X, Xu DR, Zhang Y, Zhu J, Zhu S, Zhang Q, Li X, Lu J, Su M, Hu S. The Lancet Commission on primary health care in China. *The Lancet* [in press].

56. **Dzau VJ**, McNutt M, Ramakrishnan V. Academies' action plan for germline editing. Nature. 2019 Mar;567(7747):175. doi: 10.1038/d41586-019-00813-7.

57. **Dzau VJ**, McNutt M, Bai C. Wake-up call from Hong Kong. *Science*. 14 Dec 2018: Vol. 362, Issue 6420, pp. 1215. DOI: 10.1126/science.aaw3127

58. Goy A, Nishtar S, **Dzau V**, Balatbat C, Diabo R. Health and Healthcare in the Fourth Industrial Revolution: Global Future Council on the Future of Health and Healthcare 2016-2018. Insight Report. World Economic Forum. 8 May 2019. (https://www.weforum.org/reports/health-and-healthcare-in-the-fourth-industrial-revolution-global-future-council-on-the-future-of-health-and-healthcare-2016-2018)

59. Lesher A, **Dzau VJ**. Medication-Based Treatment to Address Opioid Use Disorder. JAMA. 2019 Jun 4;321(21):2071-2072. doi: 10.1001/jama.2019.5523.

60. **Dzau VJ**, Balatbat CA. Future of Hypertension. Hypertension. 2019 Sep;74(3):450-457. doi: 10.1161/HYPERTENSIONAHA.119.13437. Epub 2019 Jul 29.

61. **Dzau VJ**, Inouye SK, Rowe JW, Finkelman E, Yamada T. Enabling Healthful Aging for All – The National Academy of Medicine Grand Challenge in Healthy Longevity. N Engl J Med 2019; 381:1699-1701 DOI: 10.1056/NEJMp1912298

62. Carayon P, Cassel C, **Dzau VJ**. Improving the System to Support Clinician Well-being and Provide Better Patient Care. JAMA. Published online October 23, 2019. doi:https://doi.org/10.1001/jama.2019.17406

63. Wu AW, **Dzau VJ**. What Can Patient Safety Teach Us About Clinician Burnout? Ann Intern Med. 2019;171(12):933-934.

64. **Dzau VJ**, Jenkins JAC. Creating a Global Roadmap for Healthy Longevity. J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(Suppl_1):S4-S6. doi: 10.1093/gerona/glz226. PMID: 31690929.

65. McNutt M, **Dzau VJ**. Academies' Call to Action: Air Pollution Threatens Global Health. Annals of Global Health, 2019: 85(1), p.145. DOI: http://doi.org/10.5334/aogh.2660

66. Wu AW, **Dzau VJ**. What Can Patient Safety Teach Us About Clinician Burnout? Ann Intern Med. 2019 Dec 17;171(12):933-934. doi: 10.7326/M19-2397. Epub 2019 Dec 10. PMID: 31816631.

67. Sim I, Stebbins M, Bierer BE, Butte AJ, Drazen J, **Dzau VJ**, Hernandez AF, Krumholz HM, Lo B, Munos B, Perakslis E, Rockhold F, Ross JS, Terry SF, Yamamoto KR, Zarin DA, Li R. Time for NIH to lead on data sharing. Science, 20 Mar 2020: Vol. 367, Issue 6484, pp. 1308-1309.

68. Shu D, Ting W, Carin L, Dzau VJ, Wong TY. Digital technology and COVID-19. Nature Medicine volume 26, 459–461(2020).

69. **Dzau VJ**, Kirch D, Nasca T. Preventing a Parallel Pandemic — A National Strategy to Protect Clinicians' Well-Being. NEJM May 13, 2020. DOI: 10.1056/NEJMp2011027

70. Kavanagh MM, Erondu NA, Tomori O, **Dzau VJ**, Okiro EA, Maleche A, Aniebo IC, Rugege U, Holmes CB, Gostin LO. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet. 2020 May 30;395(10238):1735-1738. doi: 10.1016/S0140-6736(20)31093-X. Epub 2020 May 7. PMID: 32386564; PMCID: PMC7252104.

71. **Dzau VJ**, Cohen M, McGinnis JM. Vital Directions for Health & Health Care: The North Carolina Experience. N C Med J. 2020 May-Jun;81(3):167-172. doi: 10.18043/ncm.81.3.167. PMID: 32366624.

72. **Dzau VJ**, Fineberg HV, Shine KI, Thier SO, Malina D, Morrissey S. A Half-Century of Progress in Health - A Perspective Series in Honor of the 50th Anniversary of the National Academy of Medicine. N Engl J Med. 2020 Jul 2;383(1):76-77. doi: 10.1056/NEJMe2020118. PMID: 32609986.

73. **Dzau VJ**, Finkelman EM, Balatbat CA, Verdin EM, Pettigrew RI. Achieving healthy human longevity: A global grand challenge. Sci Transl Med. 2020 Oct 21;12(566):eabd3816. doi: 10.1126/scitranslmed.abd3816. PMID: 33087500.

74. **Dzau VJ**, Balatbat C. Strategy, coordinated implementation, and sustainable financing needed for COVID-19 innovations. Lancet. 2020 Nov 7;396(10261):1469-1471. doi: 10.1016/S0140-6736(20)32289-3. PMID: 33160552; PMCID: PMC7831521.

75. **Dzau VJ**, Shine KI. Two Decades Since To Err Is Human: Progress, but Still a "Chasm". JAMA. 2020;324(24):2489–2490. doi:10.1001/jama.2020.23151

76. **Dzau VJ**, McClellan MB, McGinnis JM, Marx JC, Sullenger RD, ElLaissi W. Vital Directions For Health And Health Care: Priorities For 2021. Health Aff (Millwood). 2021 Feb;40(2):197-203. doi: 10.1377/hlthaff.2020.02204. Epub 2021 Jan 21. PMID: 33476192.

77. Lurie N, Keusch GT, **Dzau VJ**. Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development. Lancet. 2021 Mar 27;397(10280):1229-1236. doi: 10.1016/S0140-6736(21)00503-1. Epub 2021 Mar 9. PMID: 33711296; PMCID: PMC7993931.

78. **Dzau VJ**. Bench to Bedside Discovery, Innovation, Global Health Equity, and Security: A Conversation With Victor J. Dzau, MD. Circulation. 2021 Mar 16;143(11):1076-1080. doi: 10.1161/CIRCULATIONAHA.121.054151. Epub 2021 Mar 15. PMID: 33720778.

79. Chaudhry HJ, Walker-McGill C, **Dzau VJ**. Coordination Needed to Address Clinician Well-being and the Opioid Epidemic. JAMA. 2021 Jun 15;325(23):2341-2342. doi: 10.1001/jama.2021.6694. PMID: 34076682.

80. McGinnis JM, Fineberg HV, **Dzau VJ**. Advancing the Learning Health System. N Engl J Med. 2021 Jul 1;385(1):1-5. doi: 10.1056/NEJMp2103872. Epub 2021 Jun 26. PMID: 34192452.

81. Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, **Dzau VJ**, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Jul 21;22:11-14. doi: 10.1016/j.omtm.2021.06.012. PMID: 34377737; PMCID: PMC8322039.

82. **Dzau VJ**, Balatbat CA, Ellaissi WF. Revisiting Academic Health Sciences Systems a decade later: Discovery to Health to Population to Society. Lancet 2021. Accepted

III Editorials, Reviews, and Book Chapters

1. **Dzau VJ**, Szabo S, Chang YC: Aspiration of metallic mercury. *JAMA* 238:1531-1532, 1977.

2. Haber E, **Dzau VJ**, Kopelman RI, Slater EE, Barger AC: Renin specific antibody as a physiologic tool. In: Hoechst (ed). *Enzymatic Release of Vasoactive Peptides.* Proc 8th Workshop, Heidelberg, 1980.

3. **Dzau VJ**, Siwek L, Barger AC: Intrarenal resistance changes in experimental benign and malignant hypertension. In: Laragh J, Seldin D, Buhler F (eds). *Frontiers in Hypertension Research.* New York: Springer-Verlag, 165-168, 1981.

4. Carlson WD, Quay S, **Dzau VJ**, Kreisberg J, Slater E, Haber E: Biosynthesis of renin in dog kidney: Evidence for the existence of prorenin. In: Sambhi M (ed). *Heterogeneity of Renin and Renin Substrate.* New York: Elsevier-North Holland, 33-43, 1981.

5. **Dzau VJ**, Emmett N, Brenner A, Haber E: Characterization of angiotensin I generating enzymes in rat brain by affinity chromatography. In: Sambhi M (ed). *Heterogeneity of Renin and Renin Substrate.* New York: Elsevier-North Holland, 301-306, 1981.

6. **Dzau VJ**, Powell SH: Captopril. In: *Pharm Ther Rev* 5(4):1-5, 1982.

7. Berliner RW, **Dzau VJ**, Hollenberg NK, Cannon PH: Kidney and cardiovascular regulation. *Fed Proc* 42:3135, 1983.

8. Haber E, Zusman R, Burton J, **Dzau VJ**, Barger AC: Is renin a factor in the etiology of essential hypertension? *Hypertension* 5:V-8 - V-15, 1983.

9. **Dzau VJ**: Angiotensin converting enzyme inhibition in treatment of congestive heart failure and hypertension. In: Isselbacher K et al (eds). *Harrison's Principles of Internal Medicine, Updates IV.* 137-146, 1983.

10. **Dzau VJ**, Gibbons G, Levin D: Renovascular hypertension: An update on pathophysiology, diagnosis and treatment. *Am J Nephrol* 3:172-184, 1983.

11. **Dzau VJ**, Hollenberg NK, Williams GH: Neurohumoral mechanism in heart failure. Role in pathogenesis, therapy and drug tolerance. *Fed Proc* 42:3162-3169, 1983.

12. **Dzau VJ**, Pratt RE: Studies of renin biosynthesis and release. In: Sambhi, Vallerial (eds). *Mechanisms of Hypertension.* The Netherlands: Martinus Nijhoff, 365-375, 1984.

13. **Dzau VJ**: Renin inhibitors and angiotensin converting enzyme inhibitors: Rationale and comparison of results. In: Labrie F, Proulx L (eds). *Endocrinology.* Excerpta Medica, 412-418, 1984.

14. **Dzau VJ**: Evaluation and management of hypertension. In: Kloner RA (ed). *The Guide to Cardiology.* New York: John Wiley & Sons, 447-474, 1984.

15. **Dzau VJ**, Kloner RA: Definition and mechanism of heart failure. In: Kloner RA (ed). *The Guide to Cardiology.* New York: John Wiley & Sons, 377-405, 1984.

16. **Dzau VJ**: Vascular renin-angiotensin: A possible autocrine or paracrine system in control of vascular function. *J Cardiovasc Pharm* 6:S377-S382, 1984.

17. **Dzau VJ**: Vascular wall renin-angiotensin pathway in control of the circulation: A hypothesis. *Am J Med* 77(4A):31-36, 1984.

18. Gibbons G, **Dzau VJ**, Fahri E, Barger AC: Interactions of signals influencing renin release. *Ann Rev Physiol* 46:291-308, 1984.

19. Nabel E, Gibbons G, **Dzau VJ**: Pathophysiology of experimental renovascular hypertension. *Am J Kidney Dis* 8:A111-A119, 1985.

20. Nabel EG, Gibbons GH, **Dzau VJ**: Pathophysiology of experimental renovascular hypertension. *Am J Kidney Dis* 5:111-119, 1985.

21. **Dzau VJ**, Haber E: Molecular mechanisms that control renin release. *Hypertension* 7: 853-854, 1985.

22. Kopelman RI, **Dzau VJ**: Trends in the therapy of mild hypertension: A word of caution (editorial). *Arch Int Med* 145:47-49, 1985.

23. Kopelman RI, **Dzau VJ**: Trends in the therapy for mild hypertension. A word of caution. *Arch Intern Med* 145:47-49, 1985.

24. **Dzau VJ**, Schwartz SL, Creager MA: The role of prostaglandins in pathophysiology and therapy of congestive heart failure. *Heart Failure* 2:6-13, 1986.

25. **Dzau VJ**: Significance of vascular renin angiotensin pathways. *Hypertension* 8:553-559, 1986.

26. Warren S, **Dzau VJ**: Natriuretic hormones in heart failure. *Heart Failure* 2:33-39, 1986.

27. **Dzau VJ**, Creager MA: Neurohormonal mechanisms in heart failure. *Heart Failure* 2:3-5, 1986.

28. **Dzau VJ**: ACE inhibitors in heart failure: Correcting fluid and electrolyte imbalances. *Drug Therapy,* 57-68, 1986.

29. Paganelli W, Creager MA, **Dzau VJ**: Cardiac regulation of kidney function. In: Cheung TO (ed). *International Textbook of Cardiology,* 1010-1020, 1986.

30. **Dzau VJ**, Creager MA: Prostaglandins in congestive heart failure. In: Robertson JIS, Nicholls MG (eds). *The Renin-Angiotensin System.* London: Gower Publishers, 9.12 - 9.16, 1986.

31. Creager MA, **Dzau VJ**: Regional blood flow in patients with congestive heart failure following ACE inhibition. In: Robertson JIS, Nicholls MB (eds). *The Renin-Angiotensin System.* London: Gower Publishers, 9.18 - 9.22, 1986.

32. **Dzau VJ**, Pratt RE: Renin-angiotensin system: Biology, physiology and pharmacology. In: Fozzard MA, Haber E, Jennings RJ, Katz AM, Morgan HE (eds). *The Heart and Cardiovascular System Vol 1*. New York: Raven Press, 1631-1662, 1986.

33. Sacks FM, **Dzau VJ**: Adrenergic effects on plasma lipoprotein metabolism: Speculation on mechanisms of action. *Am J Med* 80(2A):71-79, 1986.

34. **Dzau VJ**, Baxter ID, Cantin M, DeBold A, Ganten D, Gross K, Husain A, Inagami T, Menard J, Poole S, Robertson JIS, Tang JS, Yamamoto K: Nomenclature for atrial peptides. *N Engl J Med* 316:1278-1279, 1987.

35. **Dzau VJ**: Renal effects of angiotensin converting enzyme inhibition in cardiac failure. *Am J Kid Dis* 10:74-80, 1987.

36. **Dzau VJ**: Renin-angiotensin system and arterial wall in hypertension. In: Nijhoff M (ed). *Arterial and Venous Systems in Essential Hypertension.* The Netherlands: Martinus Nijhoff, 153-164, 1987.

37. **Dzau VJ**, Baxter JA, Cantin M, deBold A, Genten D, Gross K, Husain A: Report of the Joint Nomenclature and Standardization Committee of the International Society of Hypertension, American Heart Association, and World Health Organization. *J Hypertension* 5:507-511, 1987.

38. Levenson DJ, **Dzau VJ**: Effects of angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis. *Kid Int J* 31(suppl 20):S-173-S-179, 1987.

39. **Dzau VJ**: Renin-angiotensin system and renal circulation in clinical congestive heart failure. *Kid Int J* 31(suppl 20):S-203-S-209, 1987.

40. **Dzau VJ**: Nomenclature for biologically active atrial peptides. *Current Opinions Cardiol* 4:643-646, 1987.

41. **Dzau VJ**, Robertson JIS, Richards AM, Gaines Das RE, Poole S: International collaborative study of the proposed international standard for atrial natriuretic factor. An initial analysis of RIA results. On behalf of the American Heart Association, International Society for Hypertension, and World Health Organization. Milan, 1987.

42. **Dzau VJ**, Poole S: International standard for atrial natriuretic factor. *ACE Rept* 46:3-5, 1987.

43. **Dzau VJ**: Vascular angiotensin pathways: a new therapeutic target. *J Cardiovasc Pharmacol* 10(Suppl 7): 9-16, 1987.

44. **Dzau VJ**: Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy. *Am J Med* 82:36-43, 1987.

45. Poole S, **Dzau VJ**: The new international standard for renin. *ACE Rept* 46:1-2, 1987.

46. Ingelfinger JR, Pratt RE, **Dzau VJ**: A basic and clinical review of the renin-angiotensin system. In: Glassock RJ (ed). *Textbook of Nephrology.* Baltimore: Williams and Wilkins, 1987.

47. Hollenberg NK, **Dzau VJ**: The renin angiotensin system. In: Maxwell, Kleeman, Narins (eds). *Clinical Disorders in Fluid and Electrolyte Metabolism.* New York: McGraw-Hill, 371-383, 1987.

48. **Dzau VJ**: Vascular angiotensin pathways: A new therapeutic target. *J Cardiovasc Pharm* 10(suppl 7):S9-S16, 1987.

49. **Dzau VJ**, Rosenthal J, Swales J: Vascular renin: A consensus view. *J Hypertension* 5 (suppl 2):577-578, 1987.

50. **Dzau VJ**: Pharmacological relevance of tissue vs plasma angiotensin converting enzyme (ACE) inhibition. *ACE Rept* 47:1-4, 1987.

51. **Dzau VJ**, Gibbons GH: Autocrine-paracrine mechanisms of vascular myocytes in hypertension. *Am J Cardiol* 60:991-1031, 1987.

52. **Dzau VJ**: Evolution of the clinical management of hypertension: Emerging role of specific vasodilators as initial therapy. *Am J Med* 82(A):36-43, 1987.

53. **Dzau VJ**, Creager MA: Clinical response to angiotensin-converting enzyme inhibition in cardiac failure. *Clin Exp Hypertension* A9:521-529, 1987.

54. **Dzau VJ**: Implications of local angiotensin production in cardiovascular physiology and pharmacology. *Am J Cardiol* 59:59A-65A, 1987.

55. **Dzau VJ**, Rosenthal J, Swales JD: Vascular renin - a consensus view. *J Hypertens* 5:77-78, 1987.

56. **Dzau VJ**: Renal and circulatory mechanisms in heart failure. *Kidney Int J* 31:1402-1416, 1987.

57. **Dzau VJ**, Creager MA: Influence of angiotensin converting enzyme on clinical outcome and survival in congestive heart failure. *Practical Cardiol* 13(2):40-49, 1987.

58. **Dzau VJ**, Sacks F: Regulation of lipoprotein metabolism by adrenergic mechanisms. *J Cardiovasc Pharmacol* 10(suppl 9):52-56, 1987.

59. **Dzau VJ**: Renal and circulatory mechanisms in congestive heart failure. *Kidney Int* 31:1402-1415, 1987.

60. **Dzau VJ**, Creager MA: Clinical response to angiotensin-converting enzyme inhibition in cardiac failure. *Clin Exp Hypertens* 9:521-529, 1987.

61. **Dzau VJ**, Gibbons GH: Autocrine-paracrine mechanisms of vascular myocytes in systemic hypertension. *Am J Cardiol* 60:991-1031, 1987.

62. **Dzau VJ**. Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control. *J Hypertens* 6:7-12, 1988.

63. **Dzau VJ**: Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanisms. *Am J Hypertens* 1:334-337, 1988.

64. **Dzau VJ**, Safar ME: Large conduit arteries in hypertension: role of the vascular renin-angiotensin system. *Circulation* 77:947-954, 1988.

65. **Dzau VJ**, Sacks FM: Regulation of lipoprotein metabolism by adrenergic mechanisms. *J Cardiovasc Pharmacol* 10(Suppl 9):2-6, 1988.

66. **Dzau VJ**, Burt DW, Pratt RE: Molecular biology of the renin-angiotensin system. *Am J Physiol* 255:563-573, 1988.

67. **Dzau VJ**, Gibbons G: Cell biology of vascular hypertrophy in systemic hypertension. *Am J Cardiol* 62:30-35, 1988.

68. Creager MA, **Dzau VJ**: Treatment of congestive heart failure with angiotensin-converting enzyme inhibitors. *Cardiology,* 53-54, Jan 1988.

69. **Dzau VJ**: Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors. *Am J Med* 84:4-8, 1988.

70. **Dzau VJ**: Vascular and renal prostaglandins as counter-regulatory systems in heart failure. *Eur Heart J* 9(suppl H):15-19, 1988.

71. **Dzau VJ**: Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive cardiac failure. *Am J Cardiol* 62:76E-81E, 1988.

72. Creager MA, **Dzau VJ**: ACE inhibitors for congestive heart failure. *Drug Ther,* 53-54, Jan 1988.

73. **Dzau VJ**: Vascular renin angiotensin system. New insights into mechanisms of action of angiotensin converting enzyme inhibitor. *Am J Med*, 84:4-8, 1988.

74. **Dzau VJ**: Recommendations of the Adult Treatment Panel of the National Cholesterol Education Program. Implications for the management of hypertension. *Hypertension* 12:471-473, 1988.

75. **Dzau VJ**: Tissue renin angiotensin system: Physiologic and pharmacologic implications. *Circulation* 77(Suppl I):I- -I-3, 1988.

76. **Dzau VJ**: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. *Circulation* 77(Suppl I):4-13, 1988.

77. **Dzau VJ**: Mechanisms of the interaction of hypertension and hypercholesterolemia in atherogenesis: The effects of antihypertensive agents. *Am Heart J*,116:1725-1728, 1988.

78. **Dzau VJ**, Pratt RE, Paul M, Nakamura N: Molecular studies of human renin synthesis and gene expression. *J Cardiol Drug Ther*, 2:459-462, 1988.

79. **Dzau VJ**: Molecular and physiological aspects of tissue renin-angiotensin system: Emphasis on cardiovascular control. *J Hypertension,* 6(suppl 3):S7-S12, 1988.

80. **Dzau VJ**: Recommendations of the National Cholesterol Education Program: Implications for the management of hypertension. *Hypertension,* 12:471-473, 1988.

81. Poole S, Rose E, Gaines D, **Dzau VJ**, Richards AM, Robertson JIS: The international standard for atrial natriuretic factor calibration by an international collaborative study. *Hypertension,* 12:629-634, 1988.

82. **Dzau VJ**, Ingelfinger JR: Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. *J Hypertensio,* 7(suppl 6):S3-S8, 1989.

83. **Dzau VJ**, Cooke JP, Rubanyi G: Significance of endothelial derived vasoactive substances. *J Vasc Med Biol*, 1:43-45, 1989.

84. Bes A, Corvol P, **Dzau VJ**, Fillastre JP, Lekieffre J, Passa P, Vasmant D, Waeber B, Zanchetti A. Circulating and tissue renin-angiotensin system: present and future. *J Cardiovasc Pharmacol*, 14(Suppl 4):S60-S65, 1989.

85. **Dzau VJ**. Treatment strategies: an evaluation of antihypertensive therapy. *Am J Med,* 86:113-115, 1989.

86. **Dzau VJ**: Beginning a new era (editorial). *J Vasc Med Biol,* 1989.

87. **Dzau VJ**, Paul M, Nakamura N, Pratt RE, Ingelfinger JR: Role of molecular biology in hypertension research (State of the Art lecture). *Hypertension,* 13:731-740, 1989.

88. **Dzau VJ**, Creager MA: Progress in angiotensin-converting enzyme inhibition in heart failure: Rationale, mechanisms, and clinical responses. *Cardiol Clin,* 7:119-130, 1989.

89. **Dzau VJ**: Treatment strategies: An evaluation of antihypertensive therapy. *Am J Med,* 86 (suppl 1B):113-115, 1989.

90. **Dzau VJ**: ACE inhibitors in hypertension: A US perspective. *Cardiology*, 76(2):23-30, 1989.

91. **Dzau VJ**: Short- and long-term determinants of cardiovascular function and therapy: Contributions of circulating and tissue renin-angiotensin systems. *J Cardiovasc Pharm* , 14:S1-S5, 1989.

92. **Dzau VJ**: Factors influencing the lipid response to selective alpha 1-inhibition. *J Cardiovasc Pharm* 2:S50-S52, 1989.

93. **Dzau VJ**: Angiotensin converting enzyme inhibitors and the hypertensive heart. *Current Opinion Cardiol* 4(suppl 2):S3-S6, 1989.

94. **Dzau VJ**: Clinical implication for therapy: Cardioprotection of angiotensin converting enzyme inhibition. *Br J Clin Pharmacol*, 28:183S-187S, 1989.

95. **Dzau VJ**: Multiple pathways of angiotensin production in the blood vessel wall: Evidence, possibilities and hypotheses. *J Hypertension*, 7:933-936, 1989.

96. **Dzau VJ**: Mechanisms of action of angiotensin converting enzyme inhibitors in hypertension: Emphasis on kidney and vascular effects. In: Clement DL (ed). *Angiotensin Converting Enzyme Inhibitors: Past, Present and Beyond.* Royal Society of Medicine Services, International Congress and Symposium series, no. 144, 1989.

97. **Dzau VJ**: Quinapril - a new angiotensin-converting enzyme inhibitor: An overview. *Angiology*, 40(4 pt 2):323-330, 1989.

98. Bes A, Corvol P, **Dzau VJ**, Fillastre JP, Lekieffre J, Passa P, Vasmant D, Waeber B, Zanchetti A: Circulating and tissue renin-angiotensin system: Present and future. *J Cardiovasc Pharm,* 14:S60-S65, 1989.

99. **Dzau VJ**, Paul M, Nakamura N, Pratt RE, Ingelfinger JR. Role of molecular biology in hypertension research. State of the Art lecture. *Hypertension,* 13:731-740, 1989.

100. Gibbons GH, **Dzau VJ**: Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension. *Cardiovasc Drug Ther*, 4:237-242, 1990.

101. **Dzau VJ**, Hirsch AT. Emerging role of the tissue renin-angiotensin systems in congestive heart failure. *Eur Hrt J*, 11(Suppl B):65-71, 1990.

102. Hirsch AT, Pinto YM, Schunkert H, **Dzau VJ**: Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. *Am J Cardio,l* 66:22D-32D, 1990.

103. **Dzau VJ**, Hirsch AT. Emerging role of the tissue renin-angiotensin systems in congestive heart failure. *Eur Heart*, 11(Suppl B):65-71, 1990.

104. **Dzau VJ**. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. *Drugs*, 39 (Suppl 2):39:1-6, 1990.

105. **Dzau VJ**: Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. *Drugs*, 39 (suppl 2):11-16, 1990.

106. **Dzau VJ**, Creager MA: Diseases of the aorta. In: Wilson JD, Braunwald E, Fauci AS, Isselbacher KJ, Martin JB, Petersdorf RG, Root RK (eds).*Harrison's Principles of Internal Medicine.* New York: McGraw-Hill. 1990.

107. Creager MA, **Dzau VJ**: Vascular diseases of the extremity. In: Wilson JD, Braunwald E, Fauci AS, Isselbacher KJ, Martin JB, Petersdorf RG, Root RK (eds). *Harrison's Principles of Internal Medicine.* New York: McGraw-Hill, 1990.

108. Kloner RA, **Dzau VJ**: Heart failure. In: Kloner RA (ed). *The Guide to Cardiology* (2nd ed), New York: Le Jacq Communications, 359-382, 1990.

109. Naftilan AJ, **Dzau VJ**: Evaluation and management of hypertension. In: Kloner RA (ed). *The Guide to Cardiology* (2nd ed). New York: Le Jacq Communications, 409-436, 1990.

110. **Dzau VJ**, Hirsch AT: Emerging role of the tissue renin-angiotensin systems in congestive heart failure. *Eur Hrt J* 11(Suppl B):65-71, 1990.

111. **Dzau VJ**: Atherosclerosis and hypertension: Mechanisms and interrelationships. *J Cardiovasc Pharm* 15:S59-S64, 1990.

112. **Dzau VJ**: The role of endothelial derived vasoactive substances in the regulation of vascular tone via structural remodeling of the blood vessels. In: Rubanyi G, Ryan U (eds). *Endothelial Regulation of Vascular Tone.* New York: Marcel Dekker, 331-339, 1991.

113. Simonson DC, **Dzau VJ**: Proceedings from Hypertension, Lipids, and Cardiovascular Disease: is insulin the missing link? Workshop IX-lipids, insulin, diabetes. *Am J Med*, 90 (Suppl 2A):85S-88S, 1991.

114. Krieger JE, **Dzau VJ**: Molecular biology of hypertension. *Hypertension*, 18 (Suppl I):I-3-I-17, 1991.

115. Schunkert H, Ingelfinger JR, **Dzau VJ**. Evolving concepts of the intrarenal renin-angiotensin system in health and disease: contributions of molecular biology. *Renal Physiol Biochem,* 14:146-154, 1991.

116. **Dzau VJ**, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary heart disease: a workshop consensus statement. *Am Heart J,* 121:1244-1263, 1991.

117. Ingelfinger JR and **Dzau VJ**. Molecular biology of renal injury: emphasis on the role of the renin-angiotensin system. *J Am Soc Nephrol*, 2:S9-S20, 1991.

118. **Dzau VJ**, Gibbons GH: Endothelium and growth factors in vascular remodeling of hypertension. *Hypertension*, 18 (Suppl III):115-121, 1991.

119. **Dzau VJ**: Renin and myocardial infarction in hypertension. *N Engl J Med,* 324:1128-1130, 1991.

120. **Dzau VJ**, Gibbons G. Does hypertension potentiate atherosclerosis via vascular hypertrophy? *J Cardiovas Pharmacol,* 17 (Suppl 2):S34, 1991.

121. Pratt RE, Gibbons GH, Itoh H, **Dzau VJ**. Molecular control of vascular smooth muscle cell growth by angiotensin. In: Imura H, Matsuo H, Masaki T (eds) *Peptide Regulation of Cardiovascular Function*. Tokyo: Harcourt Brace Jovanovich, 145-155, 1991.

122. **Dzau VJ**, Gibbons GH: The role of the endothelium in vascular remodeling. In: *Cardiovascular Significance of Endothelium-Derived Vasoactive Factors*. Rubanyi GM (ed) New York: Futura Publishing, 281-291, 1991.

123. **Dzau VJ**, Pratt RE: Renin-angiotensin system. In: *The Heart and Cardiovascular System*. Fozzard HA et al (eds) New York: Raven Press, 1817-1850, 1991.

124. Creager MA, Cooke JP, Tucker JI, **Dzau VJ**: Lipoproteins and endothelial dysfunction. In: Cardiovascular Significance of Endothelium-Derived Vasoactive Factors. Rubanyi GM (ed) New York: Futura Publishing, 251-262, 1991.

125. Mockrin SC, **Dzau VJ**, Gross KW, Horan MJ: Transgenic animals: new approaches to hypertension research. *Hypertension* 17:394-399, 1991.

126. **Dzau VJ**, Krieger JE: Molecular Biology. In: *Advances in Hypertension*. Kotchen TA, Frohlich ED (eds) J.B. Lippincott Company: New York, 193-223, 1991.

127. Cooke JP, **Dzau VJ**, Creager MA: Endothelial dysfunction in hypercholesterolemia is corrected by
L-arginine. In: *Endothelial Mechanisms of Vasomotor Control*. Drexler H, Zeiher AM, Just H (eds) Germany:Steinkopff Verlag Darmstadt, 173-181, 1991.

128. Hirsch AT and **Dzau VJ**. Tissue renin-angiotensin systems: insights regarding the pathophysiology of heart failure. *Heart Failure,* 7:59-70, 1991.

129. **Dzau VJ**. Tissue renin-angiotensin systems: concepts and clinical implications. *Focus on Hypertension*, 1:5-14, 1992.

130. **Dzau VJ**, Pratt RE, Cooke JP: Endothelin as a growth factor in vascular remodeling and vascular disease. In: Rubanyi GM (ed). *Endothelin.* London: Oxford University Press, 137-143, 1992.

131. Swales JA, **Dzau VJ**: Angiotensin-converting enzyme inhibition: research advances and clinical implications. *Am Heart J,* 123:1412-1413, 1992.

132. **Dzau VJ**, Pratt RE. Antisense technology to block autocrine growth factors. *J Vasc Surg,* 15:934-935, 1992.

133. **Dzau VJ**. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. *Am J Cardiol,* 70:4C-11C, 1992.

134. Omoigui N, **Dzau VJ**: Differential effects of antihypertensive agents in experimental and human atherosclerosis. *J Vasc Biol Med,* 3:382-391, 1992.

135. Cowley AW, **Dzau V**, Buttrick P, Cooke J, Devereux RB, Grines CL, Haidet GC, Thames MD. Working group on noncoronary cardiovascular disease and exercise in women. *Med Sci Sports Exercise,* 24:S277-S287, 1992.

136. **Dzau VJ**, Pratt RE. Tissue renin-angiotensin system in the experimental restenosis after vascular injury: evidence for local activation. *J Cardiovasc Pharmacol,* 20 (Suppl B):S28-S32, 1992.

137. **Dzau VJ**. Angiotensin converting enzyme inhibitors and the cardiovascular system. *J Hypertension,* 10 (Suppl 3):S3-S10, 1992.

138. Tsao PS, **Dzau VJ**, Cooke JP: Nitrates: Mechanisms of action and tolerance. In: *Arterial Vasodilation. Mechanisms and Therapy*. O'Rourke M, Safar M, **Dzau V** (eds), United Kingdom: Edward Arnold, 208-215, 1993.

139. **Dzau VJ**, Cooke JP, Tsao PS: Cellular mechanisms of vasodilation. In: *Arterial Vasodilation. Mechanisms and Therapy*. O'Rourke M, Safar M, **Dzau V** (eds), United Kingdom: Edward Arnold, 200-207,1993.

140. **Dzau VJ**, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. *J Hypertension,* 11(Suppl 3):S13-S18, 1993.

141. **Dzau VJ**. The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. *Curr Opin Nephrol Hypertension,* 2:27-32, 1993.

142. Lee PC, Gibbons GH, **Dzau VJ**. Cellular and molecular mechanisms of coronary artery restenosis. *Cor Art Dis,* 4:254-259, 1993.

143. **Dzau VJ**, Krieger JE: Molecular biology of hypertension. In: *Molecular Biology of the Cardiovascular System.* Roberts R (ed). Blackwell Scientific Publications: Boston, 325-353, 1993.

144. **Dzau VJ**, Creager MA: Can angiotensin converting enzyme inhibitors be differentiated? *Prog Cardiovasc Dis*.

145. Gibbons GH, **Dzau VJ**: Endothelial function in vascular remodeling. In: *The Endothelium: An Introduction to Current Research.* New York: John Wiley, 1990

146. **Dzau VJ**: Angiotensin converting enzyme inhibition and the heart. *Current Sci*

147. **Dzau VJ**: Activation of the sympathetic nervous system: A link among multiple risk factors for coronary heart disease. *Practical Cardiology*. McNamara P (ed) New Jersey: Medical Publishing Enterprises.

148. Pratt RE, **Dzau VJ**. Trophic effects of angiotensin on blood and heart vessels. In: *Renin Angiotensin System.* Robertson JIS, Nicholls G (eds). New York: Raven Press, 31.1-31.7, 1993.

149. **Dzau VJ**, Pratt RE. Cardiac, vascular, and intrarenal renin angiotensin systems in physiology and diseases. In: *Renin Angiotensin System*. Robertson JIS, Nicholls G (eds), New York: Raven Press, 42.1-42.11, 1993.

150. **Dzau VJ**, Krieger JE: Molecular Biology. In: *Advances in Hypertension*. Kotchen TA, Frohlich ED (eds) J.B. Lippincott Company: New York, 189-216, 1993.

151. **Dzau VJ**, Creager MA. Diseases of the aorta. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds). *Harrison's Principles of Internal Medicine.* New York: McGraw-Hill.

152. Omoigui N, **Dzau VJ**: Differential effects of antihypertensive agents in human and experimental atherosclerosis. *Am J Hypertension*, 6(3 Pt 2):30S-39S, 1993.

153. **Dzau VJ**. Role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocyte. *Curr Opin Nephrol Hypertens*, 2:27-32, 1993.

154. **Dzau VJ**, Gibbons GH. Vascular remodeling: Mechanisms and implications. *J Cardiovasc Pharm*, 21(Suppl 1):S1-S5, 1993.

155. **Dzau VJ**, Gibbons GH, Cooke JP, Omoigui N. Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives. *Circulation* 87:705-719, 1993.

156. Naftilan AJ, **Dzau VJ**. In: *The Guide to Cardiology*. Kloner RA (ed). Le Jacq Communications: New York. Evaluation and management of hypertension, pp-409-436, 1993.

157. **Dzau VJ**, Morishita R, Gibbons GH. Gene therapy for cardiovascular disease. *Trends in Biotechnol*, 11:205-210, 1993.

158. **Dzau VJ**, Pratt RE. Molecular and cellular biology of angiotensin-mediated growth of the cardiovascular system. In: *Cellular and Molecular Biology of the Renin Angiotensin System*. Raizaida MK, Phillips MI, Sumners C (eds), CRC Press: Boca Raton, 471-484, 1993.

159. **Dzau VJ**. Tissue renin angiotensin system in myocardial hypertrophy and failure. *Arch Intern Med* 153:937-942, 1993.

160. **Dzau VJ**. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. In: *Angiotensin and the Heart*. Grobecker H, Heusch G, Strauer BE (eds). New York: Springer Verlag, 1-14, 1993.

161. **Dzau VJ**. Tissue ACE in heart disease. *Choices in Cardiol* 7:5-9, 1993.

162. Hollenberg NK, Ingelfinger JR, **Dzau VJ**. The renin angiotensin system. In: *Clinical Disorders of Fluid and Electrolyte Metabolism*. Narins RG (ed). New York: McGraw-Hill, 477-492, 1993.

163. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, **Dzau VJ**. Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy. *Transactions Assoc Am Phys* (volume CVI), Baltimore: Cadmus Journal Service, 54-61, 1993.

164. **Dzau VJ**, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? *J Hypertension* 12(Suppl 2):S1-S5, 1994.

165. Morishita R, Gibbons GH, **Dzau VJ**. Gene therapy as potential treatment for cardiovascular diseases. In: *Cardiovascular Pharmacology and Therapeutics*. Singh BN, Dzau VJ, Vanhoutte P, Woosley RL (eds). New York: Churchill Livingstone, 51-62, 1994.

166. **Dzau VJ**, Omoigui N. Pharmacology of atherosclerosis: effects of antihypertensive drugs. In: *Cardiovascular Pharmacology and Therapeutics*. Singh BN, Dzau VJ, Vanhoutte P, Woosley RL (eds). New York: Churchill Livingstone, 987-998, 1994.

167. **Dzau VJ**, Pratt RE. Cardiovascular pharmacology of angiotensin converting enzyme inhibitors. In: *Cardiovascular Pharmacology and Therapeutics*. Singh BN, Dzau VJ, Vanhoutte P, Woosley RL (eds). New York: Churchill Livingstone, 237-248, 1994.

168. **Dzau VJ**, Gibbons GH, Lee PC. Novel drug targets in vascular pathobiology. In: *Cardiovascular Pharmacology and Therapeutics*. Singh BN, Dzau VJ, Vanhoutte P, Woosley RL (eds). New York: Churchill Livingstone, 317-324, 1994.

169. **Dzau VJ**. Tissue angiotensin systems in cardiovascular disease. In: *Heart Disease: A Textbook of Cardiovascular Medicine - Updates*. Braunwald E (ed) Philadelphia: W.B. Saunders, 485-493, 1994.

170. Cooper LT, Cooke JP, **Dzau VJ**. The vasculopathy of aging. *J Gernotol Biol Sci* 49:B191-B196, 1994.

171. **Dzau VJ**. Cell biology and genetics of angiotensin in cardiovascular disease. *J Hypertension* 12(Suppl 4):S3-S10, 1994.

172. **Dzau VJ**, Re R. Tissue angiotensin system in cardiovascular medicine: A paradigm shift? *Circulation* 89:493-498, 1994.

173. **Dzau VJ**, Creager MA. Diseases of the aorta. In: *Harrison's Principles of Internal Medicine, 13th Edition*. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds), 1131-1134, 1994.

174. Creager MA, **Dzau VJ**. Vascular diseases of the extremities. In: *Harrison's Principles of Internal Medicine, 13th Edition*. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds),1135-1144, 1994.

175. **Dzau VJ**, Gibbons GH, Morishita R, Pratt RE. New perspectives in hypertension research: Potentials of vascular biology. *Hypertension* 1132-1140, 1994.

176. **Dzau VJ**. Pathobiology of atherosclerosis and plaque complications. *Am Heart J* 128:1300-1304, 1994.

177. **Dzau VJ**, Pratt R, Gibbons GH. Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. *Drugs* 47(Suppl 4):1-13, 1994.

178. **Dzau VJ**. Circulatory regulation: the role of vascular structural remodeling. In: Willerson JT, Cohn JN (eds): *Cardiovascular Medicine*, New York: Churchill Livingstone, 1067-1079, 1995.

179. **Dzau VJ**, Gibbons GH, Kobilka BK, Lawn RM, Pratt RE. Genetic models of human vascular disease. *Circulation* 91:521-531, 1995.

180. **Dzau VJ**. Future Perspectives in cardiovascular molecular cell biology: emphasis on genetics and gene therapy. In: Diez J, Dzau VJ, Ferrari R, Frohlich ED (eds): *Molecular Cell Biology of Cardiovascular Disease*, Spain: Mosby/Doyma Libros, 455-460, 1995.

181. **Dzau VJ**. Regulation and disorders of vascular smooth muscle growth. In: Diez J, Dzau VJ, Ferrari R, Frohlich ED (eds): *Molecular Cell Biology of Cardiovascular Disease*, Spain: Mosby/Doyma Libros, 192-197, 1995.

182. **Dzau VJ**, Morishita R, Gibbons GH. Cardiovascular gene therapy: possibilities and realities. In: Gotto AM, Lenfant C, Catapano AL, Paoletti R (eds): *Multiple Risk Factors in Cardiovascular Disease. Vascular and Organ Protection*, Massachusetts: Kluwer Academic Publishers, 35-41, 1995.

183. Kloner RA, Fowler MB, **Dzau V**. Heart failure. In: *The Guide to Cardiology, Third Edition*, Connecticut: Le Jacq Communications, 407-428, 1995.

184. Hirsch AT, Muellerleile M, **Dzau VJ**. Cardiovascular tissue angiotensin systems: Activation and actions in heart failure. In: *Heart Failure*, McCall D, Rahimtoola SH (eds), New York: Chapman and Hall, 117-134, 1995.

185. **Dzau VJ**, Krieger JE, Hutchinson H. Molecular mechanisms in hypertension. In: *Molecular Cardiovascular Medicine*, Haber E (ed), New York: Scientific American, 225-241, 1995.

186. **Dzau VJ**. The role of angiotensin II in cardiovascular disease: effects of tissue ACE on atherogenesis. *Choices in Cardiology* 9:6-9, 1995.

187. **Dzau VJ**. Molecular biology of angiotensin II biosynthesis and receptors. *Can J Cardiol* Aug 11 Suppl F:21F-26F, 1995.

188. Chobanian AV, **Dzau VJ**. Renin angiotensin system and atherosclerotic vascular disease. In: *Atherosclerosis and Coronary Artery Disease*. Fuster V, Ross R, Topol EJ (eds), Philadelphia: Lippincott-Raven, 237-242, 1996.

189. Jacob HJ, Krieger JE, **Dzau VJ**, Lander ES. Genetic dissection of hypertension in experimental animal models. In: *Molecular Genetics and Gene Therapy of Cardiovascular Disease*, Mockrin SC (ed), New York: Marcel Dekker, 293-320, 1996.

190. Pratt RE, **Dzau VJ**. Pharmacological strategies to prevent restenosis. Lessons learned from blockade of the renin-angiotensin system. *Circulation* 93:848-852, 1996.

191. Rudd P, **Dzau VJ**. Hypertension: Evaluation and management. In: *Vascular Medicine: A Textbook of Vascular Biology and Disease*, Loscalzo J, Creager MA, Dzau VJ (eds), Boston: Little, Brown and Company, 609-638, 1996.

192. Stamler JS, **Dzau VJ**, Loscalzo J. The vascular smooth muscle cell. In: *Vascular Medicine: A Textbook of Vascular Biology and Disease*, Boston: Little Brown & Company, Loscalzo J, Creager MA, Dzau VJ (eds), Boston: Little, Brown and Company, 69-116, 1996.

193. Cooke JP, **Dzau VJ**. Pathophysiology of vasospasm. In:*Vascular Medicine: A Textbook of Vascular Biology and Disease*, Loscalzo J, Creager MA, Dzau VJ (eds), Boston: Little, Brown and Company, 369-386, 1996.

194. von der Leyen H, **Dzau VJ**. Future molecular approaches in the treatment of cardiovascular disease: gene therapy. In: *Vascular Medicine: A Textbook of Vascular Biology and Disease*, Loscalzo J, Creager MA, Dzau VJ (eds), Boston: Little Brown & Company, 665-674, 1996.

195. Gibbons GH, **Dzau VJ**. Molecular therapies for vascular diseases. *Science* 272:689-693, 1996.

196. Hirsch AT, Muellerleile MR, **Dzau VJ**. Contribution of tissue renin-angiotensin systems to disease progression in experimental heart failure. In: *The Cardiac-Renin Angiotensin System*. Lindpainter K, Ganten D (eds), New York: Futura Publishing.

197. **Dzau VJ**, Horiuchi M. Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis. In: *Eur Heart J* 17:978-989, 1996.

198. Horiuchi M, Yamada H, Akishita M, **Dzau VJ**. Angiotensin II Regulated Apoptosis in Cardiovascular Remodeling. In: Dhalla NS, Zahradka P, Dixon INC, Beamish RE (eds). *Angiotensin II Receptor Blockade: Physiological and Clinical Implications*. Boston: Kluwer Academic Publishers.

199. Von der Leyen HE, Mann MJ, **Dzau VJ**. Gene inhibition and gene augmentation for the treatment of vascular proliferative disorders. *Semin Intervent Cardiol* 1:1-6, 1996.

200. **Dzau VJ**. Angiotensin Converting Enzyme in the Continuum of CARDIOVASCULAR DISEASE. *Adis International*.

201. **Dzau VJ**, Horiuchi M. In Vivo Gene Transfer and Gene Modulation in Hypertension Research. *Hypertension*, 28:1132-1137, 1996.

202. Pratt RE, **Dzau VJ**. Pharmacological strategies to prevent restenosis: Lessons learned from blockade of the renin angiotensin system. *Circulation* 93:848-852, 1996.

203. **Dzau VJ**, Horiuchi M. Patholophysiological and Pharmacological Implications of Differential Expression of Angiotensin receptor Subtypes (AT1 and AT2 Receptors) in Human Myocardium: A hypothesis. *European Heart Journal* 117:978-980, 1996.

204. Mann MJ, **Dzau VJ**. Genetic manipulation of vein grafts. *Curr Opin Cardiol* 12(6): 522-7, 1997

205. **Dzau VJ**, Gibbons GH, Mann M, Braun-Dullaeus R. Future horizons in cardiovascular molecular therapeutics. *Am J Cardiol* 80(9A): 33I-39I, 1997.

206. Cooke JP, **Dzau VJ**. Nitric Oxide Synthase: Role in the Genesis of Vascular Disease. In: *Ann Rev Med*

209. **Dzau VJ**, Von Der Leyen HE, Morishita R. The Concept and Potentials of Cardiovascular Gene Therapy. In: *Dialogues In Cardiovascular Medicine: Gene Therapy Vol.2.* 1:3 1997.

210. Cooke JP, **Dzau VJ**. Dearangements of the NO synthase pathway L-arginine, and cardiovascular diseases. *Circulation* 96: 379-82, 1997.

211. **Dzau VJ**. Mechanisms of protective effects of ACE inhibition on coronary artery disease. *European Heart Journal* 19 Suppl J: J 2-6, 1998.

212. **Dzau VJ** and Horiuchi M. Vascular Remodeling-The emerging paradigm of programmed cell death (Apoptosis). Francis B. Lectureship. *Chest* 114: 1S, 1998.

213. **Dzau VJ.** Presentation of the 1998 Kober Medal to Eugene Braunwald. *Proceedings of the Association of American Physicians* 110(5); 445-450, 1998.

214. Mann MJ, Braun-Dullaeus RC, **Dzau VJ.** Cell cycle interruption to inhibit intimal hyperplasia. *Tissue Engineering of Vascular Grafts. Chapter 23,* 1999.

215. Pratt RE, **Dzau VJ.** Genomics and hypertension: Concepts, potentials, and opportunities. *Hypertension* 33(1Pt 2): 238-247, 1999.

216. Horiuchi M, Akishita M, **Dzau VJ**. Molecular and cellular mechanism of angiotensin II-mediated apoptosis. *Endocr Res* 24(3-4): 307-14, 1998.

217. Brown MD, Halpert A, McKean S, Sussman A, **Dzau VJ**. Assessing the value of hospitalists to academic health centers: Brigham and Women's Hospital and Harvard Medical School. *Am J Med* 106(2): 134-7, 1999.

218. Weir MR, **Dzau VJ**. The renin-angiotensin-aldosterone system: a specific target for hypertension management. *Am J Hypertens* 12(12 Pt 3):205S-213S, 1999.

219. **Dzau VJ**, Matter C. *Circulatory Regulation: The Role of Vascular Remodeling.* Willerson and Cohn: Cardiovascular Medicine, 2nd Edition, 2000.

220. Afshin E, Mann MJ, **Dzau VJ.** Vascular growth as an adjunct to surgical to surgical revascularization. *ACC Current Journal Review.* 9(4):43-46, 2000.

221. Afshin E, Mann MJ, **Dzau VJ.** Gene therapy in cardiovascular disease. *An Introduction to Molecular Medicine and Gene Therapy.* Chapter 8:182-201, 2000.

222. **Dzau VJ,** Mann MJ, Afshin E, Griese DP. Presidential Basic Science Lecture 1999 of American Association of Thoracic Surgery: Gene therapy and Genomic strategies for cardiovascular surgery: the emerging field of surgiomics. *The Journal of Thoracic Cardiovascular Surgery.* 121(2):206-216, 2001.

223. Mann, MJ, **Dzau VJ.** Therapeutic Application of Transciption Factor Decoy Oligonucleotides. *J Clin Invest*, 106(9):1071-1075, 2000.

224. Alexander RW, **Dzau VJ**. Vascular Biology: The Past 50 Years, *Circulation*. 102(20):IV-112, 2000.

225. Yet, S.F., Tian, R., Layne, M.D., Wang, Z.Y., Maemura, K., Solovyeva, M., Ith, B., Melo, L.G., Zhang, L., Ingwall, J.S. et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res, 89:168-173, 2001.

226. von der Leyen, H.E. and **Dzau, V.J.** Therapeutic potential of nitric oxide synthase gene manipulation. Circulation, 103, 2760-2765, 2001.

227. Mangi, A.A. and **Dzau, V.J.** Gene therapy for human bypass grafts. Ann Med, 33, 153-155, 2001.

228. Hwang, J.J., **Dzau, V.J.** and Liew, C.C. Genomics and the pathophysiology of heart failure. Curr Cardiol Rep, 3, 198-207, 2001.

229. Glueck, S.B., **Dzau, V.J.**, Lee, R. and Pratt, R.E. Challenges of comparative expression profiling studies of complex diseases: mouse models of myocardial hypertrophy. Focus on "Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy". *Physiol Genomics*, 6, 1-2, 2001.

230. Francis, S.C., Raizada, M.K., Mangi, A.A., Melo, L.G., **Dzau, V.J.**, Vale, P.R., Isner, J.M., Losordo, D.W., Chao, J., Katovich, M.J. et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? *Physiol Genomics*, 7:79-94, 2001.

231. Ehsan, A., Mann, M.J., Dell'Acqua, G. and **Dzau, V.J.** Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg, 121, 714-722, 2001.

232. **Dzau, V.J.**, Mann, M.J., Ehsan, A. and Griese, D.P. Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics. J Thorac Cardiovasc Surg, 121, 206-216, 2001.

233. **Dzau, V.J.** Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. *Hypertension*, 37, 1047-1052, 2001.

234. **Dzau, V.J.** and Glueck, S. Physiological Genomics: Who we are and where we're going. *Physiol Genomics* 7, 65-67, 2001.

235. Daviet, L., Lehtonen, J.Y., Hayashida, W., **Dzau, V.J.** and Horiuchi, M. Intracellular third loops in AT1 and AT2 receptors determine subtype specificity. *Life Sci*, 69, 509-516, 2001.

236. Butte, A.J., **Dzau, V.J.** and Glueck, S.B. Further defining housekeeping, or "maintenance," genes Focus on "A compendium of gene expression in normal human tissues". *Physiol Genomics* , 7, 95-96, 2001.

237. Braun-Dullaeus, R.C., Mann, M.J., Seay, U., Zhang, L., von Der Leyen, H.E., Morris, R.E. and **Dzau, V.J.** Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. *Arterioscler Thromb Vasc Biol*, 21, 1152-1158, 2001.

238. Mangi, A, **Dzau VJ**. Gene therapy for human bypass grafts: primary clinical outcomes in the PREVENT trial. *Annals of Medicine*, 3:153-55, 2001.

239. **Dzau VJ**. Tissue Angiotensin and Pathobiology of Vascular Disease: A Unifying Hypothesis. The Theodore Cooper Lecture, *Hypertension* 37(4):1047-1052, 2001;

240. Hwang JJ, **Dzau VJ**, Liew CC. Genomics and the pathophysiology of heart failure. *Curr Cardiol Rep* 3:198-207, 2001.

241. Francis SC, Raizada MK, Mangi AA, Melo LG, **Dzau VJ**, Vale PR, Isner JM, Losordo DW, Chao J, Katovich MJ, Berecek KH. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? *Physiological Genomics*, 7(2):79-94, 2001.

242. Melo, L.G., Agrawal, R., Zhang, L., Rezvani, M., Mangi, A.A., Ehsan, A., Griese, D.P., Dell'Acqua, G., Mann, M.J., Oyama, J. et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. *Circulation*, 105, 602-7, 2002

243. Ehsan, A., Mann, M.J., Dell'Acqua, G., Tamura, K., Braun-Dullaeus, R. **Dzau, V.J.** Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. *Circulation*, 105, 1686-1692, 2002.

244. Barrans, J.D., Allen, P.D., Stamatiou, D., **Dzau, V.J.** and Liew, C.C. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. *Am J Pathol*, 160, 2035-2043, 2002.

245. Glueck SB, **Dzau VJ**. Physiological genomics: implications in hypertension research. *Hypertension*, 39(2):310-315, 2002.

246. Aird WC, Glueck SB, **Dzau VJ**, Pratt RE. Separating the wheat from the chaff: focus on "in silico data filtering to identify new angiogenesis targets from a large in vitro gene profile data set". *Physiological Genomics*, 10(1):1-3, 2002.

247. **Dzau VJ**, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M.Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report. *Cardiovascular Drugs Therapy*, 16(2):149-60, 2002.

248. **Dzau VJ**. Transcription factor decoy. *Circulation Research*, 90(12):1234-1236, 2002.

249. Mann, M.J. and **Dzau, V.J.** Molecular approaches for the treatment of atherosclerosis. Cardiol Clin, 20, 633-643, 2002.

250. **Dzau, V.J.**, Bernstein, K., Celermajer, D., Cohen, J., Dahlof, B., Deanfield, J., Diez, J., Drexler, H., Ferrari, R., Van Gilst, W. et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther, 16:149-160, 2002.

251. **Dzau, V.J.**, Braun-Dullaeus, R.C. and Sedding, D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med, 8:1249-1256, 2002.

252. **Dzau VJ**, Glueck SB. The future of Physiological Genomics. *Physiological Genomics*, 14(3):167-168, 2003.

253. Kleimna NS, Patel NC, Allen KB, Simons M, Yla-Herttuala S, Griffin E, **Dzau VJ**. Evolving revascularization approaches for myocardial ischemia. *Am J Cardiol*, 92(9B):9N-17N, 2003.

254. **Dzau VJ**. Predicting the future of human gene therapy for cardiovascular diseases: what will the management of coronary artery disease be like in 2005 and 2110? *Am J Cardiol*, 92(9B):32N-35N, 2003.

255. **Dzau VJ**, Beatt K, Pompilio G, Smith K. Current perceptions of cardiovascular gene therapy. *Am J Cardiol* 92(9B):18N-23N, 2003.

256. Mangi, A.A., Noiseux, N., Kong, D., He, H., Rezvani, M., Ingwall, J.S. and **Dzau, V.J.** Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med, 9, 1195-1201, 2003.

257. Lopez-Ilasaca, M., Liu, X., Tamura, K. and **Dzau, V.J.** The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell, 14, 5038-5050, 2003.

258. Huber, P.E., Mann, M.J., Melo, L.G., Ehsan, A., Kong, D., Zhang, L., Rezvani, M., Peschke, P., Jolesz, F., **Dzau, V.J.** et al. Focused ultrasound (HIFU) induces localized enhancement of reporter gene expression in rabbit carotid artery. Gene Ther, 10, 1600-1607, 2003.

259. Griese, D.P., Ehsan, A., Melo, L.G., Kong, D., Zhang, L., Mann, M.J., Pratt, R.E., Mulligan, R.C. and **Dzau, V.J.** (2003) Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. *Circulation*, 108, 2710-2715.

260. Durier, S., Fassot, C., Laurent, S., Boutouyrie, P., Couetil, J.P., Fine, E., Lacolley, P., **Dzau, V.J.** and Pratt, R.E. Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness. *Circulation*, 108, 1845-51, 2003.

261. Barrans, J.D., Ip, J., Lam, C.W., Hwang, I.L., **Dzau, V.J.** and Liew, C.C. Chromosomal distribution of the human cardiovascular transcriptome. *Genomics*, 81, 519-24, 2003.

262. Anderson, L.M., Choe, S.E., Yukhananov, R.Y., Hopfner, R.L., Church, G.M., Pratt, R.E. and **Dzau, V.J.** Identification of a novel set of genes regulated by a unique liver X receptor-alpha - mediated transcription mechanism. *J Biol Chem*, 278, 15252-15256, 2003.

263. Melo, L.G., Pachori, A.S., Kong, D., Gnecchi, M., Wang, K., Pratt, R.E. and **Dzau, V.J.** Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. *Circulation*, 109:2386-2393, 2004.

264. Melo, L.G., Gnecchi, M., Pachori, A.S., Kong, D., Wang, K., Liu, X., Pratt, R.E. and **Dzau, V.J.** Endothelium-targeted gene and cell-based therapies for cardiovascular disease. *Arterioscler Thromb Vasc Biol*, 24:1761-1774, 2004.

265. McMurray, J.J., Pfeffer, M.A., Swedberg, K. and **Dzau, V.J.** Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? *Circulation*, 110:3281-3288, 2004.

266. Liew, C.C. and **Dzau, V.J.** Molecular genetics and genomics of heart failure. *Nat Rev Genet*, 5:811-825, 2004.

267. Levy, B.D., Katz, J.T., Wolf, M.A., Sillman, J.S., Handin, R.I. and **Dzau, V.J.** An initiative in mentoring to promote residents' and faculty members' careers. *Acad Med*, 79:845-850, 2004.

268. Melo LG, Pachori AS, Kong D, Gnecchi M, Wang K, Pratt RE, **Dzau VJ**. Gene and cell-based therapies for heart disease. *FASEB J*, 8(6):648-663, 2004.

269. Stampfer, M.J., Ridker, P.M., **Dzau, V.J.,** Risk Factor Criteria, *Circulation,* 109[suppl] IV 3-IV-5, 2004.

270. Gibbons, G.H., Liew, C.C., Goodarzi, M.O., Rotter, J.I., Hsueh, W.A., Siragy, H.M., Pratt, R. and **Dzau, V.J.** Genetic markers: progress and potential for cardiovascular disease. *Circulation*, 109:IV47-IV58, 2004.

271. **Dzau, V.J.** Markers of malign across the cardiovascular continuum: interpretation and application. *Circulation*, 109:IV1-IV2, 2004.

272. Melo LG, Pachori AS, Gnecchi M, **Dzau VJ.,** Genetic therapies for cardiovascular diseases, *Trends Molecul Medicine*, 11(5):240-250, 2005.

273. **Dzau V.,** The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. *J Hypertension*, Supp 23 1:S9-S17, 2005.

274. **Dzau VJ**, Gneechi M, Pachori AS, Morello F, Melo LG, Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. *Hypertension*, 46(1): 7-18, 2005

275. Pachori AS, Melo LG, **Dzau VJ**. Gene therapy: role in myocardial protection. *Hand Exp Pharmacol.* 176 Part 2: 335-350, 2006.

276. Melo LG, Pachori AS, Kong D, Gnecchi M, **Dzau VJ**. Endothelium-targeted gene and cell-based therapies for cardiovascular disease. In: *Endothelial Dysfunctions and Vascular Disease,* De Caterina R, Libby P (eds), Blackwell Publishing, 365-400, 2007.

277. Deb A, Drexler H, Dzau VJ. Tissue Regeneration of the Cardiovascular System and Stem Cells. In: *Hurst's the Heart.* Fuster V, O'Rourke R, Walsh R, Poole-Wilson P (eds). McGraw-Hill Companies. 2007.

278 Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. *Circ Res.* 2008 Nov 21;103(11):1204-19.

279. **Dzau VJ**, Molkentin JD. Helmut Drexler, MD, 1951-2009. Circulation. 2009 Dec 8;12 (23):2402-3. PubMed PMID: 20050129.

280. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011 Feb;50(2):280-9. Epub 2010 Aug 19. Review. PubMed PMID: 20727900; PubMed Central PMCID: PMC3021634.

281. Hodgkinson CP, Gomez JA, Mirotsou M, Dzau VJ. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther. 2010 Nov;21(11):1513-26. Epub 2010 Oct 22. Review. PubMed PMID: 20825283; PubMed Central PMCID: PMC2978545.

282. O'Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010 Dec;15(6):461-8. Epub 2010 5. Review. PubMed PMID: 21056945

283. Deb A, Drexler H, Mirotsou M.,**Dzau VJ**. Tissue Regeneration of the Cardiovascular System and Stem Cells. In: *Hurst's the Heart.* Fuster V, O'Rourke R, Walsh R, Poole-Wilson P (eds). McGraw-Hill Companies. 2011.

284. Voora, Deepak, **Dzau, Victor J,** Ginsburg, Geoffrey S. *Chapter 114, Cariovascular Pharmacogenetics*, Jaypee Brothers Medical Publishers Pvt. Ltd., 2012

285. Jayawardena T, Mirotsou M, **Dzau VJ**. Direct reprogramming of cardiac fibroblasts to cardiomyocytes using microRNAs. Methods Mol Biol. 2014;1150:263-72. doi: 10.1007/978-1-4939-0512-6_18. PubMed PMID: 24744005.

286. Hodgkinson CP, Gomez JA, Bareja A, Dzau VJ Stem Cell and Gene Therapy for Cardiovascular Disease Chapter 2 Paracrine Mechanisms, 2015 ISBN 978-0-12-801888-0.

287. Matsushita K, **Dzau VJ**. Mesenchymal stem cells in obesity: insights for translational applications. Lab Invest. 2017 Oct;97(10):1158-1166. doi: 10.1038/labinvest.2017.42. Epub 2017 Apr 17.

IV. Books

1. Loscalzo J, Creager MA, **Dzau VJ** (eds):*Vascular Medicine*, Boston: Little Brown & Company, 1992.

2. O'Rourke M, Safar M, **Dzau VJ** (eds): *Arterial Vasodilation. Mechanisms and Therapy* United Kingdom: Edward Arnold Ltd 1993.

3. Singh BN, **Dzau VJ**, Vanhoutte P, Woosley RL (eds): *Cardiovascular Pharmacology and Therapeutics*, New York: Churchill Livingstone, 1994.

4. Diez J, **Dzau VJ**, Ferrari R, Frohlich ED (eds): *Molecular Cell Biology of Cardiovascular Disease* Spain: Ediciones Doyma, 1995.

5. Opie LH, Zanchetti A, **Dzau VJ**. *Angiotensin Converting Enzyme Inhibitors: Scientific Basis for Clinical Use, 2d Ed.*, John Wiley & Sons, 1995.

6. Loscalzo J, Creager MA, **Dzau VJ** (eds):*Vascular Medicine, Second Edition*, Boston: Little Brown & Company: Boston, 1996.

7. Rubanyi G, **Dzau VJ**. *The Endothelium in Clinical Practice: Source and Target of Novel Concepts and Therapies*. Marcel Dekker 1997.

8. Schrier RW, **Dzau VJ**, Baxter JD, Fauci AS (eds). *Advances in Internal Medicine, Vol. 43, 1st Ed.*, Mosby-Year Book, 1997.

9. Simon DI, Rogers C, **Dzau VJ**. *Vascular Disease and Injury: Preclinical Research*. Humana Press, 2001.

10. Rubanyi G, **Dzau VJ**, Cooke JP. *Vascular Protection.* Taylor & Francis, 2001.

11. Creager MA, **Dzau VJ,** Loscalzo J. (eds.). *Vascular Medicine: A Companion to Braunwald's Heart Disease. 1st Edition.* Elsevier Inc, 2006.